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Abstract 
 
Aberrant communication between survival signalling- and cell death pathways 
enables tumour cells to resist anoikis - the subset of apoptosis triggered by loss of 
cell-extracellular matrix (ECM) contact.  Focal adhesion kinase (FAK) has been 
implicated as the key intermediate in the acquisition of anoikis resistance, as 
constitutively active FAK rescues epithelial cells from anoikis.  Pertinent to 
anoikis-related regulation, enhanced FAK-dependent signalling has been 
demonstrated to repress p53- and Fas-mediated apoptosis.  Elevated expression of 
FAK correlates with increased metastasis of human oesophageal squamous cell 
carcinoma (HOSCC).  Furthermore, downregulation of Fas as well as a loss of 
p53 tumour suppressor function are early events in HOSCC progression.  In this 
study, staurosporine (STS) was used to experimentally induce apoptosis in 
HOSCC cell lines harbouring either wild type (wt) or mutant (mt) p53-R175H.  
Dephosphorylation of FAK accompanied STS-mediated FAK cleavage and 
caspase-3 activation in the wt p53 cell lines.  Consistent with the lack of FAK 
cleavage observed post STS treatment, the mt p53-R175H cell line displayed 
sustained FAK Tyr397 phosphorylation and persistent integrin β1-activated FAK.  
However, although the survival signals transduced by integrin-activated FAK are 
attributed to protein kinase B (PKB) activation, fibronectin-mediated protection to 
STS-mediated detachment demonstrated in the wt p53 cells lines was independent 
of pPKB Ser473 phosphorylation.  Moreover, the altered regulation of FAK in the 
mt p53-R175H cell line is not due to the inability of mt p53-R175H to associate 
with FAK.  Constitutive activation of FAK has been previously shown to protect 
cells from anoikis-mediated activation of caspase-8.  Correspondingly, in the mt 
p53-R175H cell line, delayed caspase-8 activation was accompanied by the 
maintenance of FAK Tyr397 phosphorylation, integrin β1-associated FAK and a 
Fas/FAK complex.  Thus, the data presented highlight that, by interacting with 
both major apoptotic regulators, FAK is central to anoikis-related regulation.  
Moreover, through maintained FAK phosphorylation, the “hot spot” mt p53-
R175H may have a significant impact on the survival of tumor cells post cell 
detachment, by opposing the induction of anoikis.   
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Chapter 1 
General Introduction 
Central role of focal adhesion kinase in anoikis resistance 
 
1.1 Aberrant adhesion-mediated signalling is fundamental to the 
metastatic progression of tumour cells 
 
Multicellular organisms require efficient mechanisms of intercellular 
communication to maintain normal tissue homeostasis (Hynes and Zhao, 2000).  
These requirements are largely met by adhesion receptors that establish 
transmembrane connections, thereby, linking cells to components of the 
extracellular matrix (ECM) and adjacent cells.  In addition to providing 
mechanical support, these molecules significantly influence cell behavior, through 
the activation of intracellular signalling pathways.  As these pathways regulate 
diverse cellular process including cell survival, proliferation and migration, cell 
adhesion is vital to development and differentiation (De Arcangelis and Georges-
Labouesse, 2000; Bill et al., 2004).  Consequently, aberrant regulation of 
adhesion-based signalling is prevalent in many pathological conditions such as 
psoriasis, inflammation and neoplasia, and is central to tumour invasion and 
metastasis (Hanahan and Weinberg, 2000).   
 
Although the mechanism whereby tumours escape normal cellular control remains 
an enigma, decades of research have indicated that it is metastasis that causes 
approximately 90 % of deaths from solid tumours (Gupta and Massague, 2006). 
To achieve metastasis, cancer cells need to evade multiple levels of tissue 
regulation to bypass stringent cellular restraints.  Evasion of these cellular barriers 
is fueled by genomic and epigenomic instabilities (Gorgoulis et al., 2005; Gupta 
and Massague, 2006).  Thus, metastasis has been described as an evolutionary 
process as it involves the selection of a genetically diverse subpopulation of cells 
(Gupta and Massague, 2006).  Within the metastatic cascade several discrete steps 
are discernable: loss of cell adhesion from the primary tumour, invasion of 
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surrounding tissue, entry in the circulatory system and eventual colonization of a 
secondary site (Figure 1.1; Fidler, 2003).  However, since detachment from the 
primary tumour is an initial step in the metastatic cascade, the molecular basis for 
inappropriate cell adhesion-mediated signaling has become an area of intense 
research.  Moreover, in addition to facilitating metastasis, the resultant aberrant 
activation of cell survival pathways may reduce the sensitivity of cancer cells to 
the apoptosis-inducing capacity of chemotherapeutic treatment (Leu et al., 2000; 
Westhoff and Fulda, 2009).  Consequently, exploring the relationship between 
cell adhesion and cell death pathways is imperative, as it reveals the mechanism 
used by tumours to overcome normal tissue restraints, facilitating their metastatic 
progression.  
 
1.2 The concepts of anoikis and apoptosis-related death 
 
A remarkable aspect of adhesion-mediated signaling is anchorage-dependent 
survival.  The survival of many normal cell types, particularly epithelial cells, is 
dependent on cellular adhesion to a substratum (Aoudjit and Vuori, 2001; Bozzo 
et al., 2006; Kamarajan and Kapila, 2007).  Subsequent loss of contact to the 
ECM triggers the cells to undergo “apoptosis-like” death.  This subset of cell 
death is referred to as anoikis (Frisch and Francis, 1994).  Malignant tumour cells 
have reduced requirements for surface adhesion due to the evasion of anoikis-
related apoptotic pathways (Frisch and Screaton, 2001; Kupferman et al., 2007; 
Cao et al., 2009).  However, the underlying molecular events rendering tumour 
cells resistant to anoikis are cryptic.  Do cancer cells possess the inherent ability 
to constitutively activate signalling pathways, thereby abrogating substratum-
dependent survival signalling?  And if so, which apoptotic and cell adhesion 
intermediates are fundamental to substratum-deprived survival?  Knowledge of 
this nature may allow the manipulation of anoikis-related intermediates, thereby 
enhancing the susceptibility of tumour cells to anoikis-inducing chemotherapeutic 
agents. 
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Figure 1.1:   Tumour cells bypass numerous tissue-dependent barriers to achieve metastasis.  Firstly, tumour cells 
acquire a migratory phenotype that allows them to invade through the basement membrane.  Upon entering the 
circulatory or lymphatic system, cancer cells acquire the ability to survive in the absence of adhesion to the ECM 
(referred to as anoikis resistance).  Tumour cells must then adhere to the walls of a blood or lymphatic vessel at 
a secondary site and invade the surrounding tissue.  Finally to complete the metastatic cascade, cancer cells 
have to survive in the foreign environment and grow to form secondary tumour masses. © Simpson et al. (2008)
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Anoikis was first identified in endothelial (Meredith et al., 1993) and epithelial 
cells (Frisch and Francis, 1994) that were experimentally dissociated from the 
ECM.  The resultant death that ensued was accompanied by characteristic 
apoptotic features.  Apoptosis is the physiological pathway that describes the 
mechanism of programmed cell death (Kerr et al., 1972; Jin and El-Deiry, 2005).  
During apoptosis, a specific series of events lead to the organized dismantling of 
the cellular components.  The cell acquires distinct morphological features that 
include; condensation of the chromatin, apoptotic body formation, cell shrinkage 
and blebbing of membrane prior to cell lysis (Kerr et al., 1972; Kaufman and 
Hengartner, 2001).  With regard to the modification in biochemical parameters, 
there is also intranucleosomal DNA cleavage, phosphatidylserine translocation to 
the external membrane and the inactivation by cleavage of several DNA repair 
enzymes and cellular substrates (Riedl and Shi, 2004).   
 
1.2.1 Caspases - executioners of anoikis 
 
Although the exact mechanism whereby cells undergo anoikis is poorly 
understood, both the intrinsic or mitochondrial pathway and the extrinsic or death 
receptor pathway have been implicated (Figure 1.2; Lui et al., 2006; Kamarajan 
and Kapila, 2007; Kamarajan et al., 2010).  Both apoptotic pathways are 
dependent on the activation of caspases, a family of aspartate-specific cysteine 
proteases (Stennicke and Salvesen, 1998; Riedl and Shi, 2004).  Caspases are 
synthesized as inactive zymogens that become autoactivated by proteolytic 
processing in an amplified cascade (Nicholson et al., 1995).  Apoptotic stimuli 
mediated via both extrinsic and intrinsic death cascades converge on caspase-3 
(CPP32, YAMA or apopain) (Riedl and Shi, 2004).  Activated caspase-3 is 
responsible for the cleavage and disassembly of approximately 100 proteins that 
participate in survival signalling, structural and cell adhesion events (Wen et al., 
1997; Kivinen et al., 2005).  Consequently, caspase activation abrogates survival 
signalling and dismantles sites of focal contact, facilitating the apoptotic death 
process. 
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Figure 1.2: Anoikis-related stimuli converge on the activation of 
caspase-3. The mitochondrial or intrinsic death pathway is 
initiated by p53 in response to oxidative stress and DNA 
damage.  Both caspase-dependent and -independent 
apoptotic substrates are released from the inner membrane 
space of the mitochondrion and lead to the ultimate activation 
of caspase-3.  The death receptor or extrinsic pathway leads 
to the sequential activation of caspase-8 and -3.  Hence, both 
the extrinsic and intrinsic apoptotic pathways converge on the 
activation of caspase-3. Importantly, defects in either death 
cascade render tumour cells resistant to anoikis. © Simpson et 
al., (2008) 
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1.2.2 The mitochondrial death cascade and anoikis 
 
Aberrant regulation of the mitochondrial apoptotic pathway is implicated as a 
major contributor to anoikis resistance (Frisch and Francis, 1994; Ilic et al., 1998; 
Rytomaa et al., 2000; Zhang et al., 2004 (b); Lui et al., 2006).  The intrinsic 
apoptotic pathway involves the altered permeability of the mitochondrial 
membrane, and the release of apoptotic proteins from the intermembrane space 
into the cytoplasm (Figure 1.2; Wang, 2001).  The Bcl-2 family of proteins 
controls the release of mitochondrial proteins.  This family is divided into three 
categories depending on the possession of at least one of the four highly 
conserved Bcl-2 homology domains (BH1 – BH4).  (1) The anti-apoptotic factors; 
Bcl-2 and Bcl-xl, (2) the pro-apoptotic factors; Bax and Bak and (3) the „BH3-
only‟ pro-apoptotic factors which includes Bid (Zimmerman et al., 2001).  In 
viable cells, both Bax and Bak are the major initiators of the intrinsic apoptotic 
pathway and reside in the cytoplasm and outer mitochondrial membrane 
respectively (Wei et al., 2001).  In response to a death signal, Bax undergoes a 
conformational change that enables its insertion into the mitochondrial outer 
membrane, and the formation of pores.  Bak monomers also undergo 
conformational changes and oligomerization, facilitating the permeablisation of 
the mitochondrial membrane (Willis et al., 2005).   
 
Upon oligomerization of Bax or Bak, the mitochondrial outer membrane is 
permeabilized resulting in the release of proteins from the intermembrane space of 
the mitochondria into the cytoplasm (Willis et al., 2005).  Cytochrome c is one of 
the key small molecules released from the mitochondrion and results in the 
activation of the cytoplasmic protein, apoptotic protease activation factor-1 (Apaf-
1) (Li et al., 1997; Riedl and Shi, 2004).  The binding of cytochrome c to the 
adapter molecule apaf-1 induces a conformational change in apaf-1, facilitating 
the formation of the apoptosome and the recruitment of procaspase-9 (Li et al., 
1997; Jiang and Wang, 2000).  Procaspase-9 is not activated by simple cleavage, 
but rather by binding to apaf-1 (Stennicke and Salvesen, 1998).  The apoptosome 
then activates the effector caspase, caspase-3, which is cleaved by activated 
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caspase-9.  Other small molecules released from the mitochondrion are second 
mitochondria-derived activator of caspase/direct IAP binding protein with low pI 
(Smac/ DIABLO) and Omi/HrtA2 (Riedl and Shi, 2004).  Both factors indirectly 
contribute to caspase activation by inhibiting members of the inhibitor of 
apoptotic protein (IAP) family (Liu et al., 2000).    
 
Members of the Bcl-2 family of proteins have been implicated in reducing the 
susceptibility of tumour cells to anoikis.  Overexpression of the anti-apoptotic 
protein, Bcl-2 has been shown to protect epithelial cells from anchorage-
dependent cell death (Frisch and Francis, 1994).  In Madin-Darby canine kidney 
(MDCK) cells and primary mouse mammary epithelial cells, detachment from the 
ECM induces rapid mitochondrial translocation of Bax (Rytomaa et al., 2000).  
Moreover, in non-transformed intestinal cells, the release of Omi/HtrA2 and was 
associated with detachment-induced down-regulation of Bcl-XL (Lui et al., 2006). 
However, in these cells, anoikis did not involve activation of caspase-9 (Lui et al., 
2006).  
 
The p53 tumour suppressor protein controls the balance between pro-apoptotic 
and anti-apoptotic proteins (Rotter et al., 1983; Brosh and Rotter, 2009).  As the 
anti-apoptotic factors are proposed to inhibit the pro-apoptotic proteins through 
the sequestration of their BH3 domains, the ratio between the two groups 
determines the susceptibility of cells to the intrinsic death pathway.  Thus, by 
redistributing pro-apoptotic factors at the mitochondrial membrane, p53 initiates 
the intrinsic apoptotic pathway (Miyashita and Reed, 1995; Rodier et al., 2007).  
Anoikis has been demonstrated to be p53-dependent, as anchorage-deprived death 
was suppressed in fibroblasts transfected with dominant-negative p53 (Ilic et al., 
1998).  Consistent with this observation, inhibition of endogenous p53 activity in 
thyroid epithelial cells inhibited anoikis and transformed fibroblasts underwent 
detachment-induced apoptosis only when intact p53 is present (Vitale et al., 
1999).  Thus, in several cell types, substrate-deprived death is regulated by the 
Bcl-2 family of apoptotic protein and central to this regulation is the tumour 
suppressor protein, p53. 
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1.2.3 Anoikis and the death receptor pathway  
 
Studies in non-malignant epithelial and endothelial cells, and recently, in 
malignant cancer cell lines implicate the death receptor pathway in anoikis 
induction (Frisch, 1999; Marconi et al., 2004; Bozzo et al., 2006; Mawji et al., 
2007; Kamarajan et al., 2010).  The extrinsic pathway is initiated by the binding 
of the Fas death ligand (FasL), to its corresponding death receptor, Fas 
(synonyms: Apo-1, CD95, and TNFRSF6) (Figure 1.2; Nagata, 1999; Aoudjit and 
Vuori, 2001).  The binding of the death stimulus results in the recruitment of the 
adaptor protein Fas associated death domain (FADD) as well as the initiator 
procaspase-8, to form a death-inducing signalling complex (DISC) (Peter and 
Krammer, 2003).  Procaspase-8 generally has low activity in the cell, however, 
upon formation of the DISC, procaspase-8 molecules aggregate and autoactivate 
one another to form active caspase-8 (Barnhart et al., 2003).  Activated caspase-8 
then cleaves the effector caspases; procaspase-3, -6 and -7 which are cleaved into 
their active forms (Barnhart et al., 2003; Westhoff and Fulda, 2009).  Thus, the 
effector caspases become catalytically activated and commit the cell to death by 
the concomitant cleavage of structural and repair enzymes.   
 
With respect to Fas-mediated apoptosis, cells are classified as either type I or type 
II (Scaffidi et al., 1998).  In type I cells, Fas activation results in the efficient 
assembly of the DISC and processing of downstream effector caspases.  In 
contrast, in type II cells, the formation of the DISC is impaired and the Fas-
mediated death signal is transmitted via the mitochondrial apoptotic cascade.  
More recently, this hypothesis has been refined by the „lipid raft theory‟ (Simons 
and Ikonen, 1997; Chaigne-Delalande et al., 2008).  The original view that the 
lipid bilayer is a dynamic entity (Singer and Nicolson, 1972) has been revised to 
include ordered lipid assemblies that reside within the fluid membrane (Chaigne-
Delalande et al., 2008).  As these subdomains are enriched with sphingolipids and 
cholesterols they have been described as lipid rafts, detergent-resistant 
microdomains (DRMs) or glycosphingolipid-enriched microdomains (GEMs) 
(Chaigne-Delalande et al., 2008).    Subsequently, the classification of cells as 
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either type I or type II has been attributed to the localisation of Fas within or 
outside the DRMs respectively (Muppidi and Siegel, 2004).  Hence, the 
transmission of Fas-dependent death signals is reliant on the level of Fas residing 
within the lipid rafts (Legembre et al., 2006).  
 
Aberrant regulation of the death receptor signalling pathway is implicated in the 
resistance of anoikis in tumour cells and subsequently, chemotherapeutic therapies 
(Frisch, 1999; Rytoma et al., 1999; Marconi et al., 2004; Mawji et al., 2007).  
Importantly, the detachment of non-malignant cells from the ECM induces 
anoikis through activation of the Fas-mediated apoptosis (Aoudjit and Vuori, 
2001).  Both Fas and FasL levels are upregulated, whilst FLIP levels are reduced 
in HUVEC cells post detachment (Aoudjit and Vuori, 2001; Kamarajan et al., 
2010).  Moreover, these alterations in the extrinsic death intermediates were 
associated with the induction of Fas-mediated apoptosis (Aoudjit and Vuori, 
2001).   In MDCK cells, detachment-induced apoptosis occurs via the death 
receptor pathways, as overexpression of a dominant negative FADD blocked 
anoikis, and led to the activation of caspase-8 and -3 (Rytomaa et al., 1999).  
Consistent with the previous study, both Fas and FasL expression was up-
regulated post detachment.  However, the functional significance of these events 
is uncertain, as the soluble extracellular domains of the death receptors were not 
able to protect against anoikis, even though caspase-8 was activated in a FADD-
dependent manner (Rytomaa et al., 1999).  Moreover, lack of reliance on the 
death receptors was demonstrated in a study by Stupack et al., (2001), where the 
integrin β subunit was shown to recruit caspase-8 to the membrane, and activate 
caspase-8 in a death receptor-independent manner (Stupack et al., 2001).   Hence, 
although the mechanism underlying anoikis appears to be cell-type specific, 
conditions that trigger anoikis converge on the activation of caspase-8 (Kamarajan 
et al., 2010).  In contrast to normal cells, malignant cells fail to activate the death 
receptor pathway upon loss of ECM contact, despite up-regulating Fas and FasL 
(Mawji et al., 2007).  Hence, due to aberrant regulation of Fas-mediated 
apoptosis, tumour cells resist anchorage-independent death, facilitating their 
metastatic progression. 
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1.3 Influence of tumour microenvironment on anoikis regulation 
 
In normal tissue, adhesion to appropriate extracellular matrix proteins is essential 
for survival, and loss of this adhesion induces anoikis via intrinsic or extrinsic 
apoptotic pathways (Ilic et al., 1998; Kurenova et al., 2004; Kamarajan et al., 
2010).  However, tumour cells are able to overcome this regulation and survive in 
the absence of cell adhesion.  Cell anchorage is a multifaceted process involving 
adhesion molecules that interact with different structural components referred to 
as the ECM and neighboring homotypic or heterotypic cells (Grossman, 2002). 
Thus, anchorage-deprived death is associated with the loss of many different 
kinds of cell-cell/cell-matrix interactions.  Hence, the tumour microenvironment 
comprising of non-cancerous cells and the protein network surrounding the 
cancerous mass, is a key regulator of tumour biology.   
 
1.3.1 Cell-cell survival signalling  
 
Signals mediated via direct cell-cell contact of tumour cells may aid survival, as 
ECM-deprived squamous cell carcinoma cells resist anoikis (Kantak and Kramer, 
1998; Zhang et al., 2004 (a)).  At sites of adherens junctions the cell-cell 
connections are mediated by cadherins, transmembrane glycoproteins that 
maintain cell-cell adhesion via a calcium-dependent mechanism (Takeichi et al, 
1990; Yagi and Takeichi, 2000).  Of the 10 subclasses of cadherins that have been 
identified, E-cadherin/ uvomorulin, P-cadherin and N-cadherin are the most 
common and have a unique tissue-specific distribution.  E-cadherin is well 
characterized and its expression is limited to normal epithelial tissue.  As 
cadherins interact homophilically, E-cadherins only interact selectively with other 
E-cadherins and so forth (Shapiro et al., 1995).   
 
The adhesive function of cadherins is dependent on their interaction with 
cytoplasmic proteins.  In the cytoplasm, either α- or β-catenin bind to the cadherin 
to form a link between the adjacent cell and the actin cytoskeleton, thereby 
influencing structural organization as well as development of cells (Takeichi, 
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1990; De Arcangelis and Georges-Labouesse, 2000).  Consequently, altered 
cadherin expression has been reported in many tumours.  Reduced E-cadherin 
expression is associated with an increase in epithelial cell invasiveness and 
dedifferentiation that accompanies the development of various carcinomas (Van 
Aken et al., 2001).  Moreover, blockage of E-cadherin interactions induces 
anoikis (Kantak and Kramer, 1998), whilst overexpression of β-catenin, facilitates 
anchorage-independent growth in epithelial cells (Orford et al., 1999). 
 
1.3.2 Cell-substrate interactions: ultimate regulator of anoikis?  
 
Normal cells introduced into the incorrect microenvironment, due to inappropriate 
cell-substrate engagement, will be driven towards anoikis-dependent death.  
Hence, these cell-ECM connections profoundly regulate cell fate decisions as they 
suppress the proliferation of cells existing outside their appropriate environment 
(Badylak et al., 2009).  Conversely, cancer cells that overcome anoikis regulatory 
mechanisms may populate locations that would normally be incompatible to non-
transformed cells.  Thus, interactions between the ECM and the tumour cell are 
believed to be a main determinant in anoikis resistance (Zhang et al., 2004 (a); 
Kamarajan and Kapila, 2007).  The ECM is composed of a complex network of 
fibrous proteins and glycosaminoglycans that are produced locally and secreted 
via exocytosis.  This extracellular microenvironment functions as a scaffold to 
maintain tissue integrity (Badylak et al., 2009).  In addition, cells directly interact 
with the ECM via surface receptors, such as the integrins, which upon 
engagement with the ECM activate a broad range of signalling cascades that 
regulate apoptosis, cell survival and migration.  The integrins are a family of 
transmembrane glycoproteins that exist as α/β heterodimers (Gilcrease, 2007).  At 
present, 18 α subunits and 8 β subunits have been identified (Nagaprashantha et 
al., 2010).  Both subunits associate at cell adhesion sites known as focal 
adhesions.  The extracellular domains of integrins interact with components of the 
extracellular matrix, including fibronectin, collagen and laminin (Gilcrease, 
2007).  The specificity of these interactions is determined the subunit 
combinations of the integrins as well as the cell type.   
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In Chinese Hamster ovary (CHO) cells and human umbilical vein endothelial cells 
(HUVEC), anoikis is suppressed through interactions between fibronectin and the 
α5β1 integrin (Zhang et al., 1995; Fukai, et al., 1998).  Consistent with these 
reports, survival signals mediated via collagen I/α5β1 interactions protected the 
rat intestinal epithelial cell line (RIE1) from apoptotic stimuli (Lee et al., 2000). 
Mammary epithelial cells derive survival signals from a laminin-rich basement 
membrane or collagen I, utilizing α1, α2, α3 and β1-integrin chain ligation 
(Howlett et al., 1995).  In addition, by blocking the binding of α5β1 integrins to 
collagen, MDCK cells undergo anoikis (Lui et al., 2000).  In the MDA-MB-435 
breast cancer cell line, disrupting survival signals mediated via the α6β1 integrin 
increased apoptotic induction and repressed metastatic growth in vivo, whilst, 
blockage of αvβ3 integrin-mediated signals induced anoikis in breast cancer and 
melanoma (Fukai, et al., 1998; Lui et al., 2000).  Hence, it is evident that aberrant 
integrin/ECM signalling disrupts normal cellular regulation and facilitates the 
metastatic progression of cells.   
 
1.4 Signalling pathways relevant to anoikis converge on key cell 
adhesion intermediates 
 
Due to the crucial role of ECM-integrin signalling in regulating cell survival, the 
signal transduction cascades activated by cell adhesion molecules are central to 
anoikis resistance (Attwell et al., 2000; Kamarajan and Kapila, 2007).  Key 
players in integrin-mediated signal transduction are the integrin-associated non-
receptor kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK).  
Upon integrin-ECM engagement, both ILK and FAK activate various signaling 
pathways involved in cell survival and proliferation (Figure 1.3; Sonoda et al., 
1999; van Nimwegen and van der Water, 2007) including the mitogen activated 
protein kinase (MAPK)/extracellular regulated kinase (ERK) pathway and the 
phosphatidylinositol 3′kinase (PI3K) pathway with its downstream target protein 
kinase B (PKB/AKT) (Gilcrease, 2007).  Unlike FAK, ILK may activate PKB 
directly or indirectly via the PI3K cascade (Attwell et al., 2000). 
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The Jun amino-terminal kinases (JNKs) are a family of MAP kinase related 
serine/threonine kinases.  Early studies indicated that activation of the JNK-
pathway and MAP/ERK Kinase Kinase 1 (MEKK-1) pathway was critical to 
anoikis resistance, as the dissociation of epithelial cells from the extracellular 
matrix induced a substantial increase in JNK activity (Frisch et al., 1996). 
Furthermore, the blockage of the JNK pathway by a dominant-negative form of 
JNK kinase partially inhibited anoikis (Xia et al., 1995).  However,  a recent study 
demonstrated that the level of JNK activation decreased following detachment of 
A549 cells from the ECM, indicating that the role of JNK signalling in anoikis 
resistance may be not be as important as originally believed (Liu et al., 2008). 
 
Alternatively, activation of the PI3K-PKB cascade has been shown to be central 
to anoikis resistance, as enhanced PKB activation is associated with substrate-
deprived survival (Díaz-Montero et al., 2006).  Upon activation, PI3K 
phosphorylates PIP2 on the 3‟OH position to produce PI(3,4,5)P3 (PIP3).  The 
tumour suppressor phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) opposes PI3K-dependent signalling by dephosphorylating PIP3 to PIP2.  
In order for PKB to achieve full activation, phosphorylation at both serine 473 
(Ser473) of the hydrophobic tail and threonine 308 (Thr308) of the activation 
motif is required (Majumder and Sellers, 2005).  To date, several candidate 
kinases are implicated in the regulation of PKB Ser473 phosphorylation including 
the second mammalian target of rapamycin (mTOR)-containing protein complex 
mTORC2 (Sarbassov et al., 2006), choline kinase (Chua et al., 2009) and ILK 
(Attwell et al., 2000).  Acting as a second messenger, PIP3 recruits PKB via its 
pleckstrin homology (PH) domain to the peripheral membrane. Similarly, PDK1 
is also recruited via its PH domain to phosphorylate Thr308 residue of PKB 
(Majumder and Sellers, 2005).   
 
The serine-threonine kinase PKB is a central to cell survival, as anchorage-
mediated signal transduction from FAK and ILK converge on the activation of 
this kinase (Sonoda et al., 1999; Attwell et al., 2000).  Activation of PKB 
negatively regulates apoptotic processes by inhibiting caspase-9 activation, 
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inactivating the proapoptotic proteins bad and bax, (Datta et al., 1997; Cantley, 
2002) and impeding the negative regulation of NF-κB, thus, enhancing the 
transcription of antiapoptotic and prosurvival genes (Duronio, 2008).  
Consequently, reduced PKB-mediated signalling induces the mitochondrial 
translocation of Bad and Bax, thereby altering the Bad/Bcl-2 ratio and increasing 
permeability of the outer mitochondrial membrane (Datta et al., 1997).  In 
addition, PKB activation reduces the transcription of proapoptotic molecules by 
negatively regulating the Forkhead family transcription factors (Brunet et al., 
2001).  Furthermore, by enhancing p53 ubiquitination, phosphorylation of Mdm2 
by PKB antagonizes p53-mediated apoptosis (Duronio, 2008).  PKB activation 
abrogates the activity of the TSC1/TSC2 dimer, by inhibiting the rheb GTPase 
(Sarbassov et al., 2005).  Activated rheb stimulates mTORC1, leading to 
increased protein synthesis via p70 S6 kinase-mediated phosphorylation of 
eukaryotic initiation factor 4E and the ribosomal S6 protein (Sarbassov et al., 
2005).  As previously mentioned, the complete activation of PKB is achieved 
through the second mTOR complex, mTORC2, which phosphorylates PKB on 
serine 473 (Sarbassov et al., 2006).  Thus, it is apparent that based on its central 
role in coordinating cell adhesion-mediated signalling, a particular threshold level 
of PKB-mediated survival signalling is required to oppose substrate-deprived 
death (Ilic et al., 1998; Frisch et al., 1999; Attwell et al., 2000).   
 
As both FAK and ILK suppress anoikis via PKB activation (Sonoda et al., 1999; 
Attwell et al., 2000), it is difficult to discern which kinase is central to anoikis 
resistance.  Furthermore, anoikis induced by ILK inactivation is not rescued by 
FAK, suggesting that the two kinases affect anoikis in different and parallel 
pathways (Attwell et al., 2000).  Consequently, several studies have been 
undertaken to determine which survival signaling molecule is the most important 
to anoikis resistance (Guan and Shalloway, 1992; Ilic et al., 1998; Attwell et al., 
2000; Zhang et al., 2004 (a); Kamarajan and Kapila, 2007).  Although ILK has 
been shown to suppress anoikis, this protection is restricted to PKB-mediated 
survival signalling (Attwell et al., 2000).  In contrast, numerous reports have 
demonstrated that FAK offers protection from anoikis by enhanced activation of 
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PKB-mediated survival as well as directly suppressing apoptotic pathways 
(Sonoda et al., 1999; Kurenova et al., 2004; Golubovskaya et al.. 2005; Lim et al., 
2008).  Accordingly, due to its central role in integrating signals between 
extracellular and intracellular events FAK has been implicated as the key 
intermediate in the acquisition of anoikis resistance (Frisch et al., 1996; Duxbury 
et al., 2004; Zhang et al., 2004 (a); Kamarajan and Kapila, 2007). 
 
1.4.1 Focal adhesion kinase (FAK) is at the hub of cell adhesion events  
 
FAK is a 125 kDa non-receptor protein tyrosine kinase localized to sites of focal 
contact (Figure 1.4; Parsons, 2003; Kamarajan and Kapila, 2007).  The catalytic 
core of FAK is flanked by C- and N-terminal domains.  FAK is directed to focal 
adhesion sites by protein-protein interactions with the C-terminal region, which 
contains the focal adhesion targeting (FAT) sequence (Martin et al., 2002).  This 
region is also critical for interactions with paxillin, a scaffolding protein that 
mediates interactions with integrins (Schaller et al., 1995; Crowe and 
Ohannessian 2004).  The N-terminal region comprises of a sequence with high 
homology to the FERM (erythrocyte band four.1-exrin-radixin-moesin) family of 
proteins (van Nimwegen and van der Water, 2007).  The N-terminal domain of 
FAK associates with the cytoplasmic region of the β subunits of integrins 
(Schaller et al., 1995), the death-receptor complex binding protein RIP (receptor-
interacting protein) (Kurenova et al., 2004) as well as epidermal growth factor 
receptor (EGFR) (Sieg et al., 2000).   
 
Recent studies show the FERM domain directly interacts with the central region 
of FAK, thereby inhibiting its kinase activity (Cooper et al., 2003; Cohen and 
Guan, 2005).  In response to the clustering of integrins at sites of cell contact, the 
FERM domain is proposed to release its autoinhibition of FAK through the 
formation of higher affinity associations with the integrin cytoplasmic tails or 
other integrin-associated proteins (Cooper et al., 2003).  Consequently, FAK is 
activated by autophosphorylation at tyrosine 397 (pFAKTyr397) (Parsons, 2003).  
Tyr397, the main phosphorylation site of FAK both in vitro and in vivo, lies in the 
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linker region between the FERM and kinase domains (Schaller et al., 1994; van 
Nimwegen and van der Water, 2007).  The activation by autophosphorylation of 
FAK, results in the recruitment of proteins with Src homology 2 (SH2) and Src 
homology 3 domains (SH3).  An important SH2 containing protein that interacts 
with FAK at the phosphorylated Tyr397 residue is Src (Mitra and Schlaefper, 
2006).  The crystal structure of the FAK N-terminal region suggests that Src 
binding may also contribute to FAK activation by promoting release of the FERM 
domain from its binding sites on FAK (Ceccarelli et al., 2006).  In addition, two 
residues within the catalytic core, Tyr576 and Tyr577 are phosphorylated in 
response to Src binding (Calalb et al., 1995; Owen et al., 1999; Mitra and 
Schlaefper, 2006).  Thus, Src plays an integral role in FAK regulation, as full 
activation of the FAK kinase domain requires phosphorylation of all three 
tyrosine residues.  The formation of the FAK-Src complex facilitates the 
phosphorylation of Tyr925, allowing Grb2 to bind and activate the MAP kinase 
pathway (Schleapfer et al., 1994; van Nimwegen and van der Water, 2007). 
Moreover, given its location in the focal adhesion targeting domain, Tyr925 
phosphorylation may also negatively affect focal adhesion targeting (van 
Nimwegen and van der Water, 2007).   
 
In addition to Src family kinases, Tyr397-phosphorylated FAK can mediate 
interactions with SH2 domains of several other signaling proteins, including PLC-
γ1, and adaptor proteins, such as Src homology and collagen protein (SHC), Grb7, 
Nck-2, and the p85 subunit of PI3K (Sonoda et al.,1999; Parsons, 2003; Mitra et 
al., 2005; Siesser and Hanks, 2006).  Consequently, FAK activation at sites of cell 
contact increases activation of PKB, the downstream effector of the PI3K cascade 
(Majumder and Sellers, 2005).  Thus, through phosphorylation, FAK activates 
numerous downstream signalling pathways that regulate proliferation, survival 
and migration (van Nimwegen and van der Water, 2007). 
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Figure 1.3: Schematic representation of FAK.  A) The kinase domain of 
FAK is flanked by C- and N-terminal domains.  The main 
phosphorylation site, Tyr397, lies in the linker region between 
the FERM and kinase domains. Upon Tyr397 
autophosphorylation, Src, Grb7 and the p85 subunit of PI3K 
are recruited and Tyr576 and Tyr577 are phosphorylated in 
the catalytic core.  The C-terminal region contains the FAT 
sequence, which localizes FAK to focal adhesion sites and 
interacts with the scaffolding proteins, talin and paxillin. © van 
Nimwegen and van der Water, 2007 B) During attachment of 
cells, the clustering of integrins facilitates the binding of the 
FERM domain of FAK to the cytoplasmic tail of the β subunit 
of the integrins.  Consequently, FAK is unfolded and releases 
the FERM-dependent autoinhibition of FAK, allowing its 
activation by autophosphorylation at Tyr397. © Siesser and 
Hanks, 2006   
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1.5 FAK: the key player in anoikis resistance  
 
The underlying mechanism enabling tumour cells to bypass stringent anoikis-
related regulation appears to rely on constitutive activation of survival signalling 
and the repression of apoptotic pathways (Ilic et al., 1998; Kamarajan et al., 
2010).  Accordingly, studies have demonstrated that constitutive activation of 
FAK is associated with the repression of apoptotic pathways and maintained cell 
survival in the absence of cell contact (Frisch and Francis, 1994; Frisch et al., 
1996; Zhang et al., 2004 (a); Golubovskaya et al., 2005).  Increased Tyr397 
phosphorylation of FAK is associated with enhanced cell adhesion (Guan and 
Shalloway, 1992; Zhang et al., 2004 (a); Kamarajan and Kapila, 2007).  
Correspondingly, constitutively active FAK rescues epithelial cells from anoikis 
and loss of substrate adhesion reduces FAK activation (Frisch and Francis, 1994).  
In addition, a crucial role of FAK in anoikis resistance has been demonstrated as 
expression of CD2-FAK, a fusion protein that retains a high level of Tyr397 
phosphorylation when cells are held in suspension, dramatically opposed anoikis 
(Frisch et al., 1996).  Moreover, knockdown of FAK expression in oral squamous 
cell carcinoma (Zhang et al., 2004 (a)) and pancreatic adenocarcinoma (Duxbury 
et al., 2004) promotes anoikis in these cells.  
 
Enhanced activation of FAK transmits survival signals via the PI3K pathway, as 
phosphorylation of Tyr397 results in PI3K activation by phosphorylation (Figure 
1.4; Sonoda et al., 1999).    However, as previously mentioned, the PI3K cascade 
is not exclusively regulated by FAK (Attwell et al., 2000).  Furthermore, a 
definitive role of aberrant FAK activity in the progression of most tumours has 
been reported (Miyazaki et al., 2003; Lark et al., 2005; Watermann et al., 2005; 
Jiang et al., 2010).  Thus, an alternative survival role of FAK in the regulation of 
anoikis-related events has been proposed.  Although the details of this regulation 
are enigmatic, both the extrinsic and intrinsic apoptotic pathways have been 
implicated in the FAK-dependent suppression of anoikis (Kurenova et al., 2004; 
Golubovskaya et al., 2008; Lim et al., 2008).    
19 
 
 
 
Figure 1.4: FAK-mediated signalling pathways. FAK localizes to 
integrins via interactions with its C-terminal domain. As a 
consequence of FAK-integrin engagement, FAK is 
autophosphorylated at Tyr397 providing a binding site for Src.  
Src further phosphorylates FAK, increasing FAK‟s kinase 
activity.  Consequently, PI3K is recruited to FAK and activates 
PKB.  Once activated by phosphorylation, PKB initiates 
downstream survival events. Interaction of the N-terminal 
domain of FAK with p53 inhibits the transcriptional activity of 
p53, thereby also enhancing survival signalling.  An important 
transcriptional target of p53 is the death receptor, Fas.  
Binding of Grb2 to phosphorylated Tyr 925 results in the 
activation of the Grb2/Ras/ERK pathway which enhances 
survival signalling. Therefore, FAK is at the hub of survival, 
proliferation, adhesion and migration signalling. 
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1.5.1 FAK represses p53-mediated apoptosis 
 
In the absence of cell-ECM interactions, p53 has been implicated in the regulation 
of FAK-dependent anoikis (Figure 1.4; Golubovskaya et al., 2005).  Under 
conditions of ECM deprivation, thyroid epithelial cells undergo anoikis through a 
p53-dependent pathway (Vitale et al., 1998).  A study by Golubovskaya et al. 
(2005) showed that the N-terminal FERM domain of FAK specifically interacts 
with the N-terminal domain of p53.  The p53/FAK has been proposed to inhibit 
p53 activity by enhancing Mdm-2 dependent ubiquitination of p53, or 
alternatively, reducing the transcriptional activity and therefore pro-apoptotic 
effect of p53 (Golubovskaya et al., 2008; Lim et al., 2008).  In another study, 
survival signals mediated by fibronectin and integrin alpha v were shown to affect 
FAK phosphorylation and prevent p53-mediated apoptosis (Zhang et al., 2004 
(a)).  Moreover, loss of cell adhesion increased FAK nuclear localisation, 
enhanced p53 degradation and promoted cell survival (Ilic et al., 1995).  
Therefore, although considerable evidence points to a crucial role of p53 in FAK-
mediated repression of anoikis, the exact function of interplay of FAK and p53 in 
cell function remains to be clarified. 
 
1.5.2 Association between FAK and Fas-mediated apoptosis 
 
Intriguingly, in addition to the mitochondrial-mediated apoptotic pathway, FAK 
has also been implicated in the suppression of the death-receptor pathway (Figure 
1.4). A functional link between FAK and the death receptors has been 
demonstrated (Kurenova et al., 2004; Kamarajan et al., 2010).  Furthermore, a Fas 
antagonistic antibody was shown to rescue SCC from FAK-mediated anoikis 
(Kamarajan and Kapila, 2007) and abrogation of FAK expression has been shown 
to be associated with enhanced caspase-8 activation and the induction of anoikis 
(Kurenova et al., 2004; Kamarajan et al., 2010).  Therefore, although the details 
of crosstalk between Fas and FAK still need to be elucidated, the role of Fas in 
anchorage-dependent survival represents a fascinating step in anoikis control. 
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1.6 Aberrant FAK signalling in tumour progression 
 
 
Advances in the molecular profiling of primary tumours have revealed genes the 
expression of which correlate with the reoccurrence of metastatic cancer (Weigelt 
et al., 2005).  To date, numerous reports have implicated aberrant expression and 
regulation of FAK in facilitating the metastatic progression of tumour cells 
(Miyazaki et al., 2003; Lark et al., 2005; Watermann et al., 2005; Gabriel et al., 
2006; Jiang et al., 2010).  Accordingly, inappropriate expression of FAK has been 
reported in human tumours including oral carcinoma (Schnieder et al., 2002), 
breast cancer (Lark et al., 2005), colorectal carcinoma (Lark et al., 2003), 
oesophageal carcinoma (Miyazaki et al., 2003) and tongue cancer (Jiang et al., 
2010).  In a study of 55 matched pairs of breast cancer and corresponding normal 
tissue, a significant increase in FAK expression was observed by immunoblot 
analysis in the tumour cells with respect to normal tissue (Watermann et al., 
2005).  Analysis of matched normal tissue and primary human colorectal 
adenocarcinomas revealed higher levels of FAK in tumours, whereas reduced 
expression of FAK was found in liver metastases compared with the matched 
primary tumours (Ayaki et al., 2001).  Consistent with this study, reduced FAK 
expression is associated with the progression of cervical cancer and pelvic lymph 
node metastasis (Gabriel et al., 2006).  In contrast to these reports, elevated 
expression of FAK was shown to correlate with increased invasiveness and 
metastasis of HOSCC (Miyazaki et al., 2003).  However, despite these disparities, 
all studies provide compelling evidence for an important role of FAK in tumour 
formation through the aberrant regulation of apoptotic events.    
 
In addition to establishing the role of FAK in the different stages of metastatic 
progression, several reports have highlighted the important role of FAK as a 
mediator of tumourigenesis in vivo (Mclean et al., 2001; Mclean et al., 2004).  A 
study examining malignant papillomas showed that the amounts of FAK were 
similar in the fak
+/-
 and fak
+/+
 mice, suggesting that despite the presence of only a 
single operational fak allele in the fak heterozygous mice, FAK protein expression 
was elevated during tumour progression (Mclean et al., 2001).  Skin-specific 
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deletion of fak after formation of papillomas revealed that FAK is directly 
required for tumorigensis in vivo (Mclean et al., 2004).  As the resultant reduced 
tumour progression is attributed to increased apoptosis after deletion of FAK 
(Mclean et al., 2004), these models support the prominent role of FAK in 
tumourigenesis. 
 
Although a correlation between FAK mRNA levels and protein expression has 
been demonstrated (Golubovskaya et al., 2005), very few studies have examined 
the molecular events that lead to enhanced FAK expression.  Analysis of the FAK 
promoter region revealed binding sites for NF-kappa β and p53 (Golubovskaya et 
al., 2004).  Importantly, NF-kappa β induces, whilst, p53 inhibits transcription of 
FAK (Golubovskaya et al., 2004).  Thus, as aberrant regulation of both these 
proteins is associated with tumourigenesis, it is not surprising that numerous 
reports have linked inappropriate expression and/or activity of FAK to the 
metastatic progression of cancer cells.  
 
1.7 Human oesophageal squamous cell carcinoma (HOSCC) is a 
highly metastatic tumour 
 
Under normal physiological conditions, the oesophagus is lined by stratified 
squamous epithelium (Katada et al., 1997).  These epithelial cells are constantly 
exposed to a fluctuating environment that compromises both the chemical and 
physical integrity of the surface oesophageal keratinocytes.  Consequently, the 
remodelling and turnover of oesophageal epithelial cells is a finely regulated 
mechanism.  As apoptosis is fundamental to normal epithelial cell turnover 
(DeNardi and Riddell, 1991), the modulation of cell death in oesophageal 
squamous epithelium is of particular importance.  Accordingly, the balance 
between cell proliferation and survival becomes disrupted in HOSCC, enabling 
oesophageal tumour cells to escape anoikis-mediated death and metastasize (Lin 
et al., 2009).  Therefore, elucidating the molecular events that facilitate anoikis 
resistance in HOSCC is of particular importance, as HOSCC is a highly metastatic 
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tumour, which evades tissue-dependent restraints through multiple mechanisms 
(Figure 1.5; Tew et al., 2005).       
 
HOSCC is a cancer of variable geographical distribution and is currently ranked 
the sixth most common cause of cancer death worldwide (McCabe and Dlamini, 
2005).  Due to insensitivity to the apoptosis-inducing ability of chemotherapeutic 
reagents, prognosis remains poor with the survival rate over 5 years just under 
10% (Lerut, 1999; Shibakita et al., 2000; Tew et al., 2005).  The highest mortality 
rates of the disease are in China, with an elevated occurrence of the disease in 
Western Europe, Japan, South America, South Africa and the former Soviet 
Union (Pickens and Orringer, 2003).  Universally oesophageal cancer is more 
common in men and is currently the second most common cancer in the South 
African male population, and the most common cancer in the South African black 
male population (McCabe and Dlamini, 2005).  Its prevalence also increases with 
age with a peak in incidence between 65 to 70 years of age (Lerut, 1999).   
 
A multistage process has been proposed for the evolution of HOSCC, in which 
normal squamous epithelia progress from non-invasive precursor lesions, towards 
invasive cancer that metastasizes to the lymph nodes and other organs (Bird-
Lieberman and Fitzgerald, 2009).  With respect to diagnosis and prognosis, 
HOSCC tumours are placed into three categories based on their morphological 
appearance and tissue architecture.  Briefly, well-differentiated tumours have a 
high level of keratinisation whilst, poorly-differentiated tumours have reduced 
keratin levels and pleomorphic nuclei (Grace et al., 1985).  Tumours intermediate 
to the well- and poorly differentiated categories are classified as moderately-
differentiated.  Consequently, these clinicopathological categories are extremely 
broad, especially the moderately-differentiated category, into which many 
borderline cases are placed.  However, the visual classification of oesophageal 
tumours may not reflect their metastatic potential, as in vitro studies show that 
oesophageal tumour cells from all three categories achieve metastasis (Robinson 
et al., 1982).  Hence, it is evident that the visual classification of oesophageal 
tumours alone is not sufficient to predict oesophageal tumour prognosis.  
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Consequently, the molecular analysis of the protein alterations accompanying 
HOSCC progression is critical to provide a more consistent method of detecting 
and diagnosing this cancer.   
   
1.7.1 Molecular events underlying anoikis resistance in HOSCC 
  
HOSCC is highly resistant to apoptotic stimuli due the upregulation of anti-
apoptotic proteins including Bcl-2, Bcl-x, and survivin, and the suppression of 
proapoptotic proteins including p53, BAX, Fas and FasL (Chang et al., 2005; 
Takikita et al., 2009).  The loss of the tumour suppressor function of p53 is 
proposed to be an early event in the development of oesophageal carcinoma 
(Stoner and Gupta, 2001).  Mutations between exon 5 and exon 8 are common in 
HOSCC (Gamieldien et al., 1998; Li et al., 2004), with 85% of the p53 mutations 
being GC to AT transitions and 69% located in CpG dinucleotides (Wang et al., 
2003).  In particular, mutations in codons 175, 248, and 273 of p53 facilitate the 
progression of HOSCC (Wang et al., 2003; Vrba et al., 2008).  These single base 
mutations abolish the ability of p53 to transcriptionally activate apoptotic 
proteins, thereby, altering cell cycle control and suppressing apoptosis (Robert et 
al., 2000).  Consequently, due to the reduced sensitivity to apoptotic stimuli, 
HOSCC tumours harbouring a “hot spot” p53 mutant are highly resistant to 
conventional chemotherapy (Inaba et al., 1986; Robert et al., 2000). 
 
HOSCC has been shown to be nonresponsive to Fas-mediated apoptosis (Rigberg 
et al., 1999).  Both Fas and FasL have been demonstrated to be downregulated at 
early stages during the development of HOSCC (Xue et al., 2006).  FADD, on the 
other hand, was shown to be overexpressed in oesophageal carcinoma, whilst 
caspase-8 was strongly downregulated (Xue et al., 2006).  In addition, Hughes 
and colleagues demonstrated that wt Fas was retained in cytoplasm and did not 
translocate to membrane (Hughes et al., 1997).  Thus, perturbations in the Fas-
mediated death cascade are pivotal to HOSCC progression. 
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In addition to deregulation of both intrinsic and extrinsic cell death pathways, 
aberrant regulation of cell adhesion-mediated signalling pathways is implicated in 
tumour development and metastasis of oesophageal cancer (Leu et al., 2000).  
HOSCC cell lines showed higher levels of αv integrin expression when compared 
to normal oesophageal tissue (Miller and Veale, 2001).  In addition, expression of 
the α2 and β1 subunits was reduced (Miller and Veale, 2001).  Moreover, 
overexpression of FAK has been shown to be correlated with increased 
invasiveness of HOSCC (Miyazaki et al., 2003).  Hence, as FAK coordinates p53 
and Fas-dependent death processes, these studies suggest that aberrant regulation 
of FAK may be central to anoikis resistance in HOSCC.    
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Figure 1.5: Biological functions of deregulated proteins in HOSCC.  A large portion of deregulated proteins in HOSCC are 
involved in signal transduction, apoptosis and cell adhesion.  Adapted from Lin et al., (2009)
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1.8 Aims 
 
Although aberrant regulation of FAK has been implicated in anoikis resistance, 
the details of FAK-dependent anoikis regulation are cryptic.  Pertinently, an 
important role of FAK in HOSCC metastasis has been demonstrated (Miyazaki et 
al., 2003).  Thus, with the aim of characterising the molecular events that 
underpin anoikis resistance in HOSCC, we sought to:    
i. Establish the relative expression and cellular distribution of the key 
anoikis-related intermediates, FAK, p53 and Fas in a system of moderately 
differentiated HOSCC cell lines.   
ii. Ascertain whether a relationship exists between FAK-dependent signalling 
and apoptotic sensitivity in HOSCC.  
iii. Establish whether the interaction between the major apoptotic constituents 
and FAK underlies anoikis resistance in HOSCC. 
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Chapter 2 
Monitoring of typical anoikis-related intermediates in 
human oesophageal squamous cell carcinoma cell lines  
 
2.1 Introduction 
In the absence of cell-ECM contact, both the extrinsic and intrinsic apoptotic 
pathways have been implicated in the induction of anoikis (Kurenova et al., 2004; 
Golubovskaya et al., 2005).  Fundamental to this anoikis-related regulation is 
FAK, a vital mediator of survival signalling at sites of cell contact (Schaller et al., 
1992; van Nimwegen and van der Water, 2007).  Adhesion to ECM components 
including fibronectin (Zhang et al., 2004 (a)) and collagen type IV (Sanders and 
Basson, 2000; Crowe and Ohannessian, 2004) increase activation of FAK by 
Tyr397 phosphorylation.  Accordingly, increased Tyr397-phosphorylated FAK is 
associated with enhanced cell adhesion (Guan and Shalloway, 1992; Kamarajan 
and Kapila, 2007).  In addition to regulating cell adhesion-mediated signalling, 
activation of FAK, through Tyr397 autophosphorylation, regulates processes 
critical to embryonic development including migration and proliferation.  
Consequently, FAK-null embryos die at day 8.5 and exhibit impaired vascular 
development, endothelial migration and tube formation, processes under stringent 
regulation by apoptosis (Ilic et al., 1995).  Accordingly, the inhibition of FAK 
expression with oligonucleotides has been shown to induce cell rounding, 
detachment and apoptosis, whilst, constitutively active FAK suppresses anoikis 
and induces tumour formation in nude mice (Lim et al., 2008).  Therefore, due to 
its central role in coordinating cell adhesion and apoptotic events, aberrant 
regulation of FAK is implicated as the key cell adhesion-related event involved in 
the acquisition of anoikis resistance (Frisch et al., 1996; Duxbury et al., 2004; 
Zhang et al., 2004 (a); Kamarajan and Kapila, 2007).  
 
Survival signals transduced via ECM-activated FAK are reported to suppress 
apoptotic stimuli through the activation of the PI3K/PKB pathway (Sonoda et al., 
1999).  However, a report in a substrate-dependent squamous cell carcinoma cell 
29 
 
line revealed that ECM-mediated survival signals were independent of FAK-
dependent activation of PKB (Zhang et al., 2004 (a)).  Notably, increased 
activation of FAK by ECM influence, led to the suppression of p53-dependent 
apoptosis (Zhang et al., 2004 (a)).  Furthermore, under conditions of ECM 
deprivation and reduced FAK-dependent signalling, cells undergo anoikis through 
a p53-mediated pathway (Ilic et al., 1998; Zhang et al., 2004 (a)).  A specific 
interaction between the N-terminal of FAK and p53 has been demonstrated to 
inhibit p53 activity by enhancing Mdm-2-dependent ubiquitination of p53, or 
alternatively, inhibiting p53 transcriptional activity (Golubovskaya et al., 2008; 
Lim et al., 2008).  Moreover, p53 regulates FAK at a transcriptional level, as p53 
binding sites have been identified on the FAK promoter (Golubovskaya et al., 
2005).  Hence, the alternative survival role of FAK in the regulation of the p53-
mediated intrinsic apoptotic pathway may facilitate the survival of tumour cells in 
the absence of cell contact. 
 
In addition to the multiple levels of regulation identified between p53 and FAK, a 
functional link between FAK and Fas-mediated apoptosis has also been 
demonstrated (Kurenova et al., 2004; Kamarajan et al., 2010).  The interaction 
between the Fas receptor and its associated ligand (FasL) initiates the death 
receptor pathway of apoptosis (Nagata, 1999; Aoudjit and Vuori, 2001).  Both Fas 
and FasL were upregulated following detachment from the ECM and a Fas 
antagonistic antibody protects SCC cells from FAK-mediated anoikis (Ishida et 
al., 2003; Kamarajan et al., 2010).  Moreover, recent studies have shown that 
caspase-8 inhibition abrogates anoikis, further implicating Fas-mediated apoptosis 
in anoikis induction (Kamarajan et al., 2010).  In addition, p53 alters Fas 
expression by activating a p53-responsive region on the Fas promoter (Munsch et 
al., 2000; Zalcenstein et al., 2003).  Consequently, interplay between the two 
major apoptotic constituents and FAK is critical to anoikis-related regulation.   
 
Nonetheless, although these reports link aberrant regulation of FAK to anchorage-
dependent survival, the mechanism underlying resistance to anoikis remains 
obscure.  Moreover, while some information has been reported regarding the 
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prognostic significance of FAK, p53 and Fas in HOSCC progression (Miyazaki et 
al., 2003; Xue et al., 2006), there are no published reports on the role of these 
intermediates in anoikis-related signalling events.  Furthermore, HOSCC 
progression is associated with constitutive activation of FAK, aberrations in the 
Fas-mediated death cascade and loss of the tumour suppressor function of p53 
(Miyazaki et al., 2003; Xue et al., 2006).  Thus, with the aim of characterising the 
molecular events that underpin anoikis resistance in HOSCC, the expression and 
localisation of the key anoikis-related intermediates was established in a series of 
moderately differentiated HOSCC cell lines.   
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2.2 Material and Methods 
 
2.2.1 Cell lines 
The five moderately differentiated human oesophageal squamous carcinoma cell 
lines; WHCO1, WHCO3, WHCO5, WHCO6 (Veale and Thornley, 1989) and 
SNO (Bey et al., 1976) were obtained from the Cell Biology Laboratory, School 
of Molecular and Cell Biology, University of the Witwatersrand.  The HT29 cell 
line harbouring the mt p53-R273H (Bossi et al., 2006), derived from human colon 
adenocarcinoma and the caspase-3 null MCF7 cell line, derived from human 
breast carcinoma was supplied by The America Type Culture Collection (ATCC).  
Cell lines were cultured in 10 cm tissue culture dishes (Corning) and maintained 
in Dulbecco's Modified Eagles Medium (DMEM) (Appendix 1.1.1)/Hams F12 
(3:1) (Appendix 1.1.1), supplemented with 10% Foetal Calf Serum (FCS) 
(Highveld Biologicals).  Cultures were maintained in a humid, 37 °C incubator 
with 5% carbon dioxide atmosphere. 
 
Once cells achieved a confluence of 80%, the medium was aspirated and the 
monolayer of cells washed with the sterile phosphate buffered saline (PBS) 
(Appendix 1.1.3).  2 ml of a trypsin (Gibco BRL) and ethylenediaminetetra-acetic 
acid (EDTA) (BDH Laboratory reagents) solution was then dispensed into the 
culture vessel and placed into an incubator at 37 °C for 5 min.  Medium 
containing 10% FCS was then added to the cell suspension and grown as above. 
 
2.2.2. Total RNA extraction 
Total RNA was isolated from the HOSCC cell lines using the Trizol® reagent 
(GibcoBRL). Cells were grown to a confluence of 80%.  Serum containing media 
was aspirated and the cells rinsed three times in PBS.  Adhered cells were covered 
in a thin film of PBS, scraped from the culture dish and added to an Eppendorf.  
Excess PBS was removed by centrifugation at 1145 X g in a TOMY HF-120 
centrifuge for 3 min.  The supernatant was replaced with 1 ml Trizol reagent and 
vortexed briefly.  The homogenized sample was incubated at room temperature 
for 5 min.  200 μl of chloroform was added, mixed well by vigorous shaking and 
incubated at room temperature for a further 3 min. Samples were centrifuged at 12 
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000 x g at 4 °C for 15 min to separate phases.  The aqueous phase was transferred 
into a fresh Eppendorf.  500 μl of isopropyl alcohol was added to the aqueous 
phase, mixed thoroughly be shaking for 15 sec and incubated at room temperature 
for 10 min.  Samples were centrifuged at 12 000 x g at 4 °C for 10 min to pellet 
RNA.  The supernatant was removed, 1 ml 75% ethanol added to the Eppendorf 
and vortexed briefly to wash the pellet thoroughly.  Samples were centrifuged at 
12 000 x g at room temperature for 5 min to re-pellet RNA.  The supernatant was 
removed and the pellet air-dried at room temperature for 10 min.  The pellet was 
dissolved in dH2O (30-100 μl, depending on yield) by gentle pipetting, incubated 
at 60 °C for 10 min and stored at -70 °C).  Integrity of the RNA was established 
by electrophoresis of the RNA on a 1 % agarose gel (Appendix 1.4.1). 
 
2.2.3 Reverse transcription 
Once the integrity of the RNA was confirmed, the RNA was reversed transcribed 
into cDNA.  2 μl of random primers (Oligo T random hexamers) were added to 2 
μl of RNA extracted from the HOSCC cell lines, and incubated at 60 °C for 10 
min.  Samples were placed on ice for 5 min and centrifuged at 1145 x g for 1 min. 
The following was then added to the Eppendorf: 5 μl 5X MMLV-RT buffer, 0.6 
μl RNAsin, 1 μl MMLV-RT and 12.5 μl dH2O. The samples were incubated at 37 
°C for 1 hr and the reaction was terminated by incubation at 90 °C for 5 min. A 
phenol:chloroform (25:24) solution was added to the sample and vortexed briefly.  
The samples were centrifuged at 12 000 x g at room temperature for 5 min.  The 
aqueous phase was then transferred into a fresh Eppendorf, 70 μl chloroform was 
added to the Eppendorf and centrifuged as above.  The aqueous phase was 
transferred into a fresh Eppendorf and the volume measured by pipetting.  Three 
times the volume of 100 % ethanol and 10 % sodium acetate was added.  The 
sample was precipitated overnight at -20 °C.  Samples were centrifuged at 12 000 
x g at 4 °C for 20 min.  The supernatant was removed and the pellet air-dried at 
room temperature for 1 hr and resuspended in 10 μl dH2O or 1- 2 hr.  Samples 
were stored at -70 °C.  cDNA was visualized on a 1 % agarose gel (Appendix 
1.4.1). 
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2.2.4 Polymerase chain reaction (PCR)  
 As interplay between FAK and the major apoptotic constituents is the primary 
focus of this study, primers were designed to amplify the FERM domain, the 
region of FAK involved in protein-protein interactions.  Primers used to amplify 
the FERM domain were as follows: 
Forward primer 5‟ GGACAGTCACAAAGTAAAGC 3‟  
Reverse primer 5‟ ATTGTCTAAATGTTTGTTGG 3‟ 
Thermal cycle conditions included denaturation at 95 °C for 10 min and 32 cycles 
of denaturation at 95 °C for 0.5 - 1 min; annealing at 56 °C for 0.5 - 1min and 
extension at 72 °C for 1min with a final elongation at 72 °C for 10min.  PCR 
products were visualized on a 1 % agarose gel following ethidium bromide 
staining.  Fragments were sent to Inqaba Biotech for sequencing.  A representative 
sequence trace is included in Appendix 3.1. 
 
2.2.5 Antibodies  
FAK, p53 and Fas were specifically detected with rabbit polyclonal antibodies 
obtained from SantaCruz Technology.  Monoclonal mouse anti-pFAK(Tyr397) 
(Millipore) was used to detect Tyr397 autophosphorylation of FAK.  Polyclonal 
horseradish peroxidase (HRP)-bound anti-rabbit secondary antibody (Separations, 
SA) and fluoroscine isothiocyanate (FITC)-conjugated anti-rabbit secondary 
antibody (Chappel, USA) were used in the immunoblot and immunofluorescence 
experiments respectively. 
 
2.2.6 Protein estimation assay 
A protein estimation assay was performed based on the protocol proposed by 
Bramhall et al. (1969).  Cells were lysed in RIPA buffer (Appendix 1.3.2) for 30 
min at 4 °C.  2 μl of the resultant lysate was spotted onto hydrated filter paper 
disks (Whatman) and allowed to dry.  Bovine serum albumin (BSA) (BDH 
Laboratory reagents) was solubilized in single lysis buffer to create the protein 
standard concentrations; 1 μg, 3 μg, 6 μg, 12 μg, 16 μg and 20 μg.  The protein 
standards were spotted onto the disk to create a standard curve.  Paper disks were 
dried in the fume hood.  Samples were fixed to the support medium with 7.5 % 
trichloroacetic acid (TCA) for 45 min.  Excess acid was removed with 0.25 % 
34 
 
Coomasie Blue (Appendix 1.2.1) and then stained in Coomasie Blue for 1 hr.   
The filter paper was destained with a destain solution (Appendix 1.2.2) for 1 hr.  
Stained samples were cut out of the filter paper and incubated in elution solution 
(Appendix 1.2.3) overnight.  The following day, the absorbance of the elution 
solution was determined at 596nm (Beckman Du
®
64 Spectrophotometer). 
 
2.2.7 Immunoblot analysis 
40 µg of protein per lane was separated on a 10% SDS-PAGE gel (Appendix 
1.4.4) according to Laemmli (1970) at a constant current of 18 milliamperes (mA) 
with electrophoresis running buffer pH 8.3.  Samples were electro-blotted onto a 
nitrocellulose membrane (Sartorius), using the Biorad mini trans-blot system at 
400 mA for 3 hr (4 °C) in Western Blot Transfer Buffer (Appendix 1.5.1). After 
transfer was complete, the nitrocellulose membranes were rinsed twice with PBS 
(see Appendix 1.1.3), and stored overnight at 4 °C.  Transfer efficiency was 
checked by staining the gel with Coomasie Blue (Appendix 1.2.1).  Non-specific 
binding sites on the membrane were pre-blocked in blocking buffer (Appendix 
1.5.2) for 1 hr.  Blots were incubated with anti-FAK for 1 hr or overnight with p-
FAK(Tyr397) in 1 % BSA.  Washing was performed 6 times at 5-min intervals 
with PBS to remove any residual antibody.  Following incubation in HRP-
conjugated secondary membranes were washed 6 times at 5 min intervals with 
PBS before being exposed to the SuperSignal West Pico Chemiluminescent 
working solution (Appendix 1.5.3), from the West Pico Chemiluminescent 
Substrate Kit (Pierce, USA) for 5 min.  Blots were sealed in polyethylene wrap 
and exposed to hyperfilm™ MP autoradiography film (Amersham, UK) for 10 
min.  Film was developed in developer (see Appendix 1.5.4) for 5 min, rinsed 
briefly in H2O before fixing (see Appendix 1.5.5) for 5 min.  Each immunoblot 
was repeated three times. 
 
2.2.8 Indirect immunofluorescence 
The visual determination of FAK, p53 and Fas was determined by indirect 
immunofluorescence.  Cultured cells were washed four times with cold PBS, 
fixed with 4% paraformaldehyde (Appendix 1.6.1) for 30 min and washed twice 
with PBS.  Following permeabilisation with 0.25 % Triton X-100 for 10 min, cells 
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were rinsed twice with PBS and allowed to dry partially. A fluid barrier created 
by the DAKO pen allowed the separate incubation of antibodies.  Fixed cells were 
incubated with anti-FAK (1:250), anti-p53 (1:500) and anti-Fas (1:200) antibody 
for 1 hr at room temperature. Following incubation with the anti-rabbit 
fluoroscine isothiocyanate-conjugated secondary antibody (1:250) for 1 hr, 
Elvanol mounting agent (Dupont) was added to the wells and cells were viewed at 
400 X magnification under a Zeiss LSM 410 confocal microscope (FITC 
excitation 490, emission 525).  Immunofluorescence assays were repeated three 
times. 
 
2.2.9 Co-immunoprecipitation 
5 X 10
6
 cells were lysed in RIPA buffer (Appendix 1.3.2) for 30 min at 4 °C.  The 
lysates containing 350 μg protein were incubated with 3 μl of anti-integrin β1 at 4 
°C for 6 hr.  Then 20 μl of protein G-Sepharose beads were added to each lysate at 
4 °C for overnight. The protein G-FAK-β1 complex was centrifuged at 3000 
r.p.m. in a Sorvall® MC 12 V centrifuge for 2 min. The supernatant was decanted, 
and 800 µl Tris.HCl buffer pH 8.0 added.  The supernatant was decanted and an 
equal volume (45 µl) of double lysis buffer (Appendix 1.3.1) was added to the 
pellet. The suspension was boiled for 5 min and centrifuged for 10 min at 12000 
r.p.m. in a Sorvall® MC 12 V centrifuge.  Samples were separated by SDS-PAGE 
and blotted onto nitrocellulose membranes (See 2.2.7).  Blots were incubated in 
anti-FAK and anti-pFAKTyr397 to determine the relative association with 
integrin β1.      
 
2.2.10 Densitometry  
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) 
was used for densitometric analysis to semi-quantitatively determine the 
concentration level of protein in the western blots.   
 
 2.2.11 Image Capturing  
Images were captured on a Hewlard Packard Scanjet 4400c series scanner. 
Brightness, contrast and magnification of all images were standardised using 
Corel Paint Shop Pro X.    
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2.3 Results 
 
2.3.1 HOSCC cell lines express Tyr397-phosphorylated FAK  
 
FAK was originally isolated as a highly tyrosine phosphorylated tyrosine kinase 
from v-Src transformed chicken embryo fibroblasts, and later in epithelial tissues, 
including oesophageal keratinocytes (Schaller et al., 1992; Whitney et al., 1993).  
Pertinent to anoikis-related events, overexpression of FAK correlates with 
enhanced invasiveness and metastasis of oesophageal cancer (Miyazaki et al., 
2003).  As anoikis-related signalling has never been investigated in HOSCC, two 
control cells with documented resistance to anoikis were included in the study.  
Specifically, the colon adenocarcinoma HT29 cell line as it is highly resistant to 
apoptotic stimuli due to harbouring the transcriptionally inactive p53 mutant 
R273H (Lin-Lee et al., 2001; Bossi et al., 2006), and the MCF-7 cell line as it 
lacks functional caspase-3 and is therefore nonresponsive to caspase-related 
apoptotic events (Jánicke et al., 1998; Mooney et al., 2002).   
 
Transcription of the fak gene in the HOSCC and control cell lines was established 
by RT-PCR analyses.  The success of the RNA extraction was confirmed by the 
presence of bands at 650bp and 1500bp resolved by agarose gel electrophoresis, 
representing the 18S and 28S subunits of ribosomal RNA subunits respectively 
(Figure 2.1A).  Reverse transcription yielded a smear indicative of a broad range 
of different sized cDNA transcripts (Figure 2.1B).  Sequence analysis of the 
resultant 476bp fragment confirmed the integrity of the FERM domain across the 
cell lines (Figure 2.2).   
 
Consistent with previous studies (Schaller et al., 1992; Ilic et al., 1998; 
Golubovskaya et al., 2005), following detection with a polyclonal anti-rabbit FAK 
antibody, a band at 125 kDa was detected by immunoblot analysis across cell 
lines (Figure 2.3A).  Despite standardised protein loading of 20 μg, densitometric 
analysis revealed differential FAK expression across the cell lines, with the 
WHCO6, SNO and WHCO5 cell lines having higher FAK expression relative to 
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the other four cell lines (Figure 2.3B).  However, with respect to the seven cell 
lines, the WHCO6 cell line had the highest FAK expression overall.  Both the 
WHCO1 and WHCO3 cell lines had the lowest FAK protein expression, at 5 and 
4.5 fold less than the WHCO6 cell line respectively.   
 
The structure of the FAK protein includes: the N-terminal domain with the 
primary autophosphorylation site, Tyr397, the central catalytic kinase domain and 
the C-terminal domain containing the focal adhesion targeting (FAT) subdomain 
(Parsons, 2003).  The Tyr397 autophosphorylation site of FAK is critical to FAK-
dependent survival signalling (Sonoda et al., 1999; Parsons, 2003).  As FAK was 
differentially expressed across the seven cell lines (Figure 2.3B), we established 
whether there was a relationship between Tyr397 phosphorylated-FAK and FAK 
concentration in these cell lines.  Using the same whole cell extracts as above, a 
monoclonal antibody specific for the Tyr397 autophosphorylation site was used to 
detect Tyr397-phosphorylated FAK across the cell lines (Figure 2.3A).  Despite 
standardised loading of 80 μg, Tyr397-phosphorylated FAK was only detected in 
the cell lines with the highest FAK expression (WHCO6 and SNO) (Figure 2.3C).  
This raised the possibility that the other cell lines were resistant to FAK 
phosphorylation.  Alternatively, due to the specificity of the antibody and lower 
level of FAK expression in the other cell lines, the level of pFAKTyr397 was 
below the detection level of the monoclonal antibody.  Hence, to ascertain 
whether pFAKTyr397 was dependent on FAK concentration, we assessed if co-
immunoprecipitation of FAK would enable the detection of the 
autophosphorylation site.  Accordingly, pFAKTyr397 was detected in FAK-
immunoprecipitated samples of the WHCO1, WHCO3, WHCO5, MCF7 and 
HT29 cell lines (Figure 2.4).  Thus, the HOSCC, MCF7 and HT29 cell lines all 
express Tyr397-phosphorylated FAK.  However, pFAKTyr397 was only 
detectable by immunoblot in the cell lines with the highest FAK expression 
(WHCO6 and SNO). 
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Figure 2.1: Efficacy of RNA extraction and reverse transcription 
reaction in the HOSCC, MCF-7 and HT29 cell lines. A) The 
integrity of the RNA was established by electrophoresis of the 
RNA on a 1% agarose gel. Two bands representing 28S and 
18S (black arrows) RNA is clearly evident in the cell lines.  B) 
The presence of cDNA was verified by the electrophoresis of 
the cDNA on a 1% agarose gel. The smear is indicative of 
cDNA.  MWM – GeneRulerTM 1kb DNA ladder 
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Figure 2.2: The FERM domain is intact in HOSCC cell lines. A) RT-
PCR products were resolved by 2 % agarose gel 
electrophoresis following EtBr staining (10 μg/ml).  A band of 
476 bp was observed in HOSCC, MCF7 and HT29 cell lines. 
B) Sequence analysis of the FAK transcript revealed the 
FERM domain is intact in HOSCC, MCF7 and HT29 cell lines. 
MWM – GeneRulerTM 1kb DNA ladder 
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See next page for legend. 
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Figure 2.3: HOSCC cell lines differentially express Tyr397-
phosphorylated FAK.  A) FAK was detected at 125kDa in the 
HOSCC series of cell lines, as well as the MCF7 and HT29 
control cell lines.  A monoclonal anti-phosphoTyr397 antibody 
was used to detect autophosphorylation of FAK under normal 
tissue culture conditions.  pFAKTyr397 was only detected in 
the WHCO6 and SNO cell lines by immunoblot.  The tubulin 
loading control demonstrates equal protein loading of the 
whole cell extracts. B) Densitometric analysis revealed that the 
WHCO6 cell line expressed the highest level of FAK, whereas 
the lowest FAK expression was in the WHCO1 and WHCO3 
cell lines respectively.  C) The highest level of pFAKTyr397 
was detected in the WHCO6 cell line. Note: the expression 
levels are relative to the maximum per 20µg (FAK) and 80µg 
(pFAKTyr397) of protein in the WHCO6 cell line.  The western 
blots were repeated three times (See Appendix 2 for 
representative western blot of entire gel). 
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Figure 2.4:   HOSCC, MCF7 and HT29 cell lines express Tyr397-
phosphorylated FAK.  pFAKTyr397 was detected in the 
FAK-immunoprecipitates in the WHCO1, WHCO3, WHCO5, 
MCF7 and HT29 cell lines.  A whole cell lysate was included 
for each immunoblot to demonstrate the specificity of the 
immunoprecipitation reaction.  A negative control (protein G 
sepharose + 2μl anti-FAK antibody) was included to 
demonstrate absence of IgG chains at the size of FAK 
(125kDa). 
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2.3.2 FAK localises to the cytoplasm in HOSCC cell lines 
 
In other cell types, FAK is a cytoplasmic protein localised to sites of focal contact 
by integrin clustering (Schaller et al., 1994; Sonoda et al., 1999).  In the HOSCC, 
MCF7 and HT29 cell lines under normal tissue culture conditions, FAK was 
localised primarily to the cytoplasm (Figure 2.5).  However, even though FAK 
was named according to its localisation at focal adhesions, several reports have 
shown the accumulation of FAK in the nucleus (Levkau et al., 1998; Lobo and 
Zachary, 2000; Golubovskaya et al., 2005).  Consistent with previous reports 
(Lobo and Zachary, 2000), nuclear localisation of FAK was evident in the 
WHCO1, WHCO3 and HT29 cell lines (Figure 2.5). 
 
2.3.3 FAK and integrin β1 association in HOSCC cell lines 
 
The direct interaction between the FERM domain of FAK and the cytoplasmic tail 
of the β1 integrin subunit is an important regulator of Tyr397 phosphorylation and 
localisation of FAK (Schaller et al., 1994).  As we have shown that the protein-
protein interacting domain of FAK is intact in the HOSCC cell lines (Figure 2.2), 
we assessed by co-immunoprecipitation whether a similar association is present in 
the HOSCC cell lines.  We clearly show in the representative cell lines (WHCO6 
and SNO) an association between FAK and integrin β1 (Figure 2.6A).  The direct 
interaction between the FERM domain of FAK and the cytoplasmic tail of the β 
integrin subunit results in the rapid autophosphorylation of Tyr397 (Schaller et 
al., 1994).  Accordingly, in the representative cell lines (WHCO6 and SNO), an 
interaction between integrin β1 and Tyr397-phosphorylated FAK was detected 
(Figure 2.6B).   
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Figure 2.5: FAK localises primarily to the cytoplasm in the HOSCC, 
HT29 and MCF7 cell lines.  Although FAK was primarily 
localised to the cytoplasm in HOSCC cell lines, a small 
proportion was detected in the nucleus in the WHCO1 and 
WHCO3 cell lines under normal tissue culture conditions, 
following immunofluorescent detection.  Nuclear FAK was 
observed in the colon adenocarcinoma HT29 cell line 
harbouring mt p53-R273H.  Negligible diffuse staining was 
observed in the negative control (excluding anti-FAK 
antibody).  Scale bar = 25μm 
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Figure 2.6: Integrin β1 associates with Tyr397-phosphorylated FAK in 
HOSCC cell lines.  A) FAK was detected in complex with 
immunoprecipitated integrin β1 in the WHCO6 and SNO cell 
lines.  B) Tyr397-phosphorylated was detected by immunoblot 
analyses in the anti-integrin β1 immunoprecipitates.  A whole 
cell (W/C) WHCO6 loading control was included for each 
immunoblot to illustrate the specificity of the 
immunoprecipitation reaction.  A negative control (protein G 
sepharose + 2μl anti-integrin β1 antibody) was included to 
demonstrate absence of IgG chains at the size of FAK 
(125kDa). 
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2.3.4 HOSCC cell lines express p53 
 
In vitro, abrogation of FAK-dependent signalling induces p53-dependent 
apoptosis (Golubovskaya et al., 2005; Golubovskaya et al., 2008).  Western blot 
analysis of untreated cell lysates revealed that all of the HOSCC cell lines express 
p53 (Figure 2.7A).  Under standard tissue culture conditions, the WHCO6 cell 
line had the highest p53 expression, 1.2 fold higher than that of the SNO cell line 
and 1.3 fold higher than the HT29 cell line (Figure 2.7B).  The lowest p53 
expression was observed in the wt p53 MCF7 caspase-3 null control cell line, on 
average approximately 5 fold less than the WHCO6 and SNO cell lines (Figure 
2.7B). 
 
2.3.5 p53 is localised to the nucleus in HOSCC cell lines 
 
Nuclear import or retention of p53 is critical for its ability to control growth 
inhibition or induction of apoptosis at a transcriptional level (Ryan et al., 1994; 
Knippschild et al., 1996; Moll et al., 1996; Golubovskaya et al., 2008).  
Immunofluorescence clearly revealed in all the HOSCC cell lines that p53 is 
localised to the nucleus (Figure 2.8), supporting the role of p53 as a transcription 
factor in these cell lines.  Similar to the HOSCC cell lines, in the HT29 cell line 
harbouring the mt p53-R273H, p53 was localised to the nucleus.  Studies in breast 
cancers have reported wild-type p53 being sequestered in the cytoplasm, 
suggesting that defects in the nucleocytoplasmic transport of p53 facilitates 
tumourigenesis in these cells (Ogretmen and Safa, 1997).  Consistent with this 
previous report, p53 was localised primarily to the cytoplasm in the MCF7 cell 
line (Figure 2.8). 
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Figure 2.7: p53 is differentially expressed in the HOSCC, MCF-7 and 
HT29 cell lines under standard tissue culture conditions. 
A) Western blot analysis of the cell lysates using a polyclonal 
antibody against human p53.  The highest level of p53 
expression was observed in the WHCO6 and SNO cell lines. 
B) Densitometric analysis of the immunoblot was performed 
using Labworks™ Image Acquisition and Analysis software. 
Expression levels are relative to the maximum per 20µg of 
protein in the WHCO6 cell line.  Note: the whole cell samples 
used to detect FAK in Figure 2.3A were the same samples 
used to detect p53, and therefore, the tubulin immunoblot also 
represents the loading control for the above immunoblot. 
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Figure 2.8: p53 is primarily localised to the nucleus in HOSCC cell 
lines.  Nuclear localisation of p53 was observed in HOSCC 
and mt p53-R273H HT29 cell lines under normal tissue culture 
conditions, following immunofluorescent detection.  
Cytoplasmic localisation of p53 was observed in the caspase-
3 null MCF7 breast carcinoma cell line.  Negligible diffuse 
staining was observed in the negative control (excluding anti-
p53 antibody).  Scale bar = 25μm 
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2.3.6 HOSCC cell lines differentially express the death receptor, Fas 
 
A functional link between FAK and the Fas has been demonstrated, implicating 
the death receptor pathway in the induction of anoikis (Kurenova et al., 2004; 
Kamarajan et al., 2010).  In addition, p53 has been linked to the regulation of Fas-
mediated apoptosis, as p53 response elements have been identified on the Fas 
promoter and wt p53 has been demonstrated to increase Fas membrane trafficking 
(Bennet et al., 1998; Zalcenstein et al., 2003).  Western blot analysis of whole cell 
lysates from the HOSCC cell lines confirmed the presence of the Fas receptor 
protein (Figure 2.9A).  The polyclonal antibody used in the western blot 
procedure was raised against the full length of the Fas receptor and, therefore, 
detected both the partially glycosylated Fas protein (48kDa) and the fully mature 
glycoprotein (52kDa).  Under standard tissue culture conditions, the WHCO1, 
WHCO6 and SNO cell lines express both variants of Fas, with a higher proportion 
of the 52 kDa isoform (Figure 2.9B).  Interestingly, the WHCO3 cell line only 
expresses the 52 kDa isoform of Fas and the WHCO5 and MCF-7 cell lines only 
express the 48 kDa isoform.  The highest expression of Fas was observed in the 
52 isoform in WHCO3, on average 1.5 fold higher than the WHCO1, WHCO5 
and WHCO6 cell lines (Figure 2.9B).  As consistent with the literature, due to the 
repression of the Fas promoter by the transcriptionally inactive mt p53-R273H 
(Zalcenstein et al., 2003), Fas was not detected in the HT29 cell line by 
immunoblot analysis (Figure 2.9A). 
 
2.3.7 Peri-nuclear localisation of Fas was observed in HOSCC cell lines 
 
The level of surface expression of Fas is one of the critical parameters in 
determining the ability of cells to undergo apoptosis, as the Fas expression on the 
cell surface transmits cell death signals via the ligation of FasL (Cahuzac et al., 
2006).  The observed variation in the glycosylation of Fas across the cell lines 
prompted the investigation of the cellular distribution of the protein.  Consistent 
with previous reports of glycosylated proteins, peri-nuclear localisation of Fas in 
the vicinity of the golgi complex, was observed in the HOSCC and MCF7 cell 
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lines (Figure 2.10). Corresponding to the lack of Fas detection by immunoblot 
(Figure 2.9A), Fas was not detected by immunofluorescence in the HT29 cell line 
(Figure 2.10). 
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Figure 2.9: Fas was differentially expressed in the HOSCC, MCF-7 
and HT29 cell lines under standard tissue culture 
conditions. (A) Western blot analysis of the cell lysates using 
a polyclonal antibody against human Fas receptor. Two bands 
of varying intensity represent the 52 kDa and 48 kDa isoforms 
of Fas. (B) Densitometric analysis of the immunoblot was 
performed using Labworks™ Image Acquisition and Analysis 
software. The relative difference in the 48kDa and 52kDa 
variants of Fas was assessed across all of the HOSCC cell 
lines. The expression levels are relative to the maximum per 
20µg of protein in the WHCO6 cell line.  Note: the whole cell 
samples used to detect FAK in Figure 2.3A we were the same 
samples used to detect Fas, and therefore, the tubulin 
immunoblot in Figure 2.3A also represents the loading control 
for the above immunoblot. 
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Figure 2.10: Peri-nuclear localisation of Fas was observed in the 
HOSCC cell lines. Under standard tissue culture condition, 
HOSCC cell lines show peri-nuclear localisation of Fas, with 
a smaller percentage being localised in the cytoplasm. Akin 
to the negative control (excluding anti-Fas antibody) 
negligible diffuse staining was observed in the HT29 cell line. 
Scale bar = 15 μm 
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2.4 Discussion 
 
Interplay between FAK and apoptotic pathways has been shown to significantly 
influence cell fate decisions (Kurenova et al., 2004; Golubovskaya et al., 2008; 
Lim et al., 2008; Kamarajan et al., 2010).  The FAK gene encodes a non-receptor 
tyrosine kinase that localizes at points of cell/ECM contact (Schaller et al., 1992; 
Luo and Guan, 2010).  As a consequence of alternative splicing of the FAK gene, 
several isoforms exist.  The non-catalytically active isoform originally isolated 
from chicken fibroblasts, FAK related non-kinase (FRNK), is the most 
characterised of these isoforms (van Nimwegen and van der Water, 2007).  FRNK 
competes with FAK at sites of clustered β subunits of integrins, thereby acting as 
negative regulator of FAK-dependent signalling (Cooper et al., 2003).  The only 
other closely related family member of FAK is the 112 kDa proline-rich tyrosine 
kinase 2 (PYK2).  However, expression of PYK2 appears to be limited to cells of 
the nervous system, and cells of haematopoietic origin (van Nimwegen and van 
der Water, 2007).  Hence, due to its integral role in cell adhesion signalling in 
epithelia, in this report we focus solely on interactions between FAK and key 
apoptotic regulators.    
 
HOSCC is a highly metastatic cancer that presents symptomatically late in the 
course of the disease, therefore, the accurate diagnosis of this cancer is crucial to 
improve prognosis (Tew et al, 2005; Bird-Lieberman and Fitzgerald, 2009).  
Similar to other SCC tumours, HOSCC are histopathologically classified as 
poorly-, moderately- and well-differentiated tumours (Zhang et al., 2010).  
Although these categories reflect the differentiation status and morphology of 
oesophageal tumours, they provide limited molecular information – particularly in 
the moderately differentiated category.  Consequently, in this study, the 
identification of similarities or disparities in anoikis-related signalling within a 
series of HOSCC cell lines traditionally classified as moderately differentiated, 
may aid in refining this broad category.  Under standard tissue culture conditions, 
the WHCO6 and SNO cell lines expressed the highest level of FAK relative to the 
other moderately differentiated HOSCC cell lines, as well as the mt p53-R273H 
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HT29 and caspase-3-null MCF7 control cell lines (Figure 2.3B).  Overexpression 
of FAK has been implicated in facilitating the metastatic progression of tumour 
cells (Schneider et al., 2002; Lark et al., 2005; Gabriel et al., 2006).  Thus, as the 
moderately differentiated category is extremely broad, the WHCO6 and SNO cell 
lines may be derived from tumours that are closer to the poor end of the 
differentiation spectrum.  However, a comparison to normal oesophageal 
epithelium would be required in order to firmly establish the relationship between 
elevated FAK expression in HOSCC and normal oesophageal tissue.  Hence, due 
to the difficulty in obtaining and culturing normal oesophageal epithelium, this 
study focuses on the comparison of FAK-mediated signalling events between the 
moderately differentiated HOSCC cell lines displaying variable FAK expression 
(WHCO1, WHCO3, WHCO5, WHCO6 and SNO) and the HT29 and MCF7 
control cell lines with documented resistance to anoikis.  Specifically, the HT29 
cell line is highly resistant to apoptotic stimuli as it harbours the transcriptionally 
inactive p53 mutant R273H (Lin-Lee et al., 2001), whilst the wt p53 MCF-7 cell 
line lacks functional caspase-3 and is therefore nonresponsive to caspase-related 
apoptotic events (Jánicke et al., 1998; Mooney et al., 2002).   
 
Tyr397 autophosphorylation of FAK is critical to FAK-dependent survival 
signalling (Sonoda et al., 1999; Parsons, 2003).  pFAKTyr397 was only detected 
by immunoblot analysis in the WHCO6 and SNO cell lines (Figure 2.3A).  As 
these were the two cell lines displaying the highest FAK expression (Figure 2.3B) 
and pFAKTyr397 has previously been documented in the HT29 and MCF7 
control cell lines (Beviglia et al., 2003), FAK protein levels were concentrated via 
co-immunoprecipitation in the other cell lines.  Accordingly, pFAKTyr397 was 
detected in the FAK immunoprecipitates (Figure 2.4).  Importantly, these data 
demonstrate a relationship between FAK expression and Tyr397 phosphorylation 
levels.   
 
Overexpression of FAK and Tyr397-phosphorylated FAK are correlated with 
enhanced tumourigenesis and metastasis (Miyazaki et al., 2003; Lark et al., 2005; 
Jiang et al., 2010).  However, in this study, the variation in FAK protein 
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expression and Tyr397 levels determined by semi-quantitative analyses (Figure 
2.3B & C) excludes the possibility of using Tyr397-phosphorylated FAK as a 
molecular marker for this pathological grading of HOSCC.  Nonetheless, due the 
high relative expression of FAK and detectable level of Tyr397-phosphorylated 
FAK by immunoblot (See Figure 2.3A & B), the WHCO6 and SNO cell lines 
represent an excellent model to examine the effect of FAK-dependent signalling 
on anoikis-related events in HOSCC.   
 
Following attachment to the ECM, FAK is targeted to sites of focal contact, where 
it is autophosphorylated by integrin clustering (Owen et al., 1999).  In particular, 
the direct interaction between the C-terminal of FAK with the cytoplasmic tail of 
the β1 integrin subunit facilitates the rapid Tyr397 autophosphorylation of FAK 
(Schaller et al., 1994).  Importantly, β1 integrin was detected in complex with 
Tyr397-phosphoryated FAK (Figure 2.6).  Hence, similar to other epithelial 
tumours (Crowe and Ohannessian, 2004; Thamilselvan et al., 2007), FAK is 
autophosphorylated at sites of focal contact.  In combination with the observed 
cytoplasmic localisation of FAK (Figure 2.5), these data support an important role 
of Tyr397-phosphorylated FAK in cell adhesion signalling events in HOSCC.   
 
Increased activation of FAK by ECM influence has been demonstrated to 
suppress p53-dependent apoptosis (Zhang et al., 2004 (a)).  Corresponding to the 
elevated expression of Tyr397-phosphorylated FAK (Figure 2.3C), high p53 
expression was detected in the WHCO6 and SNO cell lines (Figure 2.7).  
Interestingly, despite the similar levels of p53 in the WHCO6 and SNO cell lines, 
there was much greater FAK expression in the WHCO6 cell line in comparison to 
the SNO cell line.  In addition, consistent with previous reports in transformed 
cells (Rotter et al., 1983; Shaulsky et al., 1990), p53 was detected in the nucleus 
by immunofluorescence in the HOSCC cell lines and the mt p53-R273H HT29 
cell line (Figure 2.8).  Consequently, the mutational status of p53 does not 
influence p53 localisation, as nuclear localisation of mt p53-R273H was observed 
in the HT29 cell line (Figure 2.8). 
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Abrogation of FAK expression has been shown to trigger the Fas-mediated death 
cascade (Kurenova et al., 2004).  Differential expression of the 48kDa and 52kDa 
isoforms of Fas was observed in the HOSCC, HT29 and MCF7 cell lines (Figure 
2.9).  Both variants 48 and 52 kDa Fas glycoproteins are known to be targeted to 
the membrane, and transduce FasL-mediated apoptotic signals (Cahuzac et al., 
2006).   Consequently, the variation in Fas expression did not influence Fas 
localisation, as predominantly peri-nuclear localisation of Fas was observed in the 
HOSCC and MCF7 cell lines (Figure 2.10).  Thus, these data validate that both 
p53 and Fas are expressed by the HOSCC cell lines.  Furthermore, no unusual 
cellular distribution of both of the major apoptotic constituents was observed in 
the HOSCC cell lines. 
 
p53 binding sites have been reported on both FAK and Fas promoters (Zalcenstein 
et al., 2003; Golubovskaya et al., 2005).  Accordingly, in the HT29 cell line 
harbouring the transcriptionally inactive mt p53-R273H, there is reduced FAK 
levels and repressed Fas expression (Figure 2.3 & 2.9).  Despite the same cellular 
distribution of FAK, p53 and Fas as the HT29 cell line, the key anoikis-related 
intermediates were differentially expressed in the HOSCC cell lines (Figure 2.3, 
2.7 & 2.9).  In particular, the expression of Tyr397-phosphorylated FAK and p53 
was elevated in the WHCO6 and SNO cell lines (Figure 2.3C & 2.7B).  
Moreover, comparable to the mt p53-R273H HT29 control cell line, nuclear p53 
was detected in the HOSCC cell lines (Figure 2.8).  As tumours expressing 
mutated p53 overexpress FAK (Golubovskaya et al., 2009), these observations 
suggest that the loss of tumour suppressor function of p53 may be responsible for 
the altered expression of the anoikis-related intermediates in the HOSCC cell 
lines.  Furthermore, endogenous p53 and overexpression of wild type p53 have 
been shown to inhibit FAK mRNA and protein levels whilst, mutant p53 did bind 
to the FAK promoter (Golubovskaya et al., 2008).  Therefore, the ability of cell 
line(s) harbouring mutant p53 to resist apoptotic stimuli and alter FAK-dependent 
signalling is reported in the subsequent chapter. 
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Chapter 3 
Apoptotic events in wt p53 HOSCC cell lines are 
accompanied by caspase-3 activation and FAK cleavage: 
opposing role of mt p53-R175H 
 
3.1 Introduction 
Increased activation of FAK by ECM influence has been demonstrated to repress 
p53-dependent apoptosis (Zhang et al., 2004 (a)).  In addition, mutant p53 has 
been reported to suppress FAK expression by disabling the FAK promoter 
(Golubovskaya et al., 2005), and, a positive correlation between FAK 
overexpression and mutant p53 has been shown (Golubovskaya et al., 2005; 
Golubovskaya et al., 2009).  Therefore, although p53 mutants are well established 
to desensitize tumours to apoptotic stimuli (Blandino et al., 1999; Tsang et al., 
2005), these studies point to mutant p53 as being intimately involved in FAK-
dependent anoikis resistance.   
 
Impairment of p53 function is attributed to mutations within the p53 coding 
domain, as well as, mutations in intermediates that regulate p53 expression and 
activity (Vousden, 2002).  The p53 protein has been well characterised and 
consists of distinct functional domains (Pavletich et al., 1993).  The N-terminal 
domain is involved in transactivation by co-activators or co-repressors, and the 
DNA-binding domain (DBD) is located within the core of the protein (Vrba et al., 
2008).  wt p53 binds to DNA as tetramers  and the C-terminal is responsible for 
this tetramerisation.  Intriguingly, a single point mutation in the DNA binding 
domain may completely inactivate p53, highlighting the significance of DNA 
binding for the tumour suppression function of p53.  Common “hot-spot” 
mutations that alter the structure of p53 include codons R175, G245, R249 and 
R282 (Cho et al., 1994; Vrba et al., 2008).  Mutations within the amino acid 
residues that make direct contact with the DNA include codons R248, R273 and 
R280 (Cho et al., 1994; Vrba et al., 2008).  (Note, hereafter mutations that alter 
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the p53 conformation will be referred to as „conformational mutants‟, whilst 
mutations that affect the DNA contact residues will be referred to as „DNA 
contact mutants‟.) 
 
 
 
Figure 3.1: The distribution and frequency of p53 mutations in 
tumours.  The vast majority of p53 mutations occur within the 
DNA binding domain.  The three most prevalent p53 mutants, 
expressed in all cancers, are the conformational (R175H) and 
contact site (R248W and R273H) p53 mutants. © Buganim 
and Rotter, (2009) TAD, transactivation domain;  PRD, 
proline-rich domain;  OD, oligomerisation domain;  DBD, DNA-
binding domain; CRD, C-terminal domain. 
 
Mutations within the DNA binding region of p53 located between exon 5 and 
exon 8 are common in HOSCC (Figure 3.1; Gamieldien et al., 1998; Li et al., 
2004).  However, Li and colleagues showed that in Chinese-derived HOSCC, 
50.0% of point mutations occurred in exon 4 (Li et al., 2004).  Furthermore, 
mutations within exon 4 were also observed in adjacent non-cancerous tissues.  
p53 mutational analysis of patients from the high risk Transkei region in South 
Africa, revealed that 17% of tumours contained a deletion, insertion or non-
synonymous point mutation in exon 5 to 8 (Gamieldien et al., 1998).  More 
recently, Vos and colleagues found that mutations were rarely observed in the 
regions flanking exon 5 and 8, however, polymorphisms were a frequent 
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occurrence in these flanking regions (Vos et al., 2003).  The sequence 
polymorphism at codon 72 that encodes for either a proline or arginine was 
identified as one of the polymorphisms.  Recent studies suggest that the 
Pro/Arg72 polymorphism may significantly contribute to the development of 
various cancers (Buyru et al., 2003; Pim and Banks, 2004).  Interestingly, Yang 
and colleagues demonstrated that the p53 Arg/Arg72 genotype was significantly 
increased in HOSCC cases compared with control subjects (Yang et al., 2008).  
However, the functional significance of the Pro/Arg72 polymorphism with respect 
to p53 function in HOSCC is yet to be determined.      
 
Irrespective of cell type, execution of anoikis ultimately converges on the 
activation of caspase-3 and as a consequence, initiates DNA fragmentation 
(Westhoff and Fulda, 2009).  Hence, although anoikis is defined as the subset of 
cell death induced by loss of cell detachment, it is inherently an apoptotic process.  
Apoptotic stimuli mediated via both intrinsic and extrinsic apoptotic pathways 
converge on caspase-3 (Ilic et al., 1998; Marconi et al., 2004; Mawji et al., 2007).  
Following activation, caspase-3 cleaves proteins within the focal adhesion, 
thereby, reducing cell attachment.  FAK is an important target for caspase-3, as 
the C-terminal fragment generated by the caspase-dependent cleavage of FAK 
harbours the focal adhesion targeting (FAT) domain, which inhibits FAK Tyr397 
phosphorylation (Gervais et al., 1998).  In this way, activation of apoptotic death 
cascades effectively abrogates FAK phosphorylation and consequently, FAK-
dependent survival signalling.   
 
Oesophageal carcinoma is a highly malignant cancer that evades anoikis-related 
control via a possible FAK-dependent mechanism, as overexpression of FAK 
correlates with enhanced oesophageal tumor metastasis (Miyazaki et al., 2003) 
Moreover, HOSCC progression is associated with loss of tumour suppressor 
function of p53 (Xue et al., 2006).  Therefore, as a direct correlation between 
FAK overexpression and mutant p53 has been demonstrated (Golubovskaya et al., 
2009), the mutational status of the DNA binding domain of p53 was established in 
the HOSCC cell lines.  In order to clarify the relationship between FAK-
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dependent signalling and apoptotic regulation in HOSCC, the classic apoptotic 
markers, DNA fragmentation and caspase-3 activation were used to verify 
whether the apoptotic pathway is still intact in the HOSCC cell lines.  The 
apoptotic-resistant HT29 cell line harbouring the transcriptionally inactive R273H 
DNA contact mutant p53 served as a mutant p53 control.  Caspase-3 independent 
events were assessed using the caspase-3 null MCF7 cell line.    Thereafter, the 
ability of mutant p53 to disrupt the caspase-3 associated cleavage of FAK, and as 
a consequence, maintain FAK dependent-signalling was determined.  Pertinently, 
the data presented in this chapter provides evidence of a unique relationship 
between loss of p53 tumour suppressor function and enhanced cell adhesion-
dependent signalling. 
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3.2 Material and Methods 
 
3.2.1 Cell lines 
As previously documented, see Chapter 2, Section 2.2.1 
 
3.2.2 RNA extraction 
As previously documented, see Chapter 2, Section 2.2.2 
 
3.2.3 Reverse transcription 
As previously documented, see Chapter 2, Section 2.2.3 
 
3.2.4 PCR 
The integrity of the DNA binding domain of p53 spanning exon 3 to 8 of the 
HOSCC cell lines was investigated by RT-PCR analysis.  Primers used to amplify 
regions spanning exon 3-8 were as follows:  
(exon3-5)  Forward:  5‟ GAA ACA TTT TCA GAC CTA TGG 3‟ 
      Reverse:  5‟ TTC TGT CAT CCA AAT ACT CC 3‟ 
(exon 6-8) Forward:  5‟ ATG ACA GAA ACA CTT TTC G 3‟  
      Reverse:  5‟ GTA GAC TGA CCC TTT TTG G 3‟.   
Thermal cycle conditions for both primer sets included denaturation at 95 °C for 
10 min and 32 cycles of denaturation at 95 °C for 0.5 - 1 min; annealing at 56 °C 
for 0.5 - 1 min and extension at 72 °C for 1 min with a final elongation at 72 °C 
for 10 min.  PCR products were visualized on a 1% agarose gel following 
ethidium bromide staining.  Fragments were sent to Inqaba Biotech for 
sequencing.  A representative sequence trace is included in Appendix 3.2. 
 
3.2.5 Genomic DNA PCR 
Genomic DNA was extracted using the DNeasy kit (Promega) according to 
instructions by the manufacturer.  The R175H mutation in exon 5 and the 
Pro/Arg72 polymorphism in exon 4 were confirmed by sequencing the respective 
exons from genomic DNA using the following primers:  
(exon 4): Forward 5‟ CCT GGT CCT CTG ACT GCT CT 3‟  
    Reverse 5‟ GCC AGG CAT TGA AGT CTC AT 3‟ 
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(exon 5)   Forward 5‟ GTT TCT TTG CTG CCG TCT TC 3‟  
    Reverse 5‟ CAA CCA GCC CTG TCG TCT CT 3‟.  
 
Thermal cycle conditions included denaturation at 95 °C for 10 min and 32 cycles 
of denaturation at 95 °C for 0.5 - 1 min; annealing at 56 °C for 0.5 - 1 min and 
extension at 72 °C for 1 min with a final elongation at 72 °C for 10 min.  PCR 
products were visualized on a 1 % agarose gel following ethidium bromide 
staining.   
 
3.2.6 Antibodies  
FAK, integrin β1 and caspase-3 were specifically detected with rabbit polyclonal 
antibodies obtained from SantaCruz Technology.  Monoclonal mouse anti-
pFAK(Tyr397) (Millipore) and rabbit anti-cleaved caspase-3 (Cell Signaling 
Technology) were used to detect autophosphorylation of FAK and caspase-3 
activation respectively.  Polyclonal horseradish peroxidase (HRP)-bound anti-
rabbit secondary antibody was used in (Separations, SA) was used in the 
immunoblot experiments. 
 
3.2.7 Protein estimation 
As previously documented, see Chapter 2, Section 2.2.6 
 
3.2.8 Immunoblot analysis 
40 µg of protein per lane was separated by 10% SDS-PAGE.  Nonspecific binding 
sites on the membrane were pre-blocked in blocking buffer (Appendix 1.5.2) for 1 
hr.  Blots were incubated with anti-FAK for 1 hr or overnight with p-
FAK(Tyr397) in 1% BSA.  Washing was performed 6 times at 5 min intervals 
with PBS to remove any residual antibody. Following incubation in HRP-
conjugated secondary membranes were washed 6 times at 5 min intervals with 
PBS before being exposed to the SuperSignal West Pico Chemiluminescent 
working solution (Appendix 1.5.3).  Film was developed in developer (see 
Appendix 1.5.4) for 5 minutes, rinsed briefly in H2O before fixing (see Appendix 
1.5.5) for 5 minutes.   Each immunoblot was repeated three times. 
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3.2.9 TUNEL 
Apoptosis was induced by 30 nM of staurosporine (Sigma).  Controls were 
incubated in vehicle (DMSO) only.  In order to measure and quantitate cell death 
the cultured oesophageal cells were assayed with the In situ Cell Death Detection 
Kit, POD (Roche).   
 
3.2.9a Preparation of sample material 
5 X 10
6
 HOSCC cells were fixed to the culture vessel with fixation solution 
(Appendix 1.7.1).  The fixed cells were then rinsed three times in PBS and 
allowed to air dry for 5 min.  A DAKO pen was used to draw circles to create 
wells on the dish.  Fixed cells within the wells were then incubated with blocking 
solution (Appendix 1.7.1) for 10 min at 25 °C.  After rinsing three times in PBS, 
the cells were incubated in permeabilisation solution (Appendix 1.7.2) for 5 min 
at room temperature.   
 
3.2.9b Labelling protocol 
5 μl of terminal deoxynucleotidyl transferase (TdT) was mixed with 45 μl of 
fluorescein-labeled deoxyuridine solution and added to each well.  In negative 
controls, TdT was removed from the reaction mix.  The culture vessel was 
incubated in a dark, humidified environment for 60 min at 37 °C.  Samples were 
covered with parafilm to prevent evaporative loss.  After the incubation, cells 
were rinsed six times in PBS.   
 
3.2.9c Signal conversion 
Incorporated flourescein-labeled nucleotides were detected by sheep anti-
flourescein antibodies conjugated with horse-radish peroxidase.  15 μl of the 
converter-POD solution was added to each sample on the culture vessel and 
incubated in a humidified environment at 37 °C for 1 hr.  The sample was covered 
with parafilm to prevent evaporative loss.  After rinsing the sample 3 times in 
PBS, 20 μl of DAB peroxide working solution (Appendix 1.7.3) was added to the 
sample and incubated at 25 °C for 10 min.  The samples were visualized by phase-
contrast light microscopy.   
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The presence of standard morphological apoptotic features was confirmed in 
apoptotic cells, before evaluating apoptotic cell number.  Five high powered fields 
(magnification X 100) with the most abundant distribution of TUNEL-positive 
cells were selected for counts in each of the cell lines.  The percentage of 
apoptotic cells in relation to total number of cells was determined by counting 100 
cells in each field.  Mean 
+
/- SD was calculated from the five field views.   
 
3.2.10 Cell detachment  
Cells were plated at a concentration of 5 × 10
6
 per 6cm tissue culture dish (Nunc).   
Following STS-treatment for 24hr, detached cells were collected, stained with 
0.4% w/v Trypan Blue solution and transferred onto a haemocytometer (Fuchs-
Rosenthal).  The entire collection process was repeated five times and the average 
detached cells per total volume calculated.  Attached cells were incubated in a 
Trypsin/EDTA solution for 5 min.  Trypsinized cells were collected, transferred 
onto a haemocytometer and counted as described above.  STS-induced detached 
cells were expressed as a percentage of total cells and mean 
+
/- SD was 
determined as above.   
 
3.2.11 Statistics 
A standard student‟s t test was used for comparative analyses (See Appendix 4.1 
& 4.2).  The level of significance was set at p < 0.05.   
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3.3 Results: 
 
3.3.1 Mutational analysis of the DNA binding domain of p53 in HOSCC cell 
lines 
 
In order to amplify the DNA binding domain of p53 spanning exon 4 to 8, the p53 
RNA transcripts (Figure 2.1A) were reversed transcribed into cDNA (Figure 
2.1B) and subject to PCR analysis.  Sequence analysis of exon 3 through to 5 
revealed that the SNO cell line harbours the conformational mt p53-R175H (G to 
A) (Figure 3.2).  As consistent with findings by Vos et al. (2003), mutational 
analysis of exon 4 revealed no mutations in the HOSCC, HT29 or MCF-7 cell 
lines.  However, the Pro/Arg 72 polymorphism on exon 4 was identified in the 
WHCO1 and SNO cell lines (Figure 3.2).   
 
Primers specific for exon 5 through to exon 8 produced a 511 bp PCR product 
(Figure 3.3).  Sequence analysis revealed no mutations in this region in the 
HOSCC cell lines.  The previously described R273H mutation in the HT29 cell 
line is located in exon 8 (Bossi et al., 2006), whilst, the MCF7 cell line expresses 
wt p53 with respect to the DNA binding domain of p53.    
 
Amplification of exon 4 from genomic DNA produced a fragment of 361bp in all 
cell lines (Figure 3.4A), whilst primers specific for exon 5 produced a fragment of 
305 bp (Figure 3.4B).  Both the Pro/Arg72 polymorphism located on exon 4 
(Figure 3.4C) and the R175H mutation located on exon 5 (Figure 3.4D) were 
confirmed by sequence analysis of the respective exons of genomic DNA.   
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A. 
 
B. 
 
 
Figure 3.2: p53 mutational analysis of exon 3-5 of the HOSCC cell 
lines. A) RT-PCR products were resolved by 1 % agarose gel 
electrophoresis following EtBr staining (10 μg/ml).  A band of 
560 bp was observed in HOSCC, MCF7 and HT29 cell lines.   
B) Representative sequence trace of the 560 bp fragment.  
Sequence analyses revealed that the SNO cell line harbours 
mt p53-R175H and the Pro/Arg72 polymorphism was detected 
in the WHCO1 and SNO cell lines. MWM = GeneRulerTM 
100bp Plus DNA ladder 
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A. 
 
B. 
 
 
 
Figure 3.3: p53 mutational analysis of exon 6-8 of the HOSCC cell 
lines. A) RT-PCR products were resolved by 1 % agarose gel 
electrophoresis following EtBr staining (10 μg/ml).  A band of 
511 bp was observed in HOSCC, MCF7 and HT29 cell lines.   
B) Representative sequence trace of the 511 bp fragment.  
Sequence analyses revealed no mutations in this region of 
p53 in the HOSCC cell lines. MWM = GeneRulerTM 100bp Plus 
DNA ladder 
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E.                    Cell lines 
 
p53 mutations 
MCF-7, WHCO3, WHCO5 and 
WHCO6 
Wild type p53 (exon 4-8) 
WHCO1 Heterozygous Pro/Arg 72 
SNO Heterozygous Pro/Arg 72 
R175H mutation on exon 5  
HT29 R273H mutation on exon 8 (Bossi et 
al., 2006) 
 
 
Figure 3.4: p53 mutational status of HOSCC cell lines. A&B) PCR 
products were visualized on a 1 % agarose gel.  A fragment 
corresponding to 361 bp for (A) exon 4 and 305 bp for (B) 
exon 5 was evident in the HOSCC, HT29 and MCF-7 cell 
lines. Fragments were sequenced to confirm the Pro/Arg72 
polymorphism on (C) exon 4 and R175H mutation on (D) exon 
5.  E) Summary of the mutational analysis of exon 4 through to 
8 of p53 in the HOSCC, MCF7 and HT29 cell lines. 
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3.3.2 STS induces apoptotic morphology in HOSCC cell lines 
 
STS is a chemotherapeutic reagent commonly used to induce apoptotic death in 
vitro.  The ability of STS to induce apoptosis in various squamous cell carcinomas 
is well documented (Qiao et al., 1996; Abiko et al., 1997; Mckeague et al., 2003; 
Zhang et al., 2004 (b); Yamagishi et al., 2006).  Typical apoptotic morphology 
and oligonucleosomal cleavage has been shown to occur subsequent to STS 
treatment (Abiko et al., 1997).   
  
As the morphology of apoptotic cells is qualitatively different to cells in the 
process of necrotic cell death, cell morphology was examined very carefully.  
Typical apoptotic morphological signs were evident in both the wt p53 
representative WHCO6 cell line and mt p53-R175H SNO cell line post STS 
treatment (Figure 3.5B).  When compared to the untreated controls, a visible 
reduction in cell volume was evident in all cell lines.  As apoptosis is 
asynchronous, various stages of apoptotic morphology were evident post STS-
treatment in each cell culture.  The small surface blebs that occur shortly after the 
onset of apoptosis, as well as large blisters are evident on the plasma membrane in 
STS-treated cells.  Thin surface echinoid protrusions that follow membrane 
blebbing were also clearly visible (black arrows; Figure 3.5B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
A.   
 
 
 
 
 
B. 
 
Figure 3.5: Morphology of STS-induced apoptotic HOSCC cells A) 
Schematic representation of the morphology of cells 
undergoing apoptosis.  Initially cells undergoing apoptosis 
round up and acquire membrane ruffles.  Then the cells 
become rigid; extending long, thin echinoid protrusions into the 
cytoplasm.  The plasma membrane begins to blister and 
ultimately lyses committing the cell to death. © Adapted from 
Collins et al. (1997). B) STS induced recognisable apoptotic 
morphology in wt p53 and mt p53 HOSCC cells.  Documented 
apoptotic morphology was observed in STS-treated HOSCC 
cells by phase-constrast microscopy. (I) Untreated HOSCC 
cells exhibit regular colony morphology with few cytoplasmic 
extensions.  (II)  STS-treated HOSCC cells show typical 
apoptotic morphology including reduction in cell volume and 
echinoid extensions of the plasma membrane (black arrow). 
Scale bar = 50μm.   
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3.3.3 Caspase-3 associated oligonucleosomal cleavage 
 
Cells entering apoptotic death pathways display distinct nuclear and cytoplasmic 
morphology including oligonucleosomal cleavage.  Nuclear disintegration was 
originally believed to be due to the activation of the endonuclease CAD/ DFF45, 
one of the major substrates of caspase-3 (Enari et al., 1998).  Associated nuclear 
cleavage yields both double-stranded, low molecular weight DNA fragments, as 
well as single strand breaks in high molecular weight DNA.  However, DFF45-
independent cleavage of has also been observed in the caspase-3 null MCF7 cell 
line (Mooney et al., 2002), indicating the involvement of caspase-independent 
events in the DNA fragmentation process.   Both the mitochondrial (intrinsic) and 
the death receptor (extrinsic) death pathways converge on the activation of 
caspase-3 (Wang, 2001; Aoudjit and Vuori, 2001).  Upon activation, caspase-3 is 
proteolytically cleaved into a 19 kDa and 10 kDa subunit (See Figure 3.6).   
 
 
 
 
 
Figure 3.6: Proteolytic processing of procaspase-3. The 32 kDa 
inactive procaspase-3 protein contains three domains: the N-
terminal prodomain (blue), a 20 kDa subunit (red) containing 
the catalytically active cysteine residue and a 10 kDa C-
terminal subunit (purple).  All caspases are activated to fully 
functional proteases by two separate events. The first is the 
proteolytic cleavage that divides the protein into a 10 kDa and 
19 kDa subunit.  This cleavage is initiated by an initiator 
caspase.  The second is an autocleavage of the prodomain 
region.  A fully functional caspase-3 is a heteroteterameric 
enzyme that consists of two 19 kDa and two 10 kDa subunits, 
with two active sites. 
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3.3.3a HOSCC cell lines express the caspase-3 precursor 
 
Caspase-3 has been demonstrated to be a prognostic marker in HOSCC, as 
positive caspase-3 expression in HOSCC tumours was shown to correlate with 
increased lifespan (Hsia et al., 2003).  Western blot analyses of whole cell lysates 
revealed that all of the HOSCC cell lines express the caspase-3 precursor (Figure 
3.7A).  Under standard tissue culture conditions, the WHCO6 cell line had the 
highest p32 expression (Figure 3.7B).  In the MCF-7 breast carcinoma cell line, 
there is a loss of procaspase-3 expression due a functional deletion in exon 3 of 
the CASP-3 gene (Jänicke et al., 1998; Mooney et al., 2002).  Consistent with the 
literature, procaspase-3 protein was not detected in the MCF-7 cell line by 
immunoblot analysis (Figure 3.7A). 
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A. 
B. 
 
        
  
Figure 3.7: The HOSCC cell lines differentially express procaspase-3 
under standard tissue culture conditions. (A) Western blot 
analysis of the cell lysates using a polyclonal antibody against 
human caspase-3.  A single band of varying intensity, 
representing the 32 kDa caspase-3 precursor was apparent in 
all HOSCC cell lines. Due to a functional deletion in the CASP-
3 gene, the MCF-7 cell line does not express caspase-3.  B) 
Semi-quantitative analyses of caspase-3 demonstrate that the 
WHCO6 cell line expresses the highest level of caspase-3 
relative to the other cell lines.  The expression levels are 
relative to the maximum per 20µg of protein in the WHCO6 
cell line.  Note: the whole cell samples used to detect FAK in 
Figure 2.3A we were the same samples used to detect 
caspase-3, and therefore, the tubulin immunoblot also 
represents the loading control for the above whole cell 
extracts. 
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3.3.4 Oligonucleosomal cleavage analysis in HOSCC cell lines 
 
Oligonucleosomal cleavage was assessed by the standard methods; TUNEL assay 
and DNA laddering on an agarose gel.  Both methods accurately identify the 
nuclear cleavage associated with apoptosis; however the laddering method 
requires the extraction of the entire cell and analysis of the pooled DNA extract 
whilst, the TUNEL method enables the identification in situ of the apoptotic 
nuclei allowing a quantitative comparative analysis. 
 
3.3.4a DNA ladder analysis   
 
Distinct oligonucleosomal cleavage was detected post STS treatment in the wt 
p53, mt p53-R175H and mt p53-R273H cell lines, as assessed by the laddering of 
DNA on an agarose gel (Figure 3.8A).  In addition, caspase-3-independent DNA 
fragmentation was confirmed in the MCF7 cell line (Figure 3.8A).       
 
3.3.4b TUNEL 
 
TUNEL was performed under serum free conditions and following treatment with 
30 nM STS.  In each instance, the efficacy of the TUNEL assay was determined 
by pre-incubation with DNase I prior to the addition of the TUNEL reagents 
(Figure 2.8B).  All HOSCC cell lines showed a significant increase in apoptotic 
positive nuclei post STS treatment (Figure 3.8C).  The highest percentage of 
TUNEL positive nuclei was observed in the mt p53-R175H and mt p53-R273H 
cell lines.  Whilst the lowest level of apoptotic nuclei was observed in the 
WHCO6 and WHCO5 cell lines respectively (Figure 3.8C).   
 
3.3.5 STS induces cell detachment in HOSCC cell lines 
 
Loss of cell-matrix contact in epithelial cells triggers cell death via anoikis-related 
apoptotic pathways (Frisch and Francis, 1994; Mawji et al., 2007).  Hence, as 
TUNEL was performed in situ and apoptotic cells lose substrate contact, the 
presence of the apoptotic DNA ladder was confirmed in both attached and 
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detached cells (Figure 3.9A).  Therefore, percentage detachment was used to 
compare STS-mediated apoptosis between wt and mt p53 cell lines (Figure 3.9B).  
Accordingly, in both the mt p53-R175H and mt p53-R273H cell lines, the highest 
levels of TUNEL positive nuclei corresponded to the lowest percentage of cell 
detachment.  Conversely, the low level of TUNEL-positive nuclei in the wt p53 
HOSCC cell lines, were associated with higher levels of cell detachment with 
respect to the mt p53 cell lines (Figure 3.9B). 
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See next page for legend.
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B. 
 
C. 
 
 
Figure 3.8: STS induction of internucleosomal DNA fragmentation in 
wt and mt p53 HOSCC cell lines.  A) Apoptotic DNA ladder 
analysis in HOSCC cell lines under serum-free (SS) conditions 
and treated with 30 nM STS (STS).  B)  The SNO cell line was 
pre-incubated with 5 U/ml DNase I for 5 min prior to the 
addition of the TUNEL reagents, to determine the efficacy of 
the TUNEL assay.  Pre-treatment with DNase I caused a 
distinct staining of all nuclei in the preparation as viewed by 
phase-contrast microscopy.  Cells were unstained in the 
preparation. iii) TUNEL stained nuclei in the SNO cell lines.  
Dark nuclei, stained by DAB substrate are indicative of 
oligonucleosomal cleavage.  C) The percentage of TUNEL-
positive nuclei was determined in the wt, mt and caspase-3 
null cell lines.  The highest percentage of apoptotic nuclei was 
observed in the mt p53-R175H SNO cell line (89%).  Bars 
represent standard deviation.  MW = GeneRulerTM 100bp Plus 
DNA ladder * p < 0.05  
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Figure 3.9: The p53-R175H and p53-R273H mt cell lines are resistant 
to STS-mediated detachment A) The apoptotic DNA ladder 
was evident in both the genomic DNA extracted from 
detached (Det) cells and attached (At) STS-treated HOSCC, 
HT29 and MCF7 cells. B) STS induced cell detachment in 
the HOSCC cell lines. The lowest percentage of cell 
detachment was observed in the mt p53 SNO cell line (28%), 
followed by the mt p53-R273H HT29 cell line (23%).  Bars 
represent standard deviation.  MW = GeneRulerTM 100bp 
Plus DNA ladder * p < 0.05  
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3.3.6 STS induces FAK cleavage and caspase-3 activation in HOSCC cell 
lines harbouring wt p53 
 
Survival signals transduced by FAK are eliminated by caspase-dependent 
cleavage of the C-terminal portion of FAK harboring the focal adhesion targeting 
(FAT) domain (Cooper et al., 2003).  In addition to abrogating integrin-associated 
FAK, this fragment inhibits FAK signalling, further enhancing the apoptotic effect 
of FAK cleavage (Gervais et al., 1998; Cooper et al., 2003).  
 
The expression of FAK decreased in all the wt p53 HOSCC cell lines after 24 
hours treatment with STS, which was associated with the formation of the double 
cleavage product, in the range of 85 kDa (Figure 3.10).  Caspase-3 was activated 
in a similar time course to the formation of the cleavage product in the wt p53 
HOSCC cell lines.  No caspase-3 activation or FAK cleavage was observed post 
STS-treatment in the mt p53-R175H, mt p53-R273H or MCF7 cell lines (Figure 
3.10).   
 
3.3.7 The mt p53-R175H SNO cell line maintains integrin-associated FAK 
post STS treatment. 
 
The release of the FAT domain of FAK post caspase-3 activation abrogates the 
association between FAK and integrin β1 (Gervais et al., 1998; van Nimwegen 
and van der Water, 2007).  In contrast to the wt p53 WHCO6 cell line, the mt p53-
R175H SNO cell line was resistant to FAK cleavage (Figure 3.10).  Therefore, the 
possibility that the mt p53-R175H cell lines was maintaining cell adhesion-
dependent signalling post STS treatment was explored.  In the representative wt 
p53 WHCO6 cell line, caspase-3 activation and FAK cleavage (Figure 3.10) was 
accompanied by abrogation of the FAK/integrin β1 interaction (Figure 3.11).  In 
contrast, corresponding to the lack of caspase-3 activation (Figure 3.10), the 
FAK/integrin β1 association was detected post STS treatment in the mt p53-
R175H cell line (Figure 3.11).    
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See next page for legend. 
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Figure 3.10: The p53-R175H and p53-R273H mt cell lines are resistant to FAK cleavage and caspase-3 activation. 
The expression of FAK decreased in WHCO1, WHCO3, WHCO5 and WHCO6 cell lines decreased after 
treatment with STS, which was associated with the formation of the double cleavage product, in the range of 
85 kDa.  Caspase-3 is activated with a time course corresponding to the formation of the cleavage product in 
the HOSCC cell lines. Note, in the mt p53 SNO and HT29 cell lines, neither FAK cleavage nor caspase-3 
activation was detected.  A standardized whole cell loading control from the SNO cell line (L/C) was included 
in the first lane of each immunoblot to allow for comparison of wt p53 cell lines.  An apoptotic control (A/C) 
from the WHCO6 wt p53 cell line was included in the first lane of each immunoblot in the mt p53 and 
caspase-3 null cell lines.  W/C = lysate from cell line SS = Serum-free conditions.  
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Figure 3.11: STS-mediated events do not abrogate the FAK/integrin β1 association in the mt p53-R175H cell line.  
FAK cleavage is associated with the complete abrogation of the FAK/integrin β1 interaction in the wt p53 
WHCO6 cell line.   However, in the mt p53-R175H SNO cell line, the complex between FAK and integrin β1 
was still detected post STS treatment.  Note: the samples used to detect FAK expression in Figure 3.10 
were the same samples used for immunoprecipitation, and therefore, also represent a loading control for 
the FAK/integrin β1 immunoprecipitation reaction.  W/C = lysate from cell line SS = Serum-free conditions.  
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3.4 Discussion 
 
Although the ability of mutant p53 to resist apoptotic stimuli is well established 
(Blandino et al., 1999; Zalcenstein et al., 2003; Golubovskaya et al., 2008 (a); 
Lim et al., 2008), the role of mt p53 in anoikis resistance has never been explored.  
In particular, the “hot-spot” conformation mt p53-R175H confers resistance to 
apoptosis by repressing key anoikis-related intermediates including the FAK 
promoter and caspase-3 levels (Tsang et al., 2005; Golubovskaya et al., 2008 (a)).  
Thus, with the aim of establishing the role of mt p53 in anoikis-related events, we 
made use of this unique model to compare STS-mediated apoptosis in HOSCC 
cell lines expressing wt p53 (WHCO1, WHCO3, WHCO5 and WHCO6) with the 
HOSCC cell line (SNO) harbouring the mt p53-R175H (Figure 3.2).  In addition, 
the highly prevalent Pro/Arg72 polymorphism was detected in both the WHCO1 
and SNO cell lines (Figure 3.4).  The HT29 cell line harbouring the other 
prevalent DNA contact mutation, R273H was also included in the comparison, 
whilst, the caspase-3-null MCF7 cell line served as a negative control for caspase-
independent apoptotic events (Jánicke et al., 1998; Lin-Lee et al., 2001; Mooney 
et al., 2002).    
 
In the wt p53 HOSCC cell lines, definitive STS-induced apoptosis was evidenced 
by typical apoptotic morphology (Figure 3.5), oligonucleosomal cleavage (Figure 
3.8A) and caspase-3 activation (Figure 3.10).  Despite the Pro/Arg72 
polymorphism, the WHCO1 cell line responded to STS in the same manner as the 
other wt p53 cell lines (Figure 3.10).  Hence, for the rest of this report, the 
WHCO1 cell line is classified as a wt p53 cell line.  Although, typical apoptotic 
morphology (Figure 3.5) and distinct oligonucleosomal cleavage was detected in 
the mt p53 cell lines (SNO and HT29) (Figure 3.8A) no caspase-3 activation was 
detected post STS-treatment (Figure 3.10).  Interestingly, despite the lack of 
caspase-3 activation, the highest percentage of TUNEL-positive nuclei was 
observed in the mt p53 cell lines post STS-treatment (Figure 3.8C).  The ability of 
STS to induce caspase-3 independent oligonucleosomal cleavage was 
demonstrated in the caspase-3 null MCF-7 cell line (Figure 3.8A).   
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As TUNEL was performed in situ and the apoptotic DNA ladder was detected in 
both adhered and detached cells (Figure 3.9A), percentage detachment was used 
to compare STS-mediated apoptosis between the wt and mt p53 cell lines.  
Accordingly, in the p53-R175H and p53-R273H cell lines, the high level of 
TUNEL-positive nuclei (Figure 3.8C) corresponded to the lowest percentage of 
cell detachment (Figure 3.9B).  Thus, p53-R175H and p53-R273H do not protect 
the SNO and HT29 cell lines from STS-mediated oligonucleosomal cleavage.  
However, in comparison to the wt cell lines, the p53-R175H and p53-R273H cell 
lines were resistant to STS-mediated detachment and caspase-3 activation.  
Consequently, these data reveal a link between loss of tumour suppressor function 
of p53 and enhanced cell adhesion-dependent signalling. 
 
Survival signals transduced by FAK are eliminated by caspase-dependent 
cleavage of FAK (Gervais et al., 1998; Cooper et al., 2003).  We show distinct 
cleavage of FAK, which corresponded to caspase-3 activation, in the wt p53 
HOSCC cell lines (Figure 3.10).  The lack of caspase-3 expression in the MCF-7 
emphasized the involvement of caspase activity in FAK cleavage, despite the 
presence of oligonucleosomal cleavage.  Conversely, corresponding to resistance 
to STS-mediated detachment, no FAK cleavage was detected by immunoblot in 
the mt p53 cell lines (Figure 3.10).  Consequently, FAK-dependent signalling is 
maintained in the mt p53 cell lines post oligonucleosomal cleavage. 
 
Loss of cell-matrix contact in epithelial cells reduces integrin-mediated FAK 
survival signalling, thereby triggering anoikis (Frisch and Francis, 1994; Zhang et 
al., 2004 (a)).  Importantly, the cleavage of FAK induces the loss of integrin-
associated FAK at sites of focal contact (Schaller et al., 1994; van Nimwegen and 
van der Water, 2007).  Accordingly, the absence of FAK cleavage in the SNO cell 
line was accompanied by the maintenance of the FAK/integrin β1 association 
(Figure 3.11).  Importantly, these data strongly support the notion that mt p53-
R175H facilitates anchorage-independent survival through the maintenance of 
FAK-dependent signalling.   
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In summary, even though HOSCC is highly resistant to the apoptosis-inducing 
ability of chemotherapeutic reagents (Leu et al., 2000; Lin et al., 2009), the data 
presented shows that oligonucleosomal cleavage was still inducible by the widely 
used apoptosis-inducing agent STS in the wt, mt and caspase-3 null cell lines 
(Figure 3.8A).  However, both mt p53-R175H SNO and p53-R273H HT29 cell 
lines were resistant to STS-mediated detachment (Figure 3.9B).  In addition, both 
mt p53 cell lines were resistant to caspase-3 activation and the cleavage of the C-
terminal of FAK (Figure 3.10).  Thus, sustained integrin β1-dependent activation 
of FAK (Figure 3.11) may be responsible for the resistance to STS-mediated 
detachment observed in the mt p53 cell lines.  Survival signals mediated by ECM 
proteins are transmitted via the integrins, thereby activating FAK (Kamarajan and 
Kapila, 2007).  Hence, due to the persistent activation of FAK observed in the mt 
p53-R175H cell line, these data strongly advocate a critical role of mt p53 in the 
maintenance of cell adhesion-dependent survival signalling.  Consequently, the 
effect of p53 mutational status on the ECM/FAK-mediated suppression of 
apoptotic events forms the basis of the next chapter.     
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Chapter 4 
The role of extracellular matrix-mediated activation of FAK 
in the suppression of apoptosis in HOSCC cell lines:  
wt vs. mt p53-R175H 
 
4.1 Introduction 
ECM-mediated signals play a particularly important role in the maintenance of 
normal tissue architecture, through the regulation of cell survival (Badylak et al., 
2009).  During metastatic progression, however, cells lose this anchorage 
dependence, allowing them to survive in inappropriate environments (Badylak et 
al., 2009).  Consequently, loss of dependence on ECM-mediated signalling is a 
hallmark characteristic of tumour cells (Westhoff and Fulda, 2009).  Therefore, 
the molecular analysis of ECM-mediated suppression of cell death is imperative 
as it reveals the underlying mechanism that enables tumour cells to evade these 
signals and escape anoikis.  
 
Survival signals mediated by ECM proteins are transmitted via the integrins.  
Several factors, including tissue origin and matrix composition, determine which 
set of integrins transduce ECM-mediated survival signals.  In an experimental 
setting, fibronectin (FN) has been demonstrated to be a potent inhibitor of anoikis 
via the activation of FAK-dependent survival signalling (Ilic et al., 1998; Zhang et 
al., 2004 (a)).  FN is a large glycoprotein, found in soluble form in plasma and 
other body fluids as well as large cross-linked insoluble subunits in certain ECM 
(Parsons, 2003).  Each fibronectin (FN) molecule consists of two 220 kDa chains 
joined together by disulfide bonds (Hynes and Yamada, 1982).  There are several 
isoforms of FN, all of which arise from the alternative splicing of a single gene 
(Kamarajan and Kapila, 2007).  Several cell adhesive sites are present on FN 
including the central arginine-glycine-aspartic acid (RGD) binding site, 
recognized by the α5β1 integrin (Kamarajan and Kapila, 2007).   
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Early studies on an immortalized thyroid cell line, demonstrated that cells 
underwent apoptosis when the α5β1-FN interaction was blocked (Ilic et al., 1998).  
Moreover, apoptosis triggered by serum removal was prevented by coating culture 
plates with FN (Ilic et al., 1998).  Importantly, an altered FN-matrix induced by 
inflammation has been shown to induce anoikis in human periodontal ligament 
cells (Dai et al., 2005).  In addition, survival signals mediated by FN via the αvβ1 
integrin subunit were sufficient to protect aggregated substrate-dependent SCC 
cells from detachment-induced death (Zhang et al., 2004 (a)).  The survival 
signals transduced by FN-integrin engagement via FAK are attributed to 
activation of the growth factor-PI3K pathway, as phosphorylation of Tyr397 
results in PI3K activation by phosphorylation (Sonoda et al., 1999).  The PI3K 
pathway negatively regulates apoptosis, through direct phosphorylation by the 
serine/threonine protein kinase, PKB.  Once activated by phosphorylation, PKB 
initiates downstream survival events.  Among these are the inhibition of several 
pro-apoptotic proteins including Bad and caspase-9 (Datta et al., 1999).    
           
In the previous chapter we reported that the cleavage of FAK corresponded to 
caspase-3 activation (Figure 3.10) and abrogation of the integrin β1/FAK 
association (Figure 3.11).  Moreover, the mt p53-R175H and p53-R273H cell 
lines were resistant to STS-mediated detachment (Figure 3.9B) and FAK cleavage 
(Figure 3.10).  Consequently, FAK-dependent signals were maintained post STS 
treatment in the mt p53 cell lines.  Uniquely, by analyzing the influence of FN-
mediated signalling on apoptotic events, the data presented in this chapter 
demonstrate that loss of the tumour suppressor function of p53 and maintained 
FAK-dependent signalling are critical factors underlying anoikis resistance.  
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4.2 Materials and Methods 
 
4.2.1 Cell lines 
As previously documented, see Chapter 2, Section 2.2.1 
 
4.2.2 Antibodies  
FAK and caspase-3 were specifically detected with rabbit polyclonal antibodies 
obtained from SantaCruz Technology.  Monoclonal mouse anti-pFAK(Tyr397) 
(Millipore) and anti-PKBSer473 (Cell Signalling) were used to detect 
phosphorylation of FAK and PKB respectively.  Polyclonal horseradish 
peroxidase (HRP)-bound anti-rabbit secondary antibody (Separations, SA) was 
used in the immunoblot experiments. 
 
 4.4.3 Protein estimation assay 
As previously documented, see Chapter 2, Section 2.2.6 
 
4.4.4 Immunoblot analysis 
20 µg of protein per lane was separated by 10% SDS-PAGE.  Nonspecific binding 
sites on the membrane were pre-blocked in blocking buffer for 1 hr.  Blots were 
incubated with: anti-FAK (1:500) or anti-caspase-3 (1:750) for 1 hr; anti-
pFAK(Tyr397) in 1% BSA (1:500) overnight or anti-pPKB(Ser473) (1:1000) in 
5% BSA overnight.  Following incubation in HRP-conjugated secondary 
membranes were exposed to the SuperSignal West Pico Chemiluminescent 
working solution, from the West Pico Chemiluminescent Substrate Kit (Pierce, 
USA) for 5 minutes.  Blots were exposed to film and developed as documented in 
Chapter 2, Section, 2.2.7.  Each immunoblot was repeated three times. 
 
4.4.5 Cell detachment 
As previously documented, see Chapter 3, Section 3.2.10 
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4.4.6 Densitometry  
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) 
was used for densitometric analysis to quantitatively determine the concentration 
level of FAK in the Western blots.  
 
4.4.7 Statistics 
SigmaPlot (version 11.0) was used for statistical analyses.  Statistical differences 
between untreated and treated cells within each cell line were determined by one 
way ANOVA analysis followed by a pair-wise comparison using the Holm-Sidak 
method (See Appendix 4.3).  The level of significance was set at p < 0.05.  
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4.3 Results 
 
4.3.1 FN increases Tyr397 phosphorylation of FAK  
 
In order to assess whether FN-mediated signalling opposes apoptotic stimuli, the 
optimal FN concentration was first determined.  As Tyr397 phosphorylation was 
clearly detected by immunoblot in the WHCO6 cell line (Figure 2.3A), WHCO6 
cells were seeded onto tissue culture dishes, previously coated with 10 μg/ml and 
20 μg/ml FN respectively.  Following 24hr, the same time interval of STS-
mediated apoptotic induction (Figure 3.8), cells were analysed for pFAKTyr397.  
Despite standard FAK expression, pFAKTyr397 increased 2.1 fold and 1.9 fold 
post FN treatments of 10 μg/ml and 20 μg/ml respectively (Figure 4.1A).  Hence, 
these data demonstrate that all RGD sites are saturated at 10 μg/ml FN.  Thus, 10 
μg/ml was selected as the appropriate FN concentration to assess the opposing 
effect of increased FN-mediated FAK activation on apoptosis.  Cells were seeded 
onto tissue culture dishes coated with FN, allowed to settle for 2hr, before the 
removal of serum and the addition of STS.  Corresponding to increased 
pFAKTyr397, cells seeded onto 10 μg/ml FN demonstrated increased edge 
extension and a flattened morphology (Figure 4.1B). 
 
4.3.2 FN treatment reduces STS-mediated detachment in wt p53 cell lines 
 
Previous studies have reported reduced levels of apoptosis in non-transformed and 
transformed cells seeded onto dishes coated with FN (Ilic et al., 1998; Zhang et 
al., 2004 (a)).  Due to the increased phosphorylation of FAK observed post FN 
treatment in the representative WHCO6 cell line, we examined whether FN would 
repress STS-mediated apoptosis via sustained activation of FAK in the HOSCC 
cell lines.  As STS-mediated detachment was demonstrated to be a more accurate 
representation of apoptotic sensitivity than TUNEL (Figure 3.9), the ability of FN 
to oppose STS-mediated detachment was assessed across the cell lines.  In 
comparison to serum-free conditions, FN treatment prior to STS treatment 
reduced STS-mediated detachment in the wt p53 cell lines (Figure 4.2).  
Moreover, with respect to three of four wt p53 cell lines (WHCO1, WHCO3 and 
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WHCO6) there was a significant reduction (p < 0.05) in STS-mediated 
detachment between the FN-pretreated and the STS control cells (Figure 4.2).  In 
addition, corresponding to the resistance to detachment observed in the mt p53 
cell lines, no appreciable difference between cell detachment post FN treatment 
was evident between cells seeded onto FN or control cells (Figure 4.2).   The 
caspase-3 null MCF7 cell line showed a similar trend to the mt p53 cell lines.    
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A. 
 
                                                 
                   
                 
B. 
 
 
Figure 4.1: FN increases pFAKTyr397 in the WHCO6 cell line.   A) FN 
treatment increased pFAKTyr397 2.1 fold at 10 μg/ml.  No 
appreciable difference in pFAKTyr397 was observed between 
10 μg/ml and 20 μg/ml FN.  B) Increased edge extension was 
observed post FN treatment in the WHCO6 cell line, when 
compared to serum-free control. W/C = WHCO6 whole cell 
lysate. SS = serum free conditions 
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Figure 4.2: FN treatment reduces STS-mediated detachment in wt p53 cell lines. Wt p53 cells seeded onto FN prior 
to STS-treatment exhibit reduced detachment when compared to STS treated cells.  No appreciable 
difference in detachment between FN and STS-treated cells was observed in the mt p53 and caspase-3 null 
cell lines. Results were analysed using one-way ANOVA with Holm-Sidak method.  Bars represent standard 
deviation. *p <0.05 
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4.3.3 FAK cleavage is independent of cell detachment or FN-mediated signalling 
 
We have clearly demonstrated that the cleavage of the C-terminal of FAK corresponded 
to caspase-3 activation (See Figure 3.10).  In addition, FAK cleavage was only 
observed in the wt p53 HOSCC cell lines (WHCO1, WHCO3, WHCO5 and WHCO6).  
Hence, as these data demonstrates that the mt p53 cell lines may be maintaining FAK-
dependent signalling, we examined whether cells seeded onto FN prior to STS treatment 
would demonstrate reduced FAK cleavage.  Although FN offered protection to STS-
mediated detachment in the wt p53 cell lines (Figure 4.2), there was no difference in 
FAK cleavage between FN-treated cells and control cells (Figure 4.3).  Consistent with 
the previous demonstration (Figure 3.10), STS treatment was not accompanied by FAK 
cleavage in the mt p53-R175H, mt p53-R273H or caspase-3 null cell lines (Figure 4.3).     
 
4.3.4 Survival signals transduced by FN are independent of FAK(Tyr397) or 
PKB(Ser473) phosphorylation 
 
Survival signals transduced by FN-integrin engagement via FAK are attributed to 
activation of PKB-mediated signalling (Sonoda et al., 1999; Diaz-Montero et al., 2006).  
Hence, we examined whether increased PKB-dependent signalling was responsible for 
the FN-mediated reduction in cell detachment observed in the wt p53 cell lines (Figure 
4.2).  The wt p53 WHCO6 cell line, which showed a significant decrease in STS-
mediated cell detachment post FN treatment, was compared to the mt p53-R175H SNO 
cell line that demonstrated no appreciable change in cell detachment.  In order for PKB 
to achieve full activation, phosphorylation at the Ser473 site is required (Sarbassov et 
al., 2006).  Although FN increased pFAKTyr397 in the WHCO6 cell line and reduced 
STS-mediated detachment, FN treatment did not maintain pFAKTyr397 or 
pPKBSer473 (Figure 4.4).  Conversely, in the mt p53-R175H SNO cell line, 
pFAKTyr397 and pPKBSer473 were not influenced by STS treatment (Figure 4.4). 
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A. 
 
 
 
See next page for legend. 
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B. 
 
Figure 4.3: FN treatment does not alter FAK expression in HOSCC cell lines. A) FN treatment did not oppose FAK 
cleavage in wt p53 cell lines.  FAK was not cleaved in mt p53-R175H, mt p53-R273H or caspase-3- null cell 
lines.  B) Densitometric analyses of FAK expression post STS/FN treatment.  FN did not appreciably 
influence the level of FAK expression post STS treatment in the wt or mt p53 cell lines.  Note: A SNO loading 
control was included in the first lane of each immunoblot to normalise protein loading and allow for 
densitometric comparison between immunoblots. 
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Figure 4.4: FN-dependent signals are independent of pFAKTyr397 
and pPKBSer473 phosphorylation in HOSCC cell lines.  
Dephosphorylation of both pFAKTyr397 and pPKBSer473 
accompanies FAK cleavage in the wt p53 WHCO6 cell line.  
pFAKTyr397 and pPKBSer473 were not influenced by STS/FN 
treatment in the mt p53-R175H SNO cell line.  Tubulin was 
included as the loading control.  A SNO loading control (L/C) is 
included in the first lane of each WHCO6 immunoblot to allow 
for comparison.  
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4.4 Discussion 
 
As loss of anchorage dependence is pivotal to the metastastic progression of 
tumours, characterization of cell adhesion events is critical to enhance the 
understanding of anoikis-related signalling.  In the anchorage-dependent HOSCC 
cell lines, survival signals transduced via the ECM were assessed by culturing the 
cells in the absence of serum and on tissue culture dishes coated with insoluble 
FN.  The enhanced cell adhesion induced by FN/integrin engagement is attributed 
to increased activation of FAK by Tyr397 phosphorylation (Sonoda et al., 1999; 
Zhang et al., 2004 (a)).  Consistent with previous reports in fibroblasts and 
epithelial tumours (Vitale et al., 1998; Zhang et al., 2004 (a)), FN increased 
Tyr397 phosphorylation (Figure 4.1A) and edge extension (Figure 4.1B) in the 
representative WHCO6 cell line.   
 
FAK cleavage corresponded to caspase-3 activation in the wt p53 cell lines, 
whilst, the mt p53 cell lines were resistant to STS-mediated detachment (See 
Figures 3.9B & 3.10).  Moreover, the mt p53-R175H cell line maintained integrin 
β1-activated FAK post STS treatment (Figure 3.11).  Thus, making use of this 
unique model of moderately-differentiated oesophageal carcinoma cell lines, we 
examined whether FN-mediated signalling protected the wt p53 and detachment-
resistant mt p53 cell lines from apoptotic death, as assessed by cell detachment.  
Notably, FN significantly reduced STS-mediated detachment (p < 0.05) in three 
of the wt p53 cell lines (WHCO1, WHCO3 and WHCO6), whilst cell detachment 
was not influenced in the mt p53 and caspase-3-null cell lines (Figure 4.2).  
Although FAK cleavage corresponded to increased cell detachment and caspase-3 
activation (Figure 3.10), FN did not offer protection to FAK cleavage in the wt 
p53 cell lines (Figure 4.3).  Hence, as the apoptotic ladder was detected in both 
attached and detached cells (Figure 3.9A), these data suggest that caspase 
activation, and consequently FAK cleavage, are not influenced by cell 
detachment.  This is the first documentation of ECM-dependent suppression of 
apoptotic stimuli in the highly metastatic HOSCC.  Pertinently, the mt p53 cell 
lines were unaffected by FN-mediated survival signalling and the mt p53-R175H 
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cell line maintained FAK-dependent signalling post STS treatment (Figure 4.4).  
Thus, in combination with the observed resistance to STS-mediated detachment, 
these data corroborate an important role of persistent FAK activation in anoikis 
resistance.   
 
Survival signals transduced via FN are attributed to activation of the PI3K 
cascade, and consequently, PKB Ser473 phosphorylation (Sonoda et al., 1999).  
However, contradictory reports indicate that FN-mediated survival signalling is 
cell-type dependent (Ilic et al., 1998; Zhang et al., 2004 (a)).  Thus, as no 
significant difference in FAK cleavage was evident, we examined whether FN-
treated cells maintained pFAKTyr397 and pPKBSer473 post STS treatment.  The 
generation of FAK cleavage products in the region of 85kDa have been reported 
to repress FAK phosphorylation (Gervais et al., 1998) and, thus, reduce FAK-
dependent survival signalling.  Furthermore, dephosphorylation of FAK has been 
shown to occur rapidly post STS treatment (Beviligia et al., 2003; Lim et al., 
2008).  Consistent with these studies, in the representative wt p53 cell line 
(WHCO6), attenuation of FAK and PKB phosphorylation corresponded to FAK 
cleavage and caspase-3 activation (Figure 4.4).  Hence, the cleavage of the C-
terminal from FAK abrogates FAK and PKB activity in the wt p53 WHCO6 cell 
line.  In contrast, in the detachment-resistant mt p53 cell line, STS induced 
oligonucleosomal cleavage was not accompanied by FAK cleavage or reduced 
FAKTyr397/PKBSer473 phosphorylation (Figure 4.4).  Thus, although FN 
treatment significantly reduced STS-mediated detachment in three of the wt p53 
HOSCC cell lines, no appreciable difference in FAK cleavage was observed.  
Furthermore, FAK cleavage was associated with abrogation of pFAKTyr397 and 
pPKBSer473 in the wt p53 WHCO6 cell line.  Therefore, even though FN 
mediated-signals have been demonstrated to suppress apoptosis via PI3K-
dependent PKB activation in other cell types (Sonoda et al., 1999; Zhang et al., 
2003), seeding HOSCC cells onto FN prior to STS treatment did not maintain 
FAK or PKB phosphorylation.  Accordingly, these observations point to an 
alternative survival role of FAK in the suppression of apoptotic stimuli.    
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In contrast, the absence of FAK cleavage corresponded to the maintenance of 
pFAKTyr397 and pPKBSer473 in the mt p53-R175H SNO cell line (Figure 4.4).  
Hence, these data indicate that the repressive effect that mt p53-R175H has been 
established to have on the FAK promoter (Golubovskaya et al., 2008 (a)), may be 
responsible for the constitutive phosphorylation and the maintenance of PKB-
dependent survival signalling observed in the SNO cell line.     
 
Sustained activation of FAK has been proposed to protect tumour cells from 
anoikis by repressing p53-dependent apoptosis (Ilic et al., 1998; Golubovskaya e t 
al., 2008 (a)).  Thus, the lack of dependence on cell adhesion-dependent signalling 
in mt p53-R175H cell line supports the notion that mt p53-R175H is intimately 
involved in conferring growth resistance via a FAK-dependent mechanism.  
Consequently, to explore this possibility, the role of sustained activation of FAK 
on interplay between FAK and p53-mediated apoptosis forms the basis of the 
subsequent chapter.   
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Chapter 5  
Interplay between p53 and FAK: impact of the mt p53-
R175H „loss of function‟ effect on FAK regulation 
  
5.1 Introduction 
Aberrant regulation of the p53-dependent apoptotic pathway is implicated as a 
major contributor to FAK-dependent anoikis resistance (Vitale et al., 1998; 
Golubovskaya et al., 2005).  In vitro, overexpression of FAK abrogates p53-
mediated apoptosis, as well as p53-dependent transcriptional activation of 
apoptotic genes (Golubovskaya et al., 2005; Golubovskaya et al., 2008 (a)).  
Pertinent to anoikis-related regulation, ECM activation of FAK reduces p53-
dependent apoptosis (Ilic et al., 1998; Zhang et al., 2004 (a)), whilst FAK 
knockdown in combination with cisplatin treatment has been shown to trigger 
p53-mediated apoptosis (Lim et al., 2008).  Furthermore, the apoptotic events 
triggered by FAK deactivation are accompanied by rapid dephosphorylation of the 
FAK autophosphorylation site, pFAKTyr397 (Beviligia et al., 2003).  However, it 
is difficult to discern from the previous studies if cancer cells resist p53-mediated 
apoptosis due to downstream effects of FAK-dependent survival signaling, or 
whether FAK facilitates cell survival by direct inhibition of p53.  The specific 
interaction between the FERM domain of FAK and N-terminal of p53 has been 
proposed to inhibit p53 activity by enhancing Mdm-2-dependent ubiquitination of 
p53 (Lim et al., 2008) or alternatively, inhibiting p53 transcriptional activity by 
binding to the p53 transactivation domain (Ilic et al., 1998; Zhang et al., 2004 
(a)).   Hence, in tumour cells overexpressing FAK, manipulation of the p53/FAK 
interaction may trigger p53-mediated apoptosis and thereby, enhance the 
apoptosis-inducing ability of chemotherapeutic reagents.   
 
Recently, a direct correlation between FAK overexpression and mutant p53 has 
been demonstrated (Golubovskaya et al., 2009).  p53 mutants differ in their ability 
to resist apoptotic stimuli.  Specifically, the R175H “hot spot” mutant has been 
shown to be a potent inhibitor of apoptosis (Blandino et al., 1999; Tsang et al., 
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2005; Golubovskaya et al., 2008 (a)).  It has been suggested that the R175H 
mutation limits the flexibility of p53, thereby “locking” p53 into a more rigid 
conformation that reduces its DNA-binding capacity and possibly the ability to 
interact with other proteins (Aylon and Oren, 2007).  This “loss of function” 
effect is attributed to reduced transcriptional upregulation of apoptotic 
intermediates, as the mutant is not resistant to ubiquitination (Figure 5.1; Shimizu 
et al., 2006).   
 
Furthermore, in addition to the loss of transcriptional function, some p53 mutants 
exert a gain of function (GOF) effect and exhibit a selective advantage in 
carcinogenesis (Figure 5.1; Levine et al., 1991).  GOF effects include enhanced 
cancer cell proliferation and increased tumourigenicity in vivo, suggesting that the 
GOF activity of mt p53 may play an important role in tumour progression.   In 
mouse models, mutant p53 expression in lymphoblastic leukemia cells or murine 
fibroblasts resulted in greater tumourigenicity and tissue invasiveness as 
compared to p53-null cells (Dittmer et al., 1993; Hsiao et al., 1994).  This GOF 
was attributed to altered patterns of gene expression as mt p53 has been found to 
upregulate the promoters of several genes, including multidrug resistance-1 
(MDR-1) (Chin et al., 1992).  In addition, mt p53 has been shown to 
downregulate proteins important to anoikis resistance, including caspase-3 (Tsang 
et al., 2005) and Fas (Zalcenstein et al., 2003). 
 
Since most p53 DNA binding domain (DBD) mutants do not alter the 
tetramerization domain, mt p53 is able to heterotetramerize with wt p53 (Milner 
and Medcalf, 1991).  Consequently, as the heterotetramerization of the 
conformational p53 mts with wt p53 converts the wt protein to an inactive, mutant 
conformation, p53 mutants exert dominant negative effects on co-expressed wt 
p53 (Figure 5.1; Ko and Prives, 1996; Willis et al., 2004).  Therefore, akin to the 
LOF effect, in these mutants the dominant negative effect is attributed to the 
reduced transcriptional activation of p53 targets, as the wt/mt heterotetramer does 
not bind DNA with the same affinity as the wt p53 homotetramer (Chene, 1998; 
Nicholls et al., 2002).  Furthermore, the ability of mutant p53 to inhibit wt p53 
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may be due to the mt p53 binding to components of the TFIID and TFIIH 
complexes (Wang et al., 1995).  As a consequence, mutant p53 sequesters 
transcriptional cofactors necessary for wild-type p53 activity.  Thus, the dominant 
negative effect of mutant p53 is reliant on the mutant p53 conformation, and 
consequently, the affinity of the mutant for p53 target sequences (Ko and Prives, 
1996; Willis et al., 2004). 
 
 
 
 
 
 
Figure 5.1: Diagrammatic summary of the impact of loss of p53 
function.  The phenotypic effects of p53 mutations can be 
classified as: 1) Mutations that abrogate the binding of p53 to 
its consensus DNA binding sequence.  Consequently, due to 
“loss of function” these mutants abolish the transcriptional 
activity of p53.  2)  Most missense mutations may produce a 
full-length mutant p53 capable of oligomerising with wt p53 to 
form a defective heterotetramer - these mutants exert a 
“dominant negative” function. 3) Several „gain of function‟ 
mutations confer mutant p53 with new functions independent 
of wild-type p53. GOF = gain of function; DN = dominant 
negative; LOF = Loss of function © Brosh and Rotter, 2009  
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Importantly, one way in which the prevalent “hot spot” p53 mt-R175H exerts a 
LOF effect is by abolishing the ability of p53 to transcriptionally increase FAK 
expression (Golubovskaya et al., 2008 (a)).  Pertinent to the loss of transcriptional 
regulation of FAK, we detail in the previous chapters that the mt p53-R175H cell 
line was resistant to STS-mediated FAK cleavage (Figure 3.10) and 
dephosphorylation (Figure 4.4).  Moreover, ECM-mediated protection of 
apoptotic death is independent of PKB signalling in the HOSCC cell lines, 
indicating that the activation of FAK represses cell death via an alternative 
mechanism (Figure 4.4).  Hence, in order to gain insight into the mechanism 
whereby the mt p53-R175H enhances FAK activity, we explored the influence of 
mt p53-R175H on interplay between FAK and p53.   
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5.2 Materials and Methods 
 
5.2.1 Cell lines 
As previously documented, see Chapter 2, Section 2.2.1 
 
5.2.2 Antibodies  
FAK, p53 and caspase-3 were specifically detected with a rabbit polyclonal 
antibody obtained from SantaCruz Technology.  Monoclonal mouse anti-
pFAK(Tyr397) (Millipore) was used to detect autophosphorylation of FAK.  
Polyclonal horseradish peroxidase (HRP)-bound anti-rabbit secondary antibody 
was used in (Separations, SA) and fluoroscine isothiocyanate (FITC)-conjugated 
anti-rabbit secondary antibody (Chappel, USA) were used in the immunoblot and 
immunofluorescence experiments respectively. 
 
5.2.3 Protein estimation assay 
As previously documented, see Chapter 2, Section 2.2.6 
 
5.2.4 Immunoblot analysis 
As previously documented see Chapter 2, Section 2.2.7  
 
5.2.5 Indirect immunofluorescence 
As previously documented, see Chapter 2, Section, 2.2.8 
 
5.2.6 Co-immunoprecipitation 
Cells were lysed in RIPA buffer (Appendix 1.3.2) for 30 min at 4 °C.  The lysates 
containing 350 μg protein were incubated with 3 μl of anti-p53 (Santa Cruz 
Technology) at 4 °C overnight.  20 μl of protein G-Sepharose beads were added to 
each lysate at 4 °C for overnight. The supernatant was decanted and an equal 
volume (40 µl) of double lysis buffer (Appendix 1.3.1) was added to the pellet. 
The suspension was boiled for 5 min and centrifuged for 10 min at 12000 r.p.m in 
a Sorvall® MC 12 V centrifuge.  Samples were resolved by SDS-PAGE and 
blotted onto nitrocellulose membranes (as above).  Blots were incubated in anti-
FAK to determine the relative association with p53.      
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5.2.7 Plasmids 
The pCMV-Neo-Bam-p53 and pCMV-Neo-Bam-R175Hp53 plasmids (Appendix 
5), containing the human full length p53 cDNA and R175H mutant p53 
respectively, were kindly donated by Dr. Bert Vogelstein and Dr Moshe Oren 
from the Weizmann Institute of Science, Israel.  
 
5.2.8 Preparation of competent cells for heat shock transformation 
Competent cells were prepared according to the protocol outlined by Inoue et al., 
(1990).  A colony of XL-1blue E.coli cells was inoculated in 50 ml of SOB
HS
 
(Appendix 1.9.1).  The cells were incubated at 18 °C, shaking at 180 r.p.m..  
When the cells reached an Abs of 0.6 at 600nm, the cells were incubated on ice 
for 5 min and centrifuged at 2000 x g for 10 min. The pellet was resuspended in 
15 ml of ice cold transformation buffer (TB) (Appendix 1.9.2). The cells were 
incubated on ice for 10 min, centrifuged at 8000 x g and resuspended in 4 ml of 
TB. DMSO (280 μl) was added and the cells were incubated on ice for 10 min. 
The cells (100 μl) were aliquoted into sterile Eppendorf tubes, placed in liquid 
nitrogen (10 sec) and stored at -70 °C. 
 
5.2.9 Heat shock transformation of XL-1 blue E.coli cells 
The heat shock transformation was performed according to the protocol outlined 
by Inoue et al. (1990). The competent cells prepared above were thawed on ice for 
30 min.  30 ng of plasmid DNA (empty vector, wt p53 or mt p53-R175H) was 
added to the cells.  The contents were mixed, placed on ice for 30 min and 
incubated at 42 °C for 90 sec.  Cells were placed on ice and pre-warmed SOC 
(Appendix 1.9.3) medium (37 °C) was added.  Cells were incubated at 37 °C for 
40 min and 100 μl of the transformation mixture was inoculated on selective LA 
plate (1.8.1), which was incubated overnight at 37 °C. 
 
5.2.10 Maxi-preparation to obtain adequate amount of purified plasmid 
The Maxi-preparation kit (Qiagen), an alkaline based extraction procedure, was 
used to extract a sufficient amount (up to 500 μg) of purified plasmid from 
transformed competent cells.  A single colony grown on selective LA plate was 
inoculated into 5 ml of LB (Appendix 1.8.2) containing 5% ampicillin.  The 
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culture was incubated for 8 hr at 37 °C, shaking at 180 r.p.m..  Subsequently, 200 
μl of the culture was inoculated into 100 ml of medium and incubated at 37 °C for 
16 hr, shaking at 180 r.p.m..  The culture was centrifuged at 6000 x g (J2-21 rotor, 
Beckman JA-20) for 15 min at 4 °C.  Once the pellet was resuspended in 10 ml of 
Buffer P1 and 10 ml of Buffer P2 respectively, the contents were mixed and 
incubated at TR for 5 min.  Buffer 3 (10 ml) was added, contents were mixed 
immediately and incubated on ice for 20 min.  The mixture was centrifuged at 
20000 x g for 30 min at 4 °C.  The supernatant was centrifuged at 20000 x g for 
15 min at 4 °C.  The supernatant was placed in a Qiagen-tip 500, which was 
previously preequilibrated (rinsed) with 10 ml of buffer QBT.  The Qiagen-tip 
was rinsed twice with 30 ml of Buffer QC.  The DNA was eluted with 15 ml of 
Buffer QF, mixed with 10.5 ml of isopropanol and centrifuged 15000 x g for 30 
min at 4 °C.  The resultant pellet was washed with 5 ml of 70% ethanol and 
centrifuged at 15000 x g for 10 min.  Once the supernatant was removed, the 
pellet was allowed to dry for 10 min. DNA was resuspended in sterile dH2O for 2 
hr at 4 °C. The final DNA concentration in the sample was quantified with the 
Nanodrop® ND-1000 Spectrophotometer. 
 
5.2.11 Restriction of plasmids from transformed E.coli 
A reaction mixture (10 μl) containing 10 units (U) of BamHI (Amersham), 10 U 
of EcoRV (Amersham) and 1 μl buffer B (Amersham) was used to restrict either 
15 μg of the pCMV-empty vector, pCMV-Neo-Bam-p53 or pCMV-Neo-Bam-
R175Hp53 plasmids respectively. The resultant mixture was incubated at 37 °C 
for 3 hr.  Restricted products (5 μl) and 250 ng of 1 Kb Plus DNA ladderTM 
(Gibco BRL) were each mixed with 5 μl of loading buffer (Appendix 1.11.1) and 
subject to 0.8% agarose gel electrophoreses (appendix 1.4.1) at constant voltage 
of 72V. Ethidium bromide (1%) was used to visualise the DNA under UV light.  
 
5.2.12 Transfection of WHCO6 and SNO cell lines 
The pCMV-Neo-Bam-p53 and pCMV-Neo-Bam-R175Hp53 plasmids were 
transfected into the H1299 and WHCO6 cell lines.  A day prior to the transfection, 
3 x 10
6
 of the H1299 or WHCO6 cells were seeded onto a 60 mm tissue culture 
dish.  Cells were maintained in 5 ml of tissue culture medium and 10% FCS at 37 
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°C. The transfection of the pCMV-Neo-Bam-p53 and pCMV-Neo-Bam-
R175Hp53 plasmids was performed according to the manufacturer‟s instructions 
(Invitrogen).  Transfection of the pCMV-Neo-Bam-R175Hp53 plasmid was 
performed at a 1:1 ratio of vector:Lipofectamine
TM
 2000 (referred to in text as 
low charge ratio).  With respect to the pCMV-Neo-Bam-p53 plasmid, 
transfections were performed at a 3:1 ratio of vector:Lipofectamine
TM
 2000 
(referred to in text as high charge ratio).    Briefly, transfection reagent (7 μl) 
was placed in 200 μl of serum-free tissue culture medium. This was followed by 
the addition of 21 μg of the pCMV-Neo-Bam-p53 and 7 μg pCMV-Neo-Bam-
R175Hp53 plasmids respectively, to form a mixture.  After 15 min, the mixture 
was added drop wise to the tissue culture medium in the 6 cm dish containing the 
H1299 or WHCO6 cells.  As a control, 7 μl of LipofectamineTM 2000 was mixed 
with, 7 μg/21 μg of the empty pCMV-Neo-Bam vector and 200 μl of medium for 
15 min and added to a separate dish of cells. 
 
5.2.13 Densitometry  
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) 
was used for densitometric analysis to quantitatively determine the concentration 
level of protein in the western blots.  When interpreting the transfection data, we  
considered a 1.2 fold increase (equivalent to 20 %), to be an appreciable change in 
FAK expression levels. 
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5.3 Results 
 
5.3.1 The p53/FAK association is intact in HOSCC cell lines harbouring wt 
or mt p53-R175H 
 
As the mt p53 cell lines were resistant to STS-mediated detachment and caspase-3 
activation (See Figure 3.9 & 3.10), we examined whether the inhibitory p53/FAK 
interaction (Golubovskaya et al., 2005) was intact in moderately differentiated 
HOSCC cell lines harbouring wt p53 or mt p53-R175H, as well as the HT29 cell 
line harbouring the R273H DNA contact mutant.  We clearly show by 
immunoprecipitation that FAK associates directly with wt and mt p53 (Figure 
5.2).  The p53/FAK interaction has been demonstrated to abrogate p53-dependent 
apoptosis (Golubovskaya et al., 2005; Lim et al., 2008).     
 
5.3.2 STS induces nuclear accumulation of FAK in wt and mt p53-R175H 
cell lines 
 
As staurosporine has been previously shown to enhance nuclear FAK (Lim et al., 
2008), we examined whether apoptotic events that initiate oligonucleosomal 
cleavage, both with or without caspase-3 activation, influenced the nuclear 
localisation of FAK.  The nuclear translocation of FAK has been shown to be a 
prerequisite for FAK-mediated inhibition of p53 (Lim et al., 2008).  Due to the 
disruption of the nucleus during apoptotic events, analysis of the nuclear fraction 
became impractical.  As FAK localisation has previously been demonstrated by 
fluorescence microscopy (Ossovskaya et al., 2008), STS-induced FAK nuclear 
translocation was detected by immunofluorescence in both the representative wt 
p53 cell line (WHCO6) and mt p53 cell line (SNO).  Consequently, in both wt and 
mt p53 HOSCC cell lines, FAK accumulates in the nucleus (Figure 5.3) during 
cellular conditions that initiate oligonucleosomal cleavage (See Figure 3.8A). 
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Figure 5.2: The p53/FAK association is independent of p53 
mutational status.  p53 was detected in complex with FAK in 
the wt p53, mt p53-R175H and mt p53-R273H cell lines. A 
whole cell lysate from the WHCO6 cell line was included for 
each immunoblot to demonstrate the specificity of the 
immunoprecipitation reaction.  A negative control (Lysate + 2μl 
anti-p53 antibody) was included to demonstrate the specificity 
of the co-immunoprecipitation. 
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Figure 5.3: FAK accumulates in the nucleus in both wt and mt p53 
cell lines post STS treatment.  Nuclear localisation of FAK 
was observed post STS treatment in both wt and mt p53 cell 
lines, following immunofluorescent detection.  Scale bar = 
10µm; serum-free conditions (SS), 30nM STS (STS). 
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5.3.3 The p53/FAK association is independent of FAK Tyr397 
phosphorylation 
 
Since nuclear FAK has been shown to enhance the association between p53 and 
FAK (Lim et al., 2008), we examined whether p53 remained associated with FAK 
in the wt p53 (WHCO6) and mt p53 (SNO) cell lines.  During STS-mediated 
apoptotic events, the p53/FAK interaction was maintained in both wt and mt p53 
cell lines.  Furthermore, p53 was detected in complex with the cleavage product 
of FAK (Figure 5.4A).  The inhibitory effect of FAK on p53 is independent of 
FAK phosphorylation (Lim et al., 2008).  Accordingly, STS-mediated 
dephosphorylation of FAK did not influence the p53/FAK association.  
Importantly, corresponding to the absence of FAK cleavage, FAK remained 
phosphorylated in the mt p53-R175H cell line post STS treatment (Figure 5.4B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
 
 
 
 
 
Figure 5.4: p53 associates with FAK independent of STS-mediated 
cleavage of FAK and Tyr397 phosphorylation. A) p53 was 
detected in complex with FAK in the wt p53 WHCO6 and mt 
p53-R175H SNO cells under:  normal tissue culture 
conditions/ whole cell lysate from WHCO6 cell line (W/C), 
serum-free conditions (SS) and treated with 30 nM STS (STS).  
Notably, p53 was detected in complex with cleaved FAK post 
STS treatment in the wt p53 WHCO6 cell line B) STS-
treatment results in FAK cleavage and dephosphorylation at 
Tyr397 in the wt p53 WHCO6 cell line, whilst FAK was not 
cleaved and pFAKTyr397 remained unchanged in mt p53-
R175H SNO cell line.  Mt cont = W/C control from p53-R175H 
cell line, APT cont = STS treated apoptotic control 
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5.3.4 Sequence analysis confirmed the integrity of pCMV-Neo-Bam-p53 and 
pCMV-Neo-Bam-R175Hp53 plasmids 
 
We clearly demonstrate that the R175H mutation does not interfere with the 
ability of mt p53-R175H to associate with FAK (Figure 5.2).  However, the 
detachment-resistant SNO cell line harbouring mt p53-R175H cell line was 
resistant to FAK cleavage, caspase-3 activation (Figure 3.10) and 
dephosphorylation of FAK (Figure 4.4).  In response to stress stimuli, p53 
accumulates in the nucleus and represses FAK gene transcription (Golubovskaya 
et al., 2005).  As the R175H mutation abrogates the DNA binding ability of p53, 
mt p53-R175H is resistant to the transcriptional regulation of FAK (Golubovskaya 
et al., 2008 (a)).  Hence, one possible way in which the mt p53-R175H cell line 
might evade caspase-dependent apoptosis is by upregulating the expression of the 
FAK protein.  In this way, the anti-apoptotic ability of FAK would be enhanced, 
facilitating the evasion of anoikis-related death.  This possibility was explored in 
transient transfection assays, employing plasmids encoding either wt or mt p53-
R175H.   
 
The integrity of the pCMV-Neo-Bam empty vector, pCMV-Neo-Bamp53 and 
pCMV-Neo-BamR175Hp53 plasmids was established by restriction digest 
(Figure 5.5), followed by sequence analysis (Figure 5.6).  Restriction digest of the 
pCMV-Neo-Bam empty vector generated a linear plasmid (orange), double digest 
of the pCMV-Neo-Bamp53 vector generated a 1.8kb fragment (green), whilst, 
double digest of the pCMV-Neo-BamR175Hp53 vector generated a 1.3kb 
fragment (blue).  Both the integrity of wt p53 (Figure 5.6A) and the R175H 
mutation located on exon 5 (Figure 5.6B) were confirmed by sequence analysis of 
a single colony. 
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Figure 5.5: Restriction of the purified pCMV-Neo-Bam, pCMV-Neo-
Bam-wtp53 and pCMV-Neo-Bam-R175H vectors. (a) An 
agarose gel separation of vectors extracted via (A) mini-prep 
and (B) maxi-prep. Single nick generated linear plasmid 
(orange); double digest generated 1.8kb fragment (green); 
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double digest generated 1.3kb fragment (blue); RNA 
degradation products (pink). 
 
 
 
 
Figure 5.6: Sequence analysis of the wt p53 and mt p53-R175H 
pCMV-Neo-Bam vectors.  A) wt p53 and B) the R175H 
mutation on exon 5 was confirmed by sequence analysis of a 
single colony of the pCMV-Neo-Bam-p53R175H and pCMV-
Neo-Bam-p53 vectors respectively. 
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5.3.5 Overexpression of mt p53-R175H increased FAK expression  
 
As all commercially available p53 antibodies recognize both wt and mt p53 
(Chene, 1998), the p53-null H1299 cell line (Figure 5.7) was used to optimise 
transient transfection assays with vectors containing genes encoding wt p53 or mt 
p53-R175H.   Lipofectamine is a cationic liposomic reagent widely used to 
introduce DNA encoding therapeutic proteins into cells (Azad and Rojanasakul, 
2006).  The overall positive charge of the Lipofectamine/DNA complex interacts 
with the negative charge of the plasma membrane and facilitates internalization of 
the complex into the cells by endocytosis (Azad and Rojanasakul, 2006).  The 
charge ratio of the cationic species determines the cytotoxicity of cationic 
lipsomes, with a higher charge ratio being more toxic (Dokka et al., 2000; Lv et 
al., 2006).  Previous transfection studies in the same series of HOSCC cell lines 
indicated that a low charge ratio of DNA: Lipofectamine2000 was well tolerated 
by the HOSCC cells (See Materials and Methods 5.2.12).  In addition, p53 has 
previously been successfully transfected with Lipofectamine 2000 in the H1299 
cell line under these conditions (Vikhanskaya et al., 2007). 
 
Thus, the H1299 cell line was transiently transfected with vectors encoding genes 
for either wt p53 or mt p53-R175H.  As mutant p53 does not activate expression 
of its negative regulator, MDM2 (Prives and Hall, 1999; Peng et al., 2001), it is 
more stable than wild-type p53.  Consistent with these reports, only mt p53-
R175H was detected post transfection in the H1299 cell line at the lower charge 
ratio of vector to transfectant (Figure 5.8).  Although FAK expression decreased 
post mt p53-R175H transfection at 24hr, there was an appreciable increase of 
FAK expression (1.2 fold relative to empty vector control) post 48hr transfection.   
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5.3.6 Overexpression of wt p53 did not influence FAK expression  
 
It is well established that the subset of cell death induced by cationic liposomes is 
primarily via apoptotic death pathways (Aramaki et al., 1999; Aramaki et al., 
2000).  Accordingly, the volume of Lipofectamine used in the previous 
transfection assay was sufficient to activate caspase-3 and therefore, apoptotic 
pathways (Figure 5.8).  Thus, as wt p53 was not detected post transfection with 
the low charge ratio of vector to transfectant, the transient transfection assay for 
wt p53 was repeated with three-fold DNA to transfectant.  Wt p53 was only 
detected in the H1299 cell line post 24hr of transfection.  No appreciable change 
in FAK expression was evident post wt p53 transfection (Figure 5.9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: The p53-null H1299 non-small lung carcinoma cell line 
expresses FAK. Comparable FAK expression to the WHCO1 
cell line was evident in the H1299 cell line.  p53 was not 
detected by immunoblot in the H1299 cell line.    
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See next page for legend. 
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B.      
 
C. 
 
 
Figure 5.8: Overexpression of mt p53-R175H in the H1299 cell line 
increased FAK expression.  A) Mt p53-R175H was detected 
in the H1299 cell line post transfection at the low charge ratio 
of DNA:Lipofectamine.  Caspase-3 activation was detected in 
the pCMV-empty vector control.  B&C) Densitometric analysis 
revealed that corresponding to the detection of (B) mt p53-
R175H, (C) FAK expression increased 1.2 fold relative to the 
empty vector control, post 48hr transfection.   
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See next page for legend. 
128 
 
B.                   
 
C. 
         
Figure 5.9: Overexpression of wt p53 does not repress FAK 
expression.  A) Wt p53 expression was detected in the 
H1299 cell line after 24hr post transfection at the higher 
charge ratio of DNA to transfectant reagent.  B) Densitometric 
analysis revealed that overexpression of (B) wt p53 did not 
repress (C) FAK expression.  
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5.3.7 mt p53-R175H does not protect wt p53 HOSCC cell line from STS-
dependent FAK cleavage 
   
As overexpression of mt p53-175H increased FAK expression in the H1299 cell 
line (Figure 5.8), we examined whether the previously described dominant 
negative effect of mt p53-R175H (Ko and Prives, 1996; Willis et al., 2004) was 
evident post STS treatment in the representative wt p53 WHCO6 cell line.  
WHCO6 cells were transiently transfected with mt p53-R175H for 24 hr, 
following treatment with STS for 24hr.  Corresponding to previous transfection 
assays (Figure 5.8), the introduction of mt p53-R175H into the wt p53 WHCO6 
cell line increased p53 expression 1.2 fold relative to the empty vector control 
(Figure 5.10).  Although the mt p53-R175H did not oppose STS-mediated FAK 
cleavage, FAK expression in the mt p53-R175H/STS transfected cells was 
elevated 1.4 fold relative to the STS control (Figure 5.10).   
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See next page for legend. 
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B.       
 
C. 
        
Figure 5.10: Mt p53-R175H does not protect wt p53 WHCO6 cell line 
from STS-mediated FAK cleavage.  A) p53 expression 
increased post transfection with the pCMV-Neo-Bam-
p53R175H vector in the mt p53-R175H cell line.  FAK 
cleavage was not reduced by the overexpression of mt p53-
R175H in the wt p53 cell line. B&C) Densitometric analysis 
revealed that increased (B) p53 expression corresponded to 
increased (C) FAK expression.  
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5.4 Discussion 
 
An alternative survival role of FAK has recently been shown that involves its 
nuclear translocation and repression of p53-dependent apoptosis (Golubovskaya et 
al., 2005; Lim et al., 2008).   However, this regulation has been exclusively 
demonstrated in cell lines harbouring wt p53.  The “hot spot” p53 mt-R175H is 
proposed to confer resistance to apoptosis by repressing the FAK promoter 
(Golubovskaya et al., 2008 (a)).  In addition, we have shown that the mt p53-
R175H cell line displays altered FAK regulation (Figure 3.10 & 4.4).  Thus in 
order to establish the role of mt p53-R175H on FAK regulation in oesophageal 
carcinoma, we compared interplay between p53 and FAK, in HOSCC cell lines 
expressing either wt or mt p53-R175H.   
 
The p53/FAK association is mediated via interactions between the N-terminal of 
(amino acids 206–422) and seven amino acids located in the proline-rich region of 
p53 (Golubovskaya et al., 2008 (b)).  Due to impaired flexibility, the 
conformational mt p53-R175H has reduced DNA-binding capacity (Aylon and 
Oren, 2007).  However, the R175H did not influence the ability of p53 to 
associate with FAK (Figure 5.2).  Furthermore, the proline-rich region of p53 that 
interacts with p53 contains the Pro/Arg72 polymorphism, which frequently 
changed to an arginine residue in different tumours.  Hence, in addition to the 
R175H mutation, the Pro/Arg72 polymorphism, in the mt p53-R175H cell line did 
not affect the p53/FAK association.  Moreover, during STS-mediated apoptotic 
events, the p53/FAK interaction was maintained in both wt and mt p53 cell lines 
(Figure 5.3).  Consistent with previous reports, nuclear accumulation of FAK was 
detected in both wt and mt p53-R175H cell lines post STS treatment (Figure 5.2; 
Golubovskaya et al., 2008 (a); Ossovskaya et al., 2008).  Since caspase-3 
activation was not detected in the mt p53-R175H cell line, these results suggest 
that caspase-3 dependent events do not influence stress-induced FAK nuclear 
translocation.  Although the association has been demonstrated to be enhanced 
post doxorubicin/staurosporine treatment (Lim et al., 2008), this is the first study 
to show that the association is maintained post caspase-3 activation and 
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independent of p53 mutational status.  Importantly, these data reveal that the 
altered regulation of FAK and resistance to caspase activation in the mt p53-
R175H cell line (Figure 3.9 & 3.11) is not due to the inability of mt p53-R175H 
to associate with FAK. 
 
Mt p53-R175H is resistant to the transcriptional regulation of FAK 
(Golubovskaya et al., 2008 (a)).  Emphasizing the importance of this LOF effect, 
we have established that the mt p53-R175H cell line was resistant to STS-
mediated FAK cleavage (Figure 3.9) and dephosphorylation (Figure 4.4).  
Moreover, a direct correlation between overexpression of FAK and mutant p53 
has been demonstrated in breast cancer (Golubovskaya et al., 2009).  In 
agreement with this data, overexpression of mt p53-R175H in the p53-null H1299 
cell line increased FAK expression post 48hr transfection (Figure 5.8).  
Furthermore, overexpression of wt p53 had no appreciable effect on FAK 
expression (Figure 5.9).  Therefore, in addition to loss of transcriptional 
regulation of FAK, these data demonstrate that mt p53-R175H may enhance FAK 
expression, and as a consequence FAK-dependent signalling. 
 
Several studies, in both mice and humans, have discovered cells expressing 
mutant p53 possess a carcinogenic advantage (Dittmer et al., 1993; Hsiao et al., 
1994; Liu et al., 2000).  These studies demonstrate that the p53 mutants disrupt 
normal p53 function, by reducing the activity of p53 tetramers.  Importantly, the 
tetramerization of mt p53 with wt p53 reduces the ability of the p53 tetramer to 
bind the FAK promoter (Willis et al., 2004).  Thus, as mt p53-R175H increased 
FAK expression in the p53-null H1299 cell line (Figure 5.8), we investigated 
whether the introduction of the mt p53-R175H into the wt p53 cell line was 
sufficient to abrogate FAK-dependent regulation.  Notably, although 
overexpression of mt p53-R175H did not protect the wt p53 WHCO6 cell line 
from STS-mediated FAK cleavage, the introduction of mt p53-R175H increased 
FAK expression (Figure 5.10).  Hence, these data emphasize that the mt p53-
R175H exerts a dominant negative effect on endogenous wt p53.   
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Applicable to FAK activity, we show that FAK expression is related to Tyr397-
phosphorylation (Figure 2.4).  Thus, it is evident that by increasing the expression 
of FAK, the mt p53-R175H may have a profound influence on the regulation of 
anchorage-independent death, through enhanced FAK-dependent signalling.  
Moreover, the altered regulation of FAK-directed events in the mt p53-R175H 
cell line was not due to the inability of mt p53-R175H to associate with FAK (See 
Figure 5.3).  However, the mt p53-R175H cell line was resistant to FAK 
dephosphorylation (Figure 4.4 & 5.3).  Constitutive activation of FAK protects 
cells from anoikis-mediated activation of caspase-8 (Kurenova et al., 2004).  
Hence, the persistent activation of FAK observed in mt p53-R175H cell line may 
be facilitating resistance to detachment and caspase activation, through the 
suppression of the Fas-mediated death cascade.  Therefore, to ascertain the full 
impact of mt p53-R175H in anoikis-related regulation, the investigation of the 
influence of FAK-dependent signalling on Fas-mediated death is detailed in the 
next chapter. 
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Chapter 6 
Role of FAK activation in the suppression of Fas-mediated 
apoptosis in HOSCC cell lines  
 
6.1 Introduction 
In addition to repressing p53-dependent anoikis (Frisch et al., 1998; 
Golubovskaya et al., 2005), constitutive activation of FAK has also been reported 
to suppress Fas-mediated apoptosis (Kurenova et al., 2004; Kamarajan and 
Kapila, 2007).  Substrate-deprived death was demonstrated to be accompanied by 
increased levels of Fas, FasL and enhanced formation of the DISC, whilst Fas 
attenuation by siRNA treatment rescues anoikis-mediated DISC formation (Ishida 
et al., 2003; Kamarajan et al., 2010).  Moreover, an indirect link between Fas and 
FAK-mediated signaling via receptor interacting kinase (RIP) has been 
demonstrated (Kamarajan et al., 2010).  Hence, the suppression of Fas-mediated 
apoptosis by FAK-dependent signalling represents an important component of the 
regulation of anoikis-related events.   
 
Fas expression was originally believed to be restricted to cells of the immune 
system, however, Fas is expressed in most adult tissues including liver, thymus, 
heart and ovary (Papoff et al., 1999; Siegel et al., 2000).  Importantly, Fas and its 
associated ligand, FasL, have been shown to be constitutively expressed by 
normal human oesophageal mucosal cells (Gratas et al., 1998).  Unlike Fas which 
is ubiquitously expressed, FasL is expression mainly restricted to activated T 
lymphocytes and natural killer cells (Krueger et al., 2003).  In this way, the 
immune system utilises FasL as a powerful means to eliminate compromised 
cells.  Consequently, transformed and infected cells are identified by FasL-bearing 
cells of the immune system and destroyed (Krueger et al., 2003).  Clearly, this 
immune attack is dependent on the inherent capability of the target cell to enter 
apoptosis.  Thus, the loss of control of these death pathways has dire 
consequences as compromised cells are permitting to continue proliferating.   
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In previous chapters we have shown, in the HOSCC cell line harbouring mt p53-
R175H, FAK remained phosphorylated at Tyr397 under the same apoptotic 
conditions that four wt p53 cell lines displayed FAK cleavage and caspase-3 
activation (Figure 3.9 & 4.4).  The resultant cell death that accompanies reduced 
FAK activity has been attributed to reduced survival signaling via the PI3K-
dependent signaling cascade (Sonoda et al., 1999).  However, FN-mediated 
signals were independent of PKB-dependent signalling (Figure 4.4).  In addition, 
the “hot-spot” mt p53-R175H exerts a dominant negative effect on wt p53, and 
enhances FAK expression (Golubovskaya et al., 2005).  Consistent with these 
studies, overexpression of mt p53-R175H increased FAK expression (Figure 5.8).  
Therefore, as abrogation of FAK expression has been shown to be associated with 
enhanced caspase-8 activation and the induction of anoikis (Kurenova et al., 
2004), we explored whether the persistent activation of FAK in the mt p53-
R175H cell line was accompanied by the suppression Fas-mediated apoptosis.  
Uniquely, the novel complex between Fas and FAK identified in wt and mt p53-
R175H cell lines provides unique insight into the association between sustained 
FAK activity and delayed Fas-mediated apoptosis.  Hence, the data presented in 
this chapter strongly supports our earlier contention that, the “hot spot” mt p53-
R175H may have a significant impact on the survival of tumor cells post cell 
detachment, by opposing the induction of FAK-dependent anoikis. 
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6.2 Materials and Methods 
 
6.2.1 Cell lines 
As previously documented, see Chapter 2, Section 2.2.1 
  
6.2.2 RNA extraction 
As previously documented, see Chapter 2, Section 2.2.2 
 
6.2.3 Reverse transcription 
As previously documented, see Chapter 2, Section 2.2.3 
 
6.2.4 Antibodies  
Fas and FasL were specifically detected with a rabbit polyclonal antibody 
obtained from SantaCruz Technology.  Monoclonal mouse anti-pFAK(Tyr397) 
(Millipore) and anti-caspase8 (Cell Signalling Technology) was used to detect 
autophosphorylation of FAK and activation of caspase-8 respectively.  Polyclonal 
horseradish peroxidase (HRP)-bound anti-rabbit secondary antibody was used in 
(Separations, SA) and fluoroscine isothiocyanate (FITC)-conjugated anti-rabbit 
secondary antibody (Chappel, USA) were used in the immunoblot and 
immunofluorescence experiments respectively. 
 
6.2.5 Protein estimation assay 
As previously documents, see Chapter 2, Section 2.2.6 
 
6.2.6 Immunoblot analysis 
20µg of protein per lane was resolved on a 10% SDS-PAGE and electro-blotted 
onto a nitrocellulose membrane (Sartorius).  Nonspecific binding sites on the 
membrane were pre-blocked in blocking buffer for 1 hr.  Blots were incubated 
with anti-Fas (1:650), anti-FasL (1:500) for 1hr or overnight with p-FAK(Tyr397) 
(1:500) or caspase-8 (1:500) in 1% BSA.  Following incubation in HRP-
conjugated secondary (1:5000) membranes were washed 6 times at 5 min 
intervals with PBS before being exposed to the SuperSignal West Pico 
Chemiluminescent working solution for 5 min.  Blots were sealed in polyethylene 
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wrap and exposed to hyperfilm™ MP autoradiography film (Amersham, UK) for 
10 min. 
 
6.2.7 Indirect immunofluorescence 
The visual determination of Fas and FasL was determined by indirect 
immunofluorescence.  Cultured cells were fixed with 4% paraformaldehyde for 30 
min and washed twice with PBS.  Following permeabilisation with 0.25% Triton 
X-100 for 10 min, cells were rinsed twice with PBS and allowed to dry partially. 
Fixed cells were incubated with anti-Fas (1:100) or anti-FasL (1:100) antibodies 
respectively for 1hr.  Following incubation with the anti-rabbit fluoroscine 
isothiocyanate-conjugated secondary antibody (1:250) for 1hr, Elvanol mounting 
agent was added to the wells and cells were viewed at 400 X magnification under 
a Zeiss LSM 410 confocal microscope (FITC excitation 490, emission 525). 
 
6.2.8 Co-immunoprecipitation 
Cells were lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 0.5% deoxycholate, 0.5% Triton X-100, 0.05% STS, 1 mM PMSF and 
aprotinin, for 30 min at 4 °C.  The lysates containing 350 μg protein were 
incubated with 3 μl of anti-integrin Fas (Santa Cruz Technology) at 4 °C for 6 hr.  
Then 20 μl of protein G-Sepharose beads were added to each lysate at 4 °C for 
overnight. The suspension was boiled for 5 min and centrifuged for 10 min at 
12000 r.p.m. in a Sorvall® MC 12 V centrifuge.  Samples were resolved by SDS-
PAGE and blotted onto nitrocellulose membranes (as above).  Blots were 
incubated in anti-FAK and anti-FasL to determine the relative association with 
Fas.      
 
6.2.9 Densitometry  
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) 
was used for densitometric analysis to quantitatively determine the concentration 
level of FasL, Fas and caspase-8 in the Western blots.  
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6.3 Results 
 
6.3.1 HOSCC cell lines harbouring wt or mt p53-R175H express FasL 
 
Fas-mediated apoptosis is initiated by the interaction of membrane-bound FasL, 
with its corresponding death receptor, Fas (O‟Reilly et al., 2009).  We have 
already established that the HOSCC cell lines express Fas (Figure 2.9).  
Therefore, in order to fully characterise the Fas death cascade we assessed 
whether the HOSCC series of cell lines express FasL.  The 40kDa membrane-
bound counterpart of FasL was detected in the HOSCC, HT29 and MCF7 cell 
lines (Figure 6.1A).  Under standard tissue culture conditions, the WHCO1 cell 
line had the highest FasL expression.  The lowest FasL expression was observed 
in the WHCO3 and WHCO6 cell lines, on average approximately 2 fold less than 
the WHCO1 cell line (Figure 6.1B). 
 
6.3.2 Peri-nuclear localisation of FasL was observed in HOSCC cell lines 
 
Consistent with previous reports in glycosylated proteins, distinct peri-nuclear 
localisation of FasL was observed in HOSCC cell lines, as well as the caspase-3 
null MCF7 and mt p53-R273H HT29 control cell lines (Figure 6.2).  Increased 
membrane expression of FasL has been proposed to enable oesophageal tumors to 
evade immune surveillance (Kozowski et al., 2007).  Contrary to this observation, 
no distinct membrane localisation of FasL was observed in the HOSCC cell lines 
(Figure 6.2). 
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A. 
 
 
B. 
                      
 
 
 
Figure 6.1: FasL is differentially expressed by the HOSCC, MCF-7 and 
HT29 cell lines under standard tissue culture conditions. 
(A) Western blot analysis of the cell lysates using a polyclonal 
antibody against FasL. The membrane-associated counterpart 
of FasL was detected at 40 kDa. (B) Densitometric analysis of 
the immunoblot was performed using Labworks™ Image 
Acquisition and Analysis software.  The relative difference 
FasL was assessed across all of the HOSCC cell lines. 
Expression levels are relative to the maximum per 20µg of 
protein in the WHCO6 cell line.  Note: the whole cell samples 
used to detect FAK in Figure 2.3A we were the same samples 
used to detect FasL, and therefore, the tubulin immunoblot 
also represents the loading control for the above immunoblot. 
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WHCO1           WHCO3 
     
 
WHCO5           WHCO6 
     
 
SNO             HT29 
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MCF7             Negative control 
 
     
 
 
 
Figure 6.2: Peri-nuclear localisation of FasL was observed in the 
HOSCC cell lines. Under standard tissue culture condition, 
distinct peri-nuclear localisation of FasL is evident, with a 
smaller percentage being localised in the cytoplasm.  
Negligible diffuse staining was observed in the negative 
control (excluding anti-FasL antibody). Scale bar = 15μm 
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6.3.4 STS modulates Fas and FasL expression in wt p53 HOSCC cell lines 
 
Fas and FasL have been shown to be upregulated following detachment from the 
ECM (Ishida et al., 2003; Kamarajan et al., 2010).  In addition, p53 has been 
implicated in the regulation of Fas-mediated apoptosis, as wt p53 has been 
demonstrated to increase Fas membrane trafficking (Bennet et al., 1998).  
Furthermore, the “hot spot” mt p53-R175H and p53-R273H have been 
demonstrated to suppress Fas transcriptional upregulation (Zalcenstein et al., 
2003).  Therefore, the effect of STS-mediated apoptosis on Fas and FasL 
expression was assessed in both wt and mt p53 cell lines. 
 
There was a distinct variation in Fas expression post STS treatment between wt 
and mt p53 cell lines.  In the WHCO1, WHCO3 and WHCO6 cell lines the 52 
kDa isoform increased post serum withdrawal (Figure 6.3B).  The WHCO1 cell 
line exhibited a 2 fold increase in the 52 kDa subunit of Fas post serum 
withdrawal.  Similarly in the WHCO3 and WHCO6 cell line, expression of the 
52kDa subunit of Fas increased 2.4 and 1.6 fold respectively following serum 
withdrawal (Figure 6.3B).  The partially glycosylated 48kDa subunit of Fas was 
still not detected in the WHCO3 cell line following treatment (Figure 6.3C).  
Alternatively, no change in Fas expression was evident post serum-
withdrawal/STS treatment in the SNO or MCF7 cell lines.  Consistent with 
previous reports in cell lines harbouring the mt p53-R273H (Zalcenstein et al., 
2003), Fas was only detected post serum-withdrawal in the HT29 cell line (Figure 
6.3A).  Although serum-removal had an impact on Fas expression, no substantial 
difference in Fas expression was observed between untreated and STS-treated 
HOSCC, MCF7 or HT29 cells (Figure 6.3B & C).   
 
FasL expression was upregulated post serum withdrawal in the WHCO3 and 
WHCO6 cell lines by 1.5 and 1.6 fold respectively (Figure 6.3D).  While FasL 
expression remained unchanged in the MCF-7 cell line, FasL expression increased 
post STS treatment in the WHCO1, WHCO6, SNO and HT29 cell lines (Figure 
6.4D). 
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See next page for legend. 
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B.  
     
 
   C.  
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D. 
     
 
 
 
 
Figure 6.3: The expression of Fas and FasL is modulated post serum-
withdrawal and STS-treatment in the HOSCC cell lines.   
A)  The expression of the partially glycosylated 48 kDa and 
fully glycosylated 52kDa isoform of Fas was variable among 
the cell lines.  The 48 kDa isoform was not detected in the 
WHCO3 and MCF-7 cell lines.  B&C) With exception to the 
WHCO5 cell line, the fully glycosylated (B) 52 kDa isoform of 
Fas increased in the wt p53 cell lines (WHCO1, WHCO3 and 
WHCO6).  The WHCO5 cell line does not express the 52 kDa 
isoform of Fas.  Both the (C) 48 kDa and 52 kDa variants 
remained constant in the SNO cell line. In the HT29 cell line 
both the 48 kDa and 52 kDa isoforms were only detected post 
serum withdrawal.  D) Densitometric analyses of FasL 
expression post serum-withdrawal revealed that the 40kDa 
counterpart of FasL increased post STS treatment in the 
WHCO1, SNO and HT29 cell lines.  Note: a SNO loading 
control (L/C) was included in the first lane of each immunoblot 
to allow for densitometric comparison. 
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6.3.5 The HOSCC cell lines differentially express caspase-8 
 
Fas-mediated anoikis converges on the activation of caspase-8 and -3, which 
cleave structural proteins, thereby dismantling sites of focal contact (Frisch et al., 
1999; Mawji et al., 2007).  Under standard tissue culture conditions, the 
expression of caspase-8 was relatively uniform across the HOSCC, as well as the 
HT29 and MCF7 control cell lines (Figure 6.4).  The lowest caspase-8 expression 
was observed in the WHCO3 and WHCO6 cell lines, on average approximately 2 
fold less than the WHCO1 cell line (Figure 6.4B). 
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A. 
 
 
B. 
           
 
Figure 6.4: Caspase-8 is differentially expressed in the HOSCC, MCF-
7 and HT29 cell lines under standard tissue culture 
conditions. A) Western blot analysis of the cell lysates using 
a polyclonal antibody against human caspase-8 that detected 
both caspase-8/α and -8/β isoforms.  The highest level of 
caspase-8 expression was observed in the WHCO1 and 
WHCO5 cell lines. B) Densitometric analysis of the 
immunoblot was performed using Labworks™ Image 
Acquisition and Analysis software. Expression levels are 
relative to the maximum per 20µg of protein in the WHCO6 
cell line.  Note: the whole cell samples used to detect FAK in 
Figure 2.3A we were the same samples used to detect 
caspase-8, and therefore, the tubulin immunoblot also 
represents the loading control for the above immunoblot. 
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6.3.5 Sustained integrin β1-dependent signalling is accompanied by 
delayed Fas-mediated apoptosis in the mt p53-R175H cell line 
 
We have clearly shown that the HOSCC cell line harbouring the mt p53-R175H 
was resistant to caspase-3 activation, FAK cleavage and dephosphorylation of 
FAK and PKB (Figure 3.8 & 4.4).  Thus, we investigated whether the mt p53-
R175H was resistant to Fas-mediated apoptosis as measured by caspase-8 and -3 
activation.  In comparison to the representative wt p53 WHCO6 cell line, the mt 
p53-R175H cell line was resistant to caspase-8 and -3 activation at 30 nM STS 
(Figure 6.5A).  However, definitive FAK cleavage and caspase-8 and -3 activation 
was observed post treatment with 120 nM STS (Figure 6.5A).  Aberrant β1 
integrin-dependent signaling is associated with resistance to Fas-mediated anoikis 
(Estrugo et al., 2007).  Although, the mt p53-R175H cell line maintains integrin 
β1-dependent signalling post 30 nM STS treatment (Figure 3.11), treatment with 
120 nM STS resulted in FAK dephosphorylation (Figure 6.5A) and the abrogation 
of the integrin β1-FAK association (Figure 6.5B).  
 
6.3.6 The novel complex identified between Fas and FAK is independent of 
p53-directed events. 
 
The delay in Fas-mediated apoptotic death in the mt p53-R175H cell (Figure 
6.5A) was accompanied by the maintenance of pFAKTyr397 and sustained 
integrin β1-activated FAK (Figure 4.4 & 6.5B), thus, implicating a role of FAK in 
directly regulating Fas-dependent apoptosis.  Although an indirect link between 
FAK and Fas has been reported (Kamarajan et al., 2010), we identify a novel 
complex between Fas and FAK by immunoprecipitation in wt and mt p53-R175H 
cell lines (Figure 6.6A).  The delay in caspase-8 activation observed in the mt 
p53-R175H cell line was accompanied by the maintenance of a Fas/FAK complex 
(Figure 6.6A).  Moreover, the ligation of FasL to Fas was only detected post FAK 
cleavage and in the absence of the Fas/FAK complex (Figure 6.6B & C).  As we 
have also shown that FAK interacts with p53, we assessed whether the Fas/FAK 
complex could be detected in the p53-null H1299 cell line. We clearly show by 
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immunoprecipitation the Fas/FAK complex in the p53-null H1299 cell line 
(Figure 6.7).  
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Figure 6.5: Sustained integrin β1-dependent signalling accompanies 
delayed Fas-mediated apoptosis in the mt p53-R175H cell 
line.  A) The Fas-mediated apoptotic pathway is intact in the 
mt p53-R175H cell line.  Caspase-3 and -8 were activated in a 
time course corresponding to FAK cleavage in the wt p53 
WHCO6 cell line at 30nM STS.  In contrast, activated 
caspase-3 and -8 was only detected post 120nM STS in the 
mt p53-R175H cell line.  Caspase-8/α and -8/β and the 
processed intermediates of caspase-8 (p43/41) are indicated.  
B) The association between integrin β1 and FAK was detected 
in wt and mt p53-R175H cell lines.  Abrogation of the integrin 
β1/FAK interaction was observed at 30nM STS and 120nM 
STS in the wt and mt p53-R175H cell lines respectively. 
Normal tissue culture conditions (W/C), serum-free conditions 
(SS). 
152 
 
 
 
 
Figure 6.6: Delayed Fas-mediated apoptosis in the mt p53-R175H cell 
line is accompanied by the maintenance of a Fas/FAK 
complex  A) The Fas/FAK complex, identified in the wt p53 
WHCO6 and mt p53-R175H cell lines, decreased in a time 
course corresponding to the detection of the (B) FasL/Fas 
interaction. Note, the Fas/FAK complex was maintained at 
30nM STS in the mt p53-R175H cell line.  C) Immunoblot 
analysis of the supernatant fraction from the anti-Fas 
immunoprecipitates. Fas expression increased post serum-
withdrawal in the wt p53 WHCO6 cell line, whilst Fas remained 
unchanged in the mt p53-R175H cell line. Mt cont =W/C 
control from mt p53-R175H cell line; normal tissue culture 
conditions (W/C); serum-free conditions (SS). 
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Figure 6.7: The Fas/FAK association is independent of p53-directed 
events.  A) p53-independent regulation of FAK and Fas is 
evident in the p53-null H1299 cell line.  B) The association 
between FAK and Fas was detected in the p53-null H1299 
and HOSCC cell lines. 
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6.4 Discussion 
 
The demonstration of a link between FAK-dependent signalling and the 
repression of Fas-mediated anoikis has heightened interest in the role of ECM-
activated FAK in anchorage-dependent death (Kurenova et al., 2004; Kamarajan 
et al., 2010).  In this regard, the squamous keratinocytes of the oesophagus 
presents a particularly insightful model as overexpression of FAK and reduced 
sensitivity to Fas-mediated death correlates with enhanced oesophageal tumour 
metastasis (Rigberg et al., 1999; Miyazaki et al., 2003).  Although the ability of 
mutant p53 to resist apoptotic stimuli is well established, the R175H “hot-spot” 
p53 mutant is a potentially a potent inhibitor of anoikis, by abolishing the ability 
of p53 to transcriptional regulate Fas and FAK gene transcription (Zalcenstein et 
al., 2003; Golubovskaya et al., 2008 (a)).  Pertinently, we have previously 
demonstrated resistance to staurosporine (STS)-mediated detachment and FAK 
Tyr397 dephosphorylation by a HOSCC cell line harboring mt p53-R175H 
(Figure 3.9 & 3.10).  Thus, as these data implicate mt p53-R175H as being 
intimately involved in anoikis resistance, we made use of this unique model of 
HOSCC cell lines to analyze the influence of FAK-dependent signaling on Fas-
mediated death.   
 
Fas-mediated apoptosis is initiated by the interaction of membrane-bound FasL, 
with its corresponding death receptor, Fas (synonyms: Apo-1, CD95, and 
TNFRSF6) (Aoudjit and Vuori, 2001).  Unlike Fas, which is ubiquitously 
expressed, FasL is predominantly expressed by activated T lymphocytes, as well 
as “immune privileged” tissues including the testes, ovary and retina (Krueger et 
al., 2003).  Extending the demonstration of FasL protein expression in normal 
esophageal tissue (Bennet et al., 1999), we show HOSCC cell lines, harboring 
both wt p53 or mt p53-R175H to differentially express FasL (Figure 6.1).  In 
addition, predominantly peri-nuclear localisation of FasL was observed (Figure 
6.2).  Thus, although HOSCC tumours are proposed to evade immune surveillance 
by increasing the FasL surface expression (Rigberg et al., 1999), no unusual 
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distribution of FasL was observed in this series of moderately differentiated 
tumours.     
 
Substrate-deprived death was demonstrated to be accompanied by increased levels 
of Fas (Ishida et al., 2003).  Unlike the mt p53-R273H cell line, Fas expression 
was not suppressed in the mt p53-175H cell line (Figure 2.9).  Moreover, in 
contrast to the wt p53 cell lines, Fas expression was not altered by STS treatment 
in the mt p53-R175H cell line (Figure 6.3B & C).  Therefore, the regulation of 
Fas expression in the mt p53-R175H cell line appears to be independent of p53-
directed events.  In addition, FasL levels have been demonstrated to be 
upregulated following detachment from the ECM (Ishida et al., 2003).  In 
agreement with this report, an increase in FasL expression was evident post STS 
treatment in the WHCO1, WHCO6, SNO and HT29 cell lines (Figure 6.3D).  
However, as the mt p53 cell lines were resistant to STS-mediated detachment 
(Figure 3.9), no distinct relationship between the regulation of FasL expression 
and anoikis-related events is evident in the HOSCC cell lines. 
 
Fas-mediated anoikis converges on the activation of caspase-8 and -3, which 
cleave structural proteins, thereby dismantling sites of focal contact (Frisch et al., 
1999; Mawji et al., 2007).  Despite similar expression and distribution of Fas and 
FasL to the wt p53 cell lines (Figure 2.4 & 6.1), the mt p53-R175H cell line was 
resistant to caspase-8 activation and, hence, Fas-mediated apoptosis at 30nM STS 
(Figure 6.5A).  However, definitive FAK cleavage, and activation of caspase-8 
and -3 was observed post treatment with 120nM STS in the mt p53-R175H cell 
line (Figure 6.5A).  Therefore, although Fas-mediated caspase-8 activation was 
not evident at 30nM STS, Fas-mediated apoptosis was still induced by a stronger 
apoptotic stimulus.  Thus, despite HOSCC being reported to be non-responsive to 
Fas-mediated apoptosis (Rigberg et al., 1999), the components of death receptor 
apoptotic pathway are intact in both wt and mt p53-R175H cell lines.   
 
Survival signals transduced by FAK are eliminated by caspase-dependent 
cleavage of the C-terminal portion of FAK (Cooper et al., 2003).  Accordingly, 
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STS-mediated events that result in the activation of caspase-8 and -3 were 
accompanied by the cleavage and dephosphorylation of FAK (Figure 6.5A).  
Pertinently, at low STS treatment concentrations, FAK-dependent signalling was 
maintained in the mt p53-R175H cell line.  The direct interaction between the C-
terminal of FAK with the cytoplasmic tail of the β integrin subunit facilitates the 
rapid Tyr397 autophosphorylation of FAK (Schaller et al., 1994).    
Correspondingly, the cleavage and resultant dephosphorylation of FAK 
corresponded to the attenuation of the integrin β1/FAK association (Figure 6.5B).   
Enhanced integrin β1-dependent signaling has been linked to resistance to Fas-
mediated apoptotic death, as ligand bound β1 integrin inhibits procaspase-8 
activity (Estrugo et al., 2007).  Thus, the persistent integrin β1-dependent 
activation of FAK observed at low STS treatment concentrations may be 
responsible for the resistance to caspase-8 activation in the mt p53-R175H cell 
line.  
 
An indirect link between FAK and Fas has been demonstrated to regulate Fas-
dependent apoptosis (Kamarajan et al., 2010).  However, the identification of a 
novel Fas/FAK complex reveals that FAK may be directly coordinating Fas-
mediated death (Figure 6.6A).  Intriguingly, despite the fact that we have 
previously identified an association between FAK and p53 in these HOSCC cell 
lines (Figure 5.4), the identification of the Fas/FAK complex in the p53-null 
H1299 cell line confirms the lack of dependence of this complex on p53-directed 
events (Figure 6.7).  Moreover, whilst STS-mediated dephosphorylation of FAK 
did not influence the p53/FAK association, dephosphorylation of FAK was 
accompanied by the abrogation of the Fas/FAK complex.  Importantly, caspase-8-
related apoptotic events were accompanied by the abrogation of the Fas/FAK 
association (Figure 6.5A and 6.6A).  Moreover, in the same anti-Fas 
immunoprecipitates, the ligation of FasL to Fas was only detected post FAK 
dephosphorylation and in the absence of the Fas/FAK complex (Figure 6.6B). 
Therefore, in addition to maintaining FAK-dependent survival signaling, 
sustained FAK activation may oppose anoikis by directly suppressing Fas-
mediated apoptosis.   
157 
 
Thus, despite the fact that Fas-mediated apoptosis is delayed in the SNO cell line 
harbouring the conformational mt p53-R175H, the death receptor cascade is still 
inducible in wt and mt p53-R175H HOSCC cell lines co-expressing Fas and FasL.  
Notably, in the mt p53-R175H cell line, the delay in caspase-8 activation was 
accompanied by the maintenance of integrin β1-activated FAK and the Fas/FAK 
complex (Figure 6.5).  Accordingly, enhanced FAK activation may enable 
tumours to escape anoikis, by directly suppressing Fas-mediated apoptosis. 
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Chapter 7 
General Discussion and Conclusion 
Sustained FAK-dependent signalling underpins anoikis 
resistance in oesophageal carcinoma 
  
 
7.1 p53 mutational status does not influence the expression of key 
anoikis-related intermediates in moderately differentiated HOSCC 
 
In normal tissue, as a barrier to metastasis, loss of adhesion to the ECM induces 
anoikis via the p53- or Fas-mediated apoptotic pathways (Ilic et al., 1998; 
Marconi et al., 2004; Mawji et al., 2007).  Fundamental to anoikis-related 
regulation is FAK, a cell adhesion molecule that coordinates various signalling 
cascades at sites of cell contact (Zhang et al., 2004 (a); Lui et al., 2008).  
However, although enhanced expression and activation of FAK has been shown to 
repress anoikis (Kurenova et al., 2004; Lui et al., 2008; Kamarajan et al., 2010), 
the mechanism underlying anoikis resistance is poorly defined.  Thus, the 
molecular analysis of interplay between FAK and the key apoptotic constituents is 
imperative, as it reveals the mechanism used by tumours to escape anoikis.   
 
HOSCC is a highly prevalent cancer, particularly amongst the black population in 
the South African rural regions of the Transkei and Soweto (Isaacson, 2005).  
Since most patients present with advanced metastatic disease at time of diagnosis 
(Tew et al., 2005; Jemal et al., 2009), HOSCC would appear to be highly resistant 
to anoikis.  Critically, metastatic oesophageal cancer occurs in over 50% of 
patients and remains incurable (Tew et al., 2005).  Accordingly, characterization 
of the anoikis-related signalling in HOSCC may allow the design of therapeutics 
that restores anoikis sensitivity to tumours cells, thereby, preventing their 
metastatic progression.  Hence, in this study, by examining the interaction of FAK 
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with key apoptotic regulators, we sought to understand the mechanism underlying 
anoikis resistance in HOSCC. 
 
FAK has been implicated as the key intermediate in the acquisition of anoikis 
resistance, as constitutive activation through Tyr397 phosphorylation of FAK 
maintains cell adhesion-dependent signalling and, thereby, facilitates tumour cell 
survival post detachment (Owen et al., 1999; Wang, 2001; Webb et al., 2004).  In 
this report, despite the five HOSCC cell lines being derived from moderately 
differentiated tumours, there was a distinct variation in FAK protein expression 
and Tyr397 phosphorylation levels across the cell lines (Figure 2.3).  
Overexpression of FAK and the enhanced expression of Tyr397-phosphorylated 
FAK are correlated with oesophageal tumorigenesis and metastasis (Ayaki et al., 
2001; Miyazaki et al., 2003; Gabriel et al., 2006).  Thus, the variation of FAK 
expression in the HOSCC cell lines indicates that the visual categorisation of 
oesophageal tumours may be a poor indication of molecular alterations that 
accompany oesophageal tumorigenesis – particularly in the moderately 
differentiated category.  Consequently, in this study, the identification of 
similarities or disparities in anoikis-related signalling within this series of 
moderately differentiated HOSCC cell lines, may aid in refining this broad 
category.  Specifically, the WHCO6 and SNO cell lines with elevated FAK 
expression relative to the other HOSCC cell lines (See Figure 2.3) pertinently 
facilitated the investigation of FAK-dependent signalling on anoikis-related 
events. 
 
Although p53 mutants are well established to desensitize tumours to apoptotic 
stimuli (Blandino et al., 1999; Tsang et al., 2005), several studies point to mutant 
p53 as being intimately involved in FAK-dependent anoikis resistance (Zhang et 
al., 2004 (a); Golubovskaya et al., 2005; Golubovskaya et al., 2009).  Mutations 
of the p53 gene are selected for in greater than 50% of all human cancers 
(Hollstein et al., 1991).  The most common p53 mutations are single point 
mutations in the DNA-binding domain.  These mutations lead to single amino 
acid changes that influence the sequence-specific binding or the conformation of 
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the mutant protein, abrogating its ability to induce the transcription of target 
genes.  Of the three most common “hot-spot” p53 mutants (R175H, R248H, 
R273H), mt p53-R175H mutant is known to be the most severe conformational 
p53 mutant and a potent inhibitor of apoptosis by abolishing the transcriptional 
regulation of caspase-3, Fas and FAK (Tsang et al., 2003; Zalcenstein et al., 2003; 
Golubovskaya et al., 2008 (a)).  Consequently, these studies suggest that by 
suppressing the expression of key anoikis-related intermediates, mt p53-R175H is 
potentially a potent inhibitor of anoikis. 
 
In oesophageal tumours, loss of the tumour suppressor function of p53 is a 
frequent event in HOSCC progression (Xue et al., 2006).  In particular, mt p53-
R175H is associated with the metastatic progression of HOSCC (Wang et al., 
2003).  Furthermore, the sequence polymorphism in exon 4 at codon 72 that 
encodes for either a proline or arginine is a frequent occurrence in HOSCC 
patients (Vos et al., 2003).  Consistent with these reports, sequence analysis of 
p53 in the series of moderately differentiated HOSCC cell lines revealed that the 
SNO cell line harbours the conformational mt p53-R175H and the Pro/Arg72 
polymorphism was identified in both the WHCO1 and SNO cell lines (Figure 3.2 
& 3.3).  However, despite elevated expression of FAK and comparable p53 
expression to the SNO cell line, the WHCO6 cell line harbours wt p53 (Figure 2.3 
& 2.7).  Moreover, Fas was differentially expressed by the wt and mt p53 HOSCC 
cell lines (Figure 2.9).  Accordingly, in this series of moderately differentiated 
HOSCC cell lines, no distinct relationship between the level of expression of the 
anoikis-related intermediates and the mutational status of p53 is evident.   
However, a definite correlation between FAK overexpression and mt p53 has 
been demonstrated, whilst overexpression of FAK correlates with enhanced 
oesophageal tumorigenesis (Miyazaki et al., 2003; Golubovskaya et al., 2009).  
Therefore, due to the fact that mechanism underlying anoikis resistance in 
oesophageal carcinoma is unknown, the response of wt/mt p53 HOSCC cell lines 
to apoptotic stimuli was ascertained, to achieve an understanding of the 
significance of enhanced FAK-dependent signalling on cell death events.  
 
161 
 
7.2 mt p53-R175H cell line: a model for the investigation of FAK-
dependent anoikis regulation 
 
The initiation and execution of anoikis is mediated by the intrinsic and extrinsic 
apoptotic pathways, which converge on the activation of caspases, DNA 
fragmentation and cell death (Ilic et al., 1998; Mawji et al., 2007).  Clearly, the 
integrity of these pathways is crucial for anoikis induction.  Even though HOSCC 
is highly resistant to the anti-apoptotic ability of chemotherapeutic reagents (Leu 
et al., 2000), the data presented shows that oligonucleosomal cleavage was still 
inducible by the widely used apoptosis-inducing agent STS, in both wt and mt 
HOSCC cell lines (Figure 3.8A).  Hence, the apoptotic pathway is intact in both 
wt and mt p53-R175H HOSCC cell lines.  Thus far, no similar data was found in 
the literature that shows comparable oligonucleosomal cleavage between cancer 
cell lines endogenously expressing wt p53 or p53-R175H.  Furthermore, we show 
that the p53-R175H cell line was resistant to STS-mediated detachment (Figure 
3.9) and FAK dephosphorylation (Figure 4.4).  As FAK has been previously 
shown to be rapidly dephosphorylated post STS treatment (Beviglia et al., 2003; 
Lim et al., 2008), this is the first report  of  a  mt p53-R175H  cell line  that is  
resistant to  both  STS-induced  FAK dephosphorylation and detachment.   
 
Loss of cell-matrix contact in epithelial cells reduces integrin-mediated FAK 
survival signalling, thereby triggering anoikis (Frisch and Francis, 1994; Zhang et 
al., 2004 (a)).  The direct interaction between the C-terminal of FAK with the 
cytoplasmic tail of the β subunit of the integrins facilitates the rapid 
autophosphorylation of FAK at Tyr397 (Schaller et al., 1994).  Importantly, the 
cleavage of FAK induces the loss of integrin-associated FAK at sites of focal 
contact (Schaller et al., 1994; van Nimwegen and van der Water, 2007). 
Pertinently, we show that the FAK/integrin β1 association was maintained in the 
mt p53-R175H cell line post apoptotic stimuli (Figure 3.11).  Hence, the 
mechanism whereby the mt p53-R175H confers resistance to apoptotic stimuli 
may rely on sustained integrin-activation of FAK.  Importantly, these data 
demonstrate a unique relationship between loss of tumour suppressor function of 
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p53 and enhanced cell adhesion-mediated signalling.  Consequently, the mt p53-
R175H cell line represents a unique model for the investigation of FAK-
dependent regulation of anoikis resistance in HOSCC, the intricacies of which 
may also pertain to other epithelial tumours.  Specifically, this model permits the 
dissection of the influence of p53 mutational status on crosstalk between FAK- 
and the key apoptotic regulators, p53 and Fas.   
 
7.3 ECM-activated FAK suppresses detachment: opposing role of mt 
p53-R175H  
 
Cell-ECM connections profoundly regulate cell fate decisions as they suppress the 
proliferation of cells existing outside their appropriate environment (Badylak et 
al., 2009).  Consequently, interactions between the ECM and the tumour cell are 
believed to be a major determinant in anoikis resistance (Zhang et al., 2004 (a); 
Kamarajan and Kapila, 2007).  In an experimental setting, fibronectin/integrin β1 
engagement has been demonstrated to be a potent inhibitor of anoikis via the 
activation of FAK-dependent survival signalling (Guan and Shalloway, 1992; 
Zhang et al., 2004 (a)).   However, while these studies have demonstrated that 
increased activation of FAK is associated with the repression of apoptotic 
pathways and maintained cell survival in the absence of cell contact (Guan and 
Shalloway, 1992; Zhang et al., 2004 (a); Kamarajan and Kapila, 2007), the exact 
mechanism of this regulation is poorly understood.  Thus, we explored the 
influence of FN-mediated activation of FAK on the suppression of apoptosis in wt 
and mt p53 cell lines.  Intriguingly, while FN reduced STS-mediated detachment 
in the wt p53 HOSCC cell lines (WHCO1, WHCO3 and WHCO6), the mt p53 
cell lines displayed a lack of dependence on FN-dependent signalling (Figure 
4.2).  Pertinently, as the mt p53-R175H cell line also displayed maintained 
integrin β1-activated FAK (Figure 3.11), loss of tumour suppressor function of 
p53 may be a critical factor that facilitates the anchorage-independent survival of 
oesophageal tumour cells.    
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Upon integrin-ECM engagement, FAK activate various signaling pathways 
involved in cell survival and proliferation (van Nimwegen and van der Water, 
2007).  Notably, Tyr397 phosphorylation of FAK recruits PI3K, leading to the 
activation of its downstream target protein kinase B (PKB/AKT) (Gilcrease, 
2007).  However, although the survival signals transduced by FN-integrin 
engagement via FAK are attributed to activation of the PI3K/PKB pathway 
(Sonoda et al., 1999; Dai et al., 2005), the protection to STS-mediated detachment 
demonstrated in the wt p53 cells lines was independent of PKB Ser473 
phosphorylation (Figure 4.4).  In contrast to the wt p53 cell line, both FAK- and 
PKB-mediated signalling were maintained in the mt p53-R175H cell line post 
STS treatment (Figure 4.4). Thus, these data reveal that the repressive effect that 
mt p53-R175H has been established to have on the FAK promoter (Golubovskaya 
et al., 2008 (a)), may be responsible for the maintenance of PKB-dependent 
survival signalling observed in the SNO cell line.  Furthermore, as the 
maintenance of FAK-dependent signalling was accompanied by resistance to 
detachment (Figure 3.9), these data reaffirm the notion that enhanced FAK-
dependent signalling facilitates the survival of tumour cells post detachment.   
 
7.4 Impact of “loss of function” effect of mt p53-R175H on FAK 
regulation 
 
Consequently, as the ECM-mediated protection of apoptotic death is independent 
of PKB signalling in the wt p53 HOSCC cell lines (Figure 4.4), the alternative 
survival role of FAK in the suppression of p53-dependent apoptosis was explored.  
In response to stress, the highly conserved nuclear export signal, IALKLGCLEI 
on the N-terminal domain of FAK facilitates the nuclear accumulation of FAK 
(Ossovskaya et al., 2008).  The nuclear translocation of FAK has been 
demonstrated to enhance the association between FAK and p53 (Golubovskaya et 
al., 2005; Lim et al., 2008).  Despite impaired flexibility (Aylon and Oren, 2007), 
the R175H mutation did not influence the ability of p53 to associate with FAK 
(Figure 5.4).  Moreover, consistent with previous studies (Lim et al., 2008), 
nuclear FAK was detected in the wt and mt p53-R175H cell lines post STS 
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treatment (Figure 5.3).  Thus, the altered regulation of FAK and resistance to 
caspase-3 activation in the mt p53-R175H cell line is not due to the inability of mt 
p53-R175H to associate with FAK.   
 
Upon activation by stress stimuli, wt p53 has been demonstrated to bind to the 
FAK promoter and repress FAK expression (Golubovakaya et al., 2008).  
However, due to reduced DNA-binding capacity, mt p53-R175H does not bind 
the FAK promoter (Golubovakaya et al., 2008).  Hence, one possible way in 
which mt p53-R175H SNO cell line might be evading caspase-dependent 
apoptosis is through the upregulation of FAK expression.  In this way, the anti-
apoptotic ability of FAK would be enhanced, facilitating the evasion of anoikis-
related death.  Accordingly, the overexpression of mt p53-R175H in a p53-null 
cell line increased FAK expression, whilst, wt p53 had no appreciable effect on 
FAK expression (Figure 5.8 & 5.9).  Consequently, the loss of transcriptional 
regulation of FAK in tumours harbouring mt p53-R175H may be a critical event 
in FAK-dependent anoikis resistance.     
 
As the dominant negative effect of mutant p53 leads to the inactivation of wt p53, 
mutation of one allele of p53 can result in loss of function.  Importantly, the 
tetramerization of mt p53 with wt p53 reduces the ability of the p53 tetramer to 
bind the FAK promoter (Willis et al., 2004).  Thus, due to the implication of this 
regulation in anoikis-related events, this possibility was explored by 
overexpressing mt p53-R175H in the representative wt p53 WHCO6 cell line, 
followed by the induction of apoptosis with STS.  Although the mt p53-R175H 
did not protect the wt p53 WHCO6 cell line from STS-mediated FAK cleavage, 
the expression of FAK was elevated relative to the STS control (Figure 5.10).  
Thus, these data corroborate our earlier proposal that, through a „loss of function‟ 
effect, mt p53-R175H may facilitate anoikis resistance, by enhancing FAK-
dependent signalling.  
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7.5 Gene therapy: targeting anoikis-related intermediates 
 
Although several intermediates are implicated in anoikis resistance, due to its 
central role in tumourigenesis, much attention as been focused on the role of p53 
as a potential drug target (Buganim and Rotter, 2009).  Consequently, numerous 
reports have documented the frequency and distribution of p53 mutants in various 
tumour types (Blandino et al., 1999; Zalcenstein et al., 2003; Wang et al., 2003; 
Vrba et al., 2008), allowing p53 mutants to be graded according to their 
“oncogenic power” (Buganim and Rotter, 2009).  Aberrant p53 activity may be a 
result of deregulation of upstream effectors, or alternatively, p53 may be deleted 
or inactivated by viral infection.  In these instances, targeting the upstream 
regulators of p53 or reintroduction of wt p53 represents the appropriate 
therapeutic approach.  However, in the majority of tumours, there is a loss of p53 
function due to mutation in the DNA binding domain of the protein (Petitjean et 
al., 2007).  Consequently, studies that characterize the properties of these mt p53 
proteins are imperative to the development of customized p53-based therapy.   
 
At present, there are several approaches to p53-based therapy.  In cases where p53 
is intact, but its negative regulator Mdm2 is overexpressed, abrogating the 
p53/Mdm2 interaction represents a viable therapeutic approach.  Consequently, 
peptides that target this association will restore wt p53 activity by preventing p53 
degradation.  By screening a diverse library of synthetic chemicals, one class of 
cis-imidazoline analogues (Nutlins), were shown to induce growth arrest and 
apoptosis by binding to p53 and disrupting the p53/Mdm2 association (Vassilev et 
al., 2004).  Moreover, RITA (Reactivation of p53 and induction of Tumour cell 
Apoptosis) was also demonstrated to abrogate the p53/Mdm2 association by 
binding to the p53 transactivation site (Kojima et al., 2005; Tovar et al., 2006).  
Both compounds stabilize p53 by interfering with the p53/Mdm2 complex. 
 
Alternatively, in tumours where p53 is absent due to an allelic deletion or 
truncation, wt p53 activity can be reestablished by introducing full-length p53 into 
the tumour cells.  Adenoviral serotype 5-mediated infection of wt p53 is used to 
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forcibly deliver the p53 protein to the p53-null tumour cells.  Of the numerous 
p53-based gene therapy products in clinical trials, Advexin (INGN 201, 2003) and 
ScH-58500 have shown the most promise as effective anti-cancer agents 
(Barnard, 2000).  Importantly, the efficacy of these therapies is enhanced by 
chemotherapy. 
 
Currently the most promising approach to p53-based therapy is to specifically 
target mutated p53 proteins, reverting mutated p53 proteins to a wt p53 
conformation, thereby restoring wt p53 activity.  Although this approach is highly 
ambitious, initial studies demonstrated that the DNA binding capacity of p53 can 
be restored.  The PAb241 antibody against the carboxy-terminus of p53 or the 
presence of ME1, a mouse single chain Fv fragment (scFv) against the common 
epitope of mutant p53, can restore specific DNA-binding capability to several p53 
mutants (Hansen et al., 1996; Orgad et al., 2005).  In addition, suppressor 
mutations have been demonstrated to restore the mutant conformation to a wild-
type conformation (Joerger et al., 2005; Suad et al., 2009).  Hence, the relative 
flexibility of p53 has enabled the design of small molecules that alter the structure 
of mutated p53 to partially restore its DNA binding capacity.  PRIMA-1 (P53 
Reactivation and Induction of Massive Apoptosis) was identified following a 
screen for a library of low-molecular-weight compounds.  By reestablishing DNA 
contact, PRIMA-1 was demonstrated to induce apoptosis in tumours harbouring 
mutated p53 (Rehman et al., 2005).  However, as the mechanism of PRIMA-1 
involves the restoration of p53/Hsp90 interactions, the efficacy of this molecule is 
limited to temperature sensitive p53 mutants (E285K, L194F, R280K).   
Therefore, PRIMA-1 does not significantly affect the “hot-spot” p53 mutants 
(R175H, R273H, R249S).  Alternatively, a promising compound that restores wt 
p53 activity is P53R3.  Moreover, studies show that P53R3 restores sequence 
specific DNA-binding of p53-R175H and p53-R273H (Weinmann et al., 2008).  
In addition, P53R3 was more effective than PRIMA-1 at reestablishing wt p53 
activity.  Importantly, by restoring mutationally destabilized p53, these 
compounds may reinstate p53-dependent transcriptional regulation of anoikis-
dependent genes, including FAK and Fas. 
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7.6 Fas-mediated apoptosis is delayed in mt p53-R175H cell line: 
implication for chemotherapeutic intervention 
 
Intriguingly, in addition to repressing p53-dependent anoikis (Frisch et al., 1998; 
Golubovskaya et al., 2005), FAK has also been implicated in the suppression of 
the death-receptor pathway (Kurenova et al., 2004; Kamarajan and Kapila, 2007).  
Moreover, enhanced integrin β1-dependent signaling has been linked to resistance 
to Fas-mediated apoptotic death, as ligand bound β1 integrin inhibits procaspase-8 
activity (Estrugo et al., 2007).  Thus, making use of the detachment-resistant mt 
p53-R175H cell line displaying persistent integrin β1-activated FAK, we explored 
the influence of sustained FAK activation on the Fas-mediated death cascade.   
 
Cancer cells expressing membrane-bound FasL are proposed to evade immune 
attack by inducing apoptosis in Fas-sensitive lymphoid cells (Kozowski et al., 
2007).  Consequently, as increased membrane expression of FasL and reduced 
cell surface expression of Fas have been previously reported in oesophageal 
tumours, HOSCC would appear to be highly resistant to immune surveillance 
(Rigberg et al., 1999).  Moreover, perturbations in Fas/FasL death cascade are 
pivotal to HOSCC tumour progression (Xue et al., 2006).  Contrary to these 
reports, in this series of HOSCC cell lines, no aberrant localisation of Fas (Figure 
2.10) or FasL (Figure 6.2) was observed.  Furthermore, although Fas, FasL and 
caspase-8 have been demonstrated to be strongly downregulated at early stages 
during the development of HOSCC (Xue et al., 2006), all of the moderately 
differentiated HOSCC cell lines express the comparable levels of Fas, FasL and 
caspase-8.  However, despite similar expression and distribution of Fas and FasL, 
caspase-8 activation was delayed in the mt p53-R175H cell line (Figure 6.5A).  
Moreover, although the mt p53-R175H cell line was resistant to caspase activation 
at low apoptotic stimuli, the cleavage and dephosphorylation of FAK was 
observed once the apoptotic stimulus was increased (Figure 6.5A).  Survival 
signals transduced by FAK are eliminated by caspase-dependent cleavage of the 
C-terminal portion of FAK (Cooper et al., 2003).  Correspondingly, the delay in 
caspase activation was accompanied by maintain integrin β1-activation of FAK.  
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Thus, as ligand bound β1 integrin inhibits procaspase-8 activity (Estrugo et al., 
2007), the persistent integrin β1-dependent activation of FAK observed at low 
STS treatment concentrations may be responsible for the resistance to caspase-8 
activation in the mt p53-R175H cell line.  
 
Remarkably, due to sustained integrin β1-activated FAK and delayed Fas-
mediated apoptosis, this data reveals that tumours harboring the mt p53-R175H 
may be more likely to escape the host‟s immune surveillance.  In addition, despite 
HOSCC being reported to be non-responsive to Fas-mediated apoptosis (Rigberg 
et al., 1999), caspase-8 activation was detected in both wt and mt p53-R175H cell 
lines (Figure 6.5A).  Importantly, this would suggest that although 
chemotherapeutics targeting the Fas-mediated death cascade may be a viable 
therapeutic approach in HOSCC, these reagents would be less effective in 
oesophageal tumors harboring mt p53-R175H.   
 
7.7 FAK interacts with both key apoptotic regulators: sustained FAK-
dependent signalling underpins anoikis resistance in HOSCC 
 
Considerable evidence points to a crucial role of p53 and Fas in FAK-mediated 
repression of anoikis, however, the exact function of interplay between FAK and 
the key apoptotic constituents remains to be clarified (Kurenova et al., 2004; 
Golubovskaya et al., 2008 (a); Lim et al., 2008; Kamarajan et al., 2010).  In 
particular, an indirect link between FAK and Fas has been demonstrated to 
regulate Fas-dependent apoptosis (Kamarajan et al., 2010).  However, in this 
report, the identification of a novel Fas/FAK complex reveals that FAK may be 
directly coordinating Fas-mediated death (Figure 3B).  Intriguingly, we have also 
identified an association between FAK and p53 in these HOSCC cell lines (Figure 
5.4).  Thus, FAK interacts with both key apoptotic regulators in both wt and mt 
p53-R175H cell lines.  Importantly, while the p53/FAK interaction was not 
influenced by apoptotic events (Figure 5.4), the Fas/FAK complex was abrogated 
by STS treatment (Figure 6.6A).  Significantly, the Fas/FAK complex was 
maintained at low STS treatment concentrations in the SNO cell line harbouring 
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the mt p53-R175H (Figure 6.6A).  Thus, in addition to maintaining FAK-
dependent survival signaling, sustained FAK activation may oppose anoikis by 
directly suppressing Fas-mediated apoptosis.  Overexpression of FAK correlates 
with enhanced HOSCC progression (Miyazaki et al., 2003).  Therefore, through 
interactions with both key apoptotic regulators, aberrant FAK activity would have 
an impact on both intrinsic and extrinsic death cascades.  In addition, integrin-
mediated activation of FAK enhances PKB-dependent survival signalling (Sonoda 
et al., 1999; Majumder and Sellers, 2005).  Correspondingly, sustained PKB 
activation accompanied FAK phosphorylation in the detachment-resistant mt p53-
R175H cell line (Figure 4.4).  Therefore, collectively these data provide 
compelling evidence that strongly advocate aberrant regulation of FAK-dependent 
signalling as a critical factor underlying anoikis resistance. 
 
7.8 Is FAK a possible chemopreventative target for HOSCC? 
 
Based on its overexpression in HOSCC (Miyazaki et al., 2003) and known roles 
in opposing anoikis, FAK would appear to be a potential target for cancer therapy.  
Three novel kinase inhibitors of FAK, blocking FAKTyr397 autophosphorylation, 
were recently developed, one by Novartis, TAE226 (Golubovskaya et al., 2008 
(c)) and another two by Pfizer, PF-573,228 and PF-562,271 (Roberts et al., 2008).  
TAE226 inhibited glioma and ovarian tumour growth in vivo (Golubovskaya et 
al., 2008 (c)).  Although the efficacy of PF-573,228 on tumour growth in vivo has 
not been reported; it only inhibited motility and did not inhibit cell growth in 
vitro, whilst, PF-562,271 effectively blocked kinase activity of FAK and 
decreased tumour growth (Roberts et al., 2008).  Although several kinase 
inhibitors are successful chemotherapeutic reagents, these inhibitors specifically 
target enzymes displaying deregulated tyrosine kinase activity due to mutation.  
However, multiple studies demonstrates that overexpression of FAK facilitates 
tumour progression (Miyazaki et al., 2003; Lark et al., 2005; Jiang et al., 2010).  
Thus, as there is no evidence that FAK is commonly mutated in cancer, the 
prospect that catalytic inhibitors of FAK would suppress cancer growth is poor.   
170 
 
A major concern with the use of FAK tyrosine kinase inhibitors is that FAK-
dependent signalling is not solely regulated by tyrosine phosphorylation 
(Golubovskaya et al., 2005).  Pertinently, the specific association between FAK 
and p53 is not dependent on Tyr397 phosphorylation (Lim et al., 2008).  
Accordingly, inhibition of FAK phosphorylation would not influence this 
association.  Alternatively, a synthetic peptide containing the binding sites of p53 
abrogated the p53/FAK association and reduced cancer cell viability in the MCF7 
cell line (Golubovskaya et al., 2008 (a)).  In contrast, the synthetic peptide did not 
significantly reduce growth in the normal mouse MEF and human MCF10A cells 
(Golubovskaya et al., 2008 (a)).  The variation in response to the peptide has been 
attributed the difference in intracellular signalling between the normal and 
cancerous cells.  Accordingly, cancer cells with „overactivated‟ FAK are proposed 
to be more sensitive to the peptide (Golubovskaya et al., 2008 (a)).  Hence, these 
results reported by Golubovskaya and colleagues suggest that therapeutics 
targeting the p53/FAK interaction may represent a far better alternative to FAK 
catalytic inhibitors.   
 
Alternatively, the novel complex between FAK and Fas identified in this report 
was shown to be abrogated by STS-dependent events that resulted in FAK Tyr397 
dephosphorylation (Figure 6.6A).  As the molecular characterisation of this 
association is beyond the scope of this report, it is unknown whether an inhibition 
of FAK phosphorylation would selectively induce Fas-mediated apoptosis.  
However, as the Fas/FAK association is associated with delayed Fas-mediated 
apoptosis (Figure 6.6A), further studies that characterise this complex may 
facilitate the development of specific inhibitors that re-sensitise tumours to Fas-
mediated apoptosis.  
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7.9 Conclusion 
 
The acquisition of anoikis resistance is a critical step in metastasis, as it allows 
tumour cells to survive in the circulatory and lymphatic system, and colonise 
distant sites.  However to date, the mechanism underlying resistance to anoikis 
remains cryptic.  Thus, the molecular analysis of interplay between the major cell 
adhesion and apoptotic constituents is imperative, as it reveals the „modus 
operandi‟ used by tumours to escape anoikis.  Accordingly, details of this nature 
may allow the design of therapeutics that restores anoikis sensitivity to tumours 
cells, thereby, preventing their metastatic progression. 
   
Although the mechanism underlying anoikis resistance in HOSCC is unknown, 
overexpression of FAK correlates with enhanced HOSCC progression (Miyazaki 
et al., 2003).  In addition, constitutively active FAK, through Tyr397 
autophosphorylation, rescues epithelial cells from anoikis (Owen et al., 1999; 
Wang, 2001; Webb et al., 2004).  Therefore, critical to the characterization of 
anoikis-related regulation in oesophageal carcinoma, was the use of a HOSCC cell 
line harboring mt p53-R175H and displaying resistance to detachment and Tyr397 
dephosphorylation of FAK. 
 
The data presented highlight that, by interacting with both major apoptotic 
regulators, FAK is central to anoikis-related regulation.  Moreover, through 
delayed Fas-mediated apoptotic events and maintained FAK phosphorylation, the 
“hot spot” mt p53-R175H may have a significant impact on the survival of tumor 
cells post cell detachment, by opposing the induction of anoikis.  Hence, these 
results strongly support the contention that enhanced FAK-dependent signalling 
underpins anoikis resistance in HOSCC.   
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APPENDICES 
 
Appendix 1 
 
1.1 Tissue culture 
 
1.1.1 DMEM medium solution 
 
1.37 %  DMEM 
0.37 %  Sodium bicarbonate 
2 %   Penicillin/Streptomycin solution (Penicillin: 500 U/ml; 
Streptomycin: 0.5 %) 
Make up to final volume with dH2O 
 
1.1.2 Hams F12 medium solution 
 
1.07 %  Hams F12 medium 
0.118 %  Sodium bicarbonate 
2 %  Penicillin/Streptomycin solution (Penicillin: 500 U/ml; 
Streptomycin: 0.5 %) 
Make up to final volume with dH2O 
 
MIX: 
3 volumes DMEM medium solution 
1 volume Hams F12 medium solution 
Filter sterilize 
Store at 4°C 
 
 
 
 
 
 
190 
 
1.1.3 Phosphate buffer saline (1x) 
 
136.9 mM  Sodium chloride 
2.68 mM  Potassium chloride 
10.1 mM  Disodium hydrogen phosphate dodecahydrate 
1.76 mM  Potassium dihydrogen phosphate 
Adjust pH between 7.2 to 7.3 
Make up to final volume with dH2O 
Sterilise for 20 min at 151 lbq 
Store at 4 °C 
 
1.1.4 Trypsin:Ethylenediaminetetra-acetic acid (EDTA) solution 
 
1.1.4a Trypsin solution 
 
0.01 %  Trypsin 
Make up to final volume with PBS 
 
1.1.4b EDTA solution 
 
0.004 %  EDTA 
Make up to final volume with PBS 
 
MIX: 
 
50 %   Trypsin solution 
50 %   EDTA solution 
Store at 4 °C  
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1.2 Protein estimation 
 
1.2.1 Coomassie Blue solution (0.25 %) 
 
0.25 %  Coomassie brilliant blue powder 
50 %   Methanol 
10 %   Glacial acetic acid 
Make up to final volume with dH2O 
 
1.2.2 Destaining solution 
 
12 %   Glacial acetic acid 
10 %   Methanol 
Make up to final volume with dH2O 
 
1.2.3 Elution solution 
 
66 %   Methanol 
1 %   Ammonia 
Make up to final volume with dH2O 
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1.2.4 Example of standard curve (protein estimation) 
 
 
 
Figure A: Example of a protein estimation standard curve. The 
specific BSA standards, at varying concentrations, in μg, (x-
axis) and their respective absorbance value at 596 nm (y-axis) 
were used to create the curve. The equation of the curve was 
used to calculate the unknown protein concentration in a given 
sample. R2 = linear regression. 
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1.3 Sample preparation  
 
1.3.1 Double lysis buffer 
 
123.8 mM  Tris-HCl, pH 6.8 
4 %   SDS 
20 %   glycerol 
10 %   β-mercaptoethanol 
Make up to final volume with dH2O 
Store at 4 °C 
 
1.3.2. RIPA buffer 
 
50 mM  Tris-HCl (pH 7.5) 
150 mM  NaCl 
0.5 %   Deoxycholate 
0.5 %   Triton X-100 
0.05 %  SDS 
1 mM   PMSF and aprotinin 
Make up to final volume with dH2O 
Store at 4 °C 
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1.4 Electrophoresis  
 
1.4.1 Agarose Gel (1 %)  
 
0.3 g  Agarose  
Make up to 30 ml with TAE buffer (1×)  
Heat until agarose dissolves  
Pour gel and add:  
1.5 µl EtBr  
Allow gel to set for approximately 40 minutes  
 
1.4.2 TAE Buffer (20×)  
 
1.6 M   Tris  
0.8 M   NaAc.3H2O  
40 M   EDTA Na2.2H2O  
Adjust pH to 7.2.  
Make up to 1000 ml with dH2O 
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1.4.1 Separating gel 
 
10 %   Acrylamide 
0.1 %   NN‟-methylenebisacrylamide 
375 mM  Tris-HCl, pH 8.8 
0.2 %   SDS 
Make up to final volume with dH2O 
Just before use add:  
1 mM   Ammonium persulphate 
0.25 %  N,N,N‟N‟-tetramethylenediamine (TEMED) 
 
1.4.2 Stacking gel 
 
10 %   Acrylamide 
0.1 %   NN‟-methylenebisacrylamide 
125 mM  Tris-HCl, pH 6.8 
0.2 %   SDS 
Make up to final volume with dH2O 
Just before use add:  
1 mM   Ammonium persulphate 
0.25 %  TEMED 
 
1.4.3 Tracking dye 
 
0.001 %   Bromophenol blue 
50 %  Glycerol 
Make up to final volume in dH2O 
Store at -20 °C 
 
 
 
 
 
196 
 
1.4.5 Running buffer 
 
3.74 mM  SDS 
25 mM  Tris pH 8.3 
192.5 mM  Glycine 
Make up to final volume with dH2O 
 
1.4.6 Destain solution 
 
10 %   Acetic acid 
10 %   Methanol 
Make up to final volume with dH2O 
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1.5 Western Blot 
 
1.5.1 Transfer buffer 
 
25 mM  Tris pH 8.3 
1.41 %  Glycine 
20 %   Methanol 
Make up to final volume with dH2O 
Store at 4 °C 
 
1.5.2 Blocking solution 
 
50 mM  Tris-HCl, pH 7.8 
2 mM   Calcium chloride dihydrate 
5 %   non-fat milk powder 
0.01 %  anti-foam 
0.05 %  Triton-X 100 
Make up to final volume with dH2O 
Store at 4 °C 
 
1.5.3 SuperSignal West Pico Chemiluminescent Substrate kit 
 
Before use MIX: 
50 %   Luminol/Enhancer solution 
50 %   Stable peroxide buffer 
Store in the dark 
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1.5.4 Developer 
 
6.4 M   Metol 
0.6 M   Sodium sulphite (anhydrous) 
80 mM  Hydroquinine 
0.45 mM  Sodium carbonate (anhydrous) 
34 mM  Potassium bromide 
Make up to final volume with dH2O 
Store in the dark 
 
1.5.5 Fixer 
 
0.8 M   Sodium trisulphate 
0.2 M   Sodium metasulphite 
Make up to final volume with dH2O 
Store in the dark 
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1.6 Indirect immunofluorescence and confocal microscopy 
 
1.6.1 Paraformalderhyde (4 %) 
 
Solution A 
0.14 M  Sodium dihydrogen orthophosphate (anhydrous) 
Make up to final volume with dH2O 
 
Solution B 
0.63 M  Sodium hydroxide 
Make up to final volume with dH2O 
 
DISSOLVE:  
 
4 %  paraformalderhyde in 
83%  Solution A 
17%  Solution B 
Make up to final volume 
Heat to approximately 80 °C 
Stir until solution is clear 
Allow solution to cool 
Adjust pH between 7.2 to 7.3 
Filter and store solution at 4 °C 
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1.7 TUNEL assay reagents 
 
1.7.1 Blocking solution 
 
3 %                H2O2 
Make up to final volume with methanol  
 
1.7.2 Permeabilisation solution 
 
0.1 %      Triton X-100 
Make up to final volume with 0.1 % sodium citrate solution 
 
1.7.3 DAB substrate solution 
 
1 %                DAB 
Make up to final volume with dH2O 
Add 3-5 drops 10 N HCl until solution turns brown in colour 
Store at -20 °C 
 
1.7.3a DAB peroxide substrate working solution 
 
0.05 %          DAB substrate solution 
0.015 %          H2O2 
Make up to final volume with PBS 
Store at 4 °C 
 
 
 
 
 
 
 
 
201 
 
1.8 Competent cells preparation for electroporation 
 
1.8.1 Luria agar plate 
 
1 %   Sodium chloride 
0.5 %   Yeast extract 
1 %   Tryptone 
1.5 %   Agar 
 
Make up to final volume with dH2O 
Sterilise for 20 min at 151 lbq 
Wait for solution to cool 
Pour 25 ml of solution in separate petri-dishes 
Allow 10 min for liquid agar in petri-dishes to set 
Seal petri-dishes with parafilm 
Store at 4 °C 
 
1.8.2 Luria broth 
 
1 %   Sodium chloride 
0.5 %   Yeast extract 
1 %   Tryptone 
Make up to final volume with dH2O 
Sterilise for 20 min at 151 lbq 
Store at 4 °C 
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1.9 Preparation of competent cells for heat shock transformation 
 
1.9.1 SOB 
 
2 %   Tryptone 
0.5 %   Yeast extract 
8.6 mM  Sodium chloride 
Sterilise for 20 min at 151 lbq 
ADD: 
2.5 mM  Potassium chloride 
10 mM  Magnesium sulphate 
0.5 mM  Sodium hydroxide 
Make up to final volume with dH2O 
Store at 4 °C 
 
1.9.2 Transformation buffer (TB) 
 
10 mM  Pipes 
15 mM  Calcium Chloride 
250 mM  Potassium Chloride 
Adjust pH to 6.7 
Add Manganese chloride to a final concentration of 55 mM 
Make up to final volume with dH2O 
Filter sterilize 
Store at 4 °C 
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1.9.3 SOC medium 
 
ADD: 
 
2 %  Glucose to SOB 
Make up to final volume with dH2O 
Sterilise for 20 min at 151 lbq 
Store at 4 °C 
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1.10 Mini-prep DNA plasmid extraction 
 
1.10.1 Solution A 
 
50 mM  Glucose 
25 mM  Tris-HCl, pH 8.0 
10 mM  EDTA 
Make up to final volume with dH2O 
 
1.10.2 Solution B 
 
0.8 %   Sodium hydroxide 
1 %   SDS 
Make up to final volume with dH2O 
 
1.10.3 Solution C 
 
25 %   glacial acetic acid 
Make up to final volume with dH2O 
Adjust pH to 4.8 with KOH 
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1.10.4 Mini-prep procedure (Sambrook et al., 1989) 
 
- Innoculate a single colony in 5 ml of liquid broth supplemented with 0.02 % 
Ampicillin 
- Place 1 ml of culture into Eppendorf tube 
- Centrifuge Eppendorf at RT at 8000 x g, for 30 sec 
- Discard supernatant 
- Resuspend cells in 100 μl of solution A 
- Add 200 μl of solution B 
- Leave Eppendorf at RT for 5 min 
- Add 150 μl of solution C 
- Vortex briefly and incubate on ice for 5 min 
- Centrifuge Eppendorf at 6000 x g for 20 min at 4 °C. 
- Transfer supernatant into new Eppendorf tube 
- Leave Eppendorf tube at RT for 5 min 
- Add 230 μl of isopropanol and mix by inversion of Eppendorf tube 
- Centrifuge Eppendorf at 8000 x g for 5 min 
- Discard supernatant and dry pellet 
- Add 180 μl of 99.99% ethanol and mix by inversion of Eppendorf tube 
- Spin Eppendorf in centrifuge at 8000 x g for 1 min 
- Discard supernatant and dry pellet for 15 min at 37 °C 
- Add 40 μl of sterile dH2O 
- Incubate at 4 °C for 3 hours 
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1.11 Restriction of plasmids 
 
1.11.1 Loading buffer 
 
Tris-Acetate-EDTA (TAE) 20X 
1 M   Tris pH 7.2 
0.5 M   Sodium acetate 
25.5 mM  EDTA 
Make up final volume in dH2O 
Sterilise for 20 min at 151 lbq 
MIX: 
50 %   2X TAE (10 % of 20X TAE; Make to final volume with dH2O) 
50 %   glycerol 
0.001 %  Bromophenol blue 
Store at -20 °C 
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Appendix 2 
 
 
 
 
 
 
 
 
Figure B: Western blot analysis of FAK using a full gel. An entire 10% 
SDS-PAGE gel was electro-transferred onto nitrocellulose and 
probed with an anti-FAK antibody.  FAK was specifically 
detected at 125 kDa.  Non-specific binding of the anti-FAK 
antibody is not evident. 
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Appendix 3 
 
3.1 FAK sequence trace 
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3.2 p53 sequence traces 
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Appendix 4 
 
4.1 Statistical results of TUNEL assay 
 
Table 1: Paired t test analysis of apoptotic nuclei in STS-treated cells  
 
  
WHCO1 
 
WHCO3 
  
WHCO5 
  
WHCO6 
  
SNO 
  
MCF7 
  
HT29 
  
Treatment SS STS SS STS SS STS SS STS SS STS SS STS SS STS 
Mean 1.333 27.333 1.667 28.000 2.000 20.000 0.333 24.333 0.333 89.000 1.000 54.000 1.000 70.667 
SD 0.577 3.590 1.155 3.606 1.000 4.359 0.577 3.055 0.577 4.000 1.000 7.810 1.000 15.177 
SEM 0.333 6.692 0.667 2.082 0.577 2.517 0.333 1.764 0.333 2.309 0.577 4.509 0.577 8.762 
 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 HT29 
T -3.881 -12.047 -6.971 -13.37 -13.314 -13.858 -7.934 
P 0.018 <0.001 0.002  <0.001  <0.001 <0.001 0.001 
 
*Indicates significant difference (p <0.05) 
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4.2 Statistical results of cell detachment assay 
 
 
Table 2: Paired t test analysis of the effect of STS cell detachment 
 
  
WHCO1 
  
WHCO3 
  
WHCO5 
  
WHCO6 
  
SNO 
  
MCF7 
  
HT29 
  
  SS STS SS STS SS STS SS STS SS STS SS STS SS STS 
Mean 2.667 47.333 1.667 86.333 3.333 77.667 2.333 51.000 2.667 27.667 3.333 32.333 1.333 23.000 
SD 2.082 6.110 2.082 6.658 1.528 3.055 1.528 4.583 1.528 4.509 2.082 4.041 0.577 4.359 
SEM 1.202 3.528 1.202 3.844 0.882 1.764 0.882 2.646 0.882 2.603 1.202 2.333 0.333 2.517 
 
  WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 HT29 
t  -11.985 -21.021 -37.694 -17.45 -10.186 -11.049 -8.535 
P <0.001 <0.001  <0.001 <0.001 <0.001  <0.001 0.001 
 
*Indicates significant difference (p <0.05) 
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4.3 Statistical results of effect of FN on cell detachment 
 
 
 
Table 3: One way ANOVA analysis of the effect of FN on STS-mediated cell detachment 
 
 
Comparison WHCO1 WHCO3 WHCO5 WHCO6 SNO MCF7 HT29 
30nM STS vs. FN <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
30nM STS vs. Serum-free c <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
FN + 30nM STS vs. FN <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
FN + 30nM ST vs. Serum-free c <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
30nM STS vs. FN + 30nM STS <0.001 <0.001 0.035 0.019 0.085 0.07 0.052 
Serum-free control vs. FN 0.032 0.011 0.477 0.903 0.768 0.927 0.715 
 
*Indicates significant difference (p <0.05) 
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4.3.1 WHCO1 
 
One Way Repeated Measures Analysis of Variance  
 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.540) 
 
Equal Variance Test: Passed (P = 0.901) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 5.667 1.528 0.882  
FN 3 0 11.667 2.082 1.202  
FN + 30nM STS 3 0 24.667 3.786 2.186  
30nM STS 3 0 39.667 2.082 1.202  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 8.667 4.333    
Between Treatments 3 2048.250 682.750 97.536 <0.001  
Residual 6 42.000 7.000    
Total 11 2098.917     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. Serum-free c 34.000 15.739 <0.001 0.009 
30nM STS vs. FN 28.000 12.961 <0.001 0.010 
FN + 30nM ST vs. Serum-free c 19.000 8.795 <0.001 0.013 
30nM STS vs. FN + 30nM STS 15.000 6.944 <0.001 0.017 
FN + 30nM STS vs. FN 13.000 6.018 <0.001 0.025 
FN vs. Serum-free control 6.000 2.777 0.032 0.050 
 
Comparison Significant?  
30nM STS vs. Serum-free c Yes  
30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
30nM STS vs. FN + 30nM STS Yes  
FN + 30nM STS vs. FN Yes  
FN vs. Serum-free control Yes  
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4.3.2  WHCO3 
 
One Way Repeated Measures Analysis of Variance  
 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.883) 
 
Equal Variance Test: Passed (P = 0.795) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 7.667 2.517 1.453  
FN 3 0 20.667 5.132 2.963  
FN + 30nM STS 3 0 61.333 5.132 2.963  
30nM STS 3 0 88.000 4.000 2.309  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 34.667 17.333    
Between Treatments 3 12300.917 4100.306 213.311 <0.001  
Residual 6 115.333 19.222    
Total 11 12450.917     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. Serum-free c 80.333 22.441 <0.001 0.009 
30nM STS vs. FN 67.333 18.809 <0.001 0.010 
FN + 30nM ST vs. Serum-free c 53.667 14.992 <0.001 0.013 
FN + 30nM STS vs. FN 40.667 11.360 <0.001 0.017 
30nM STS vs. FN + 30nM STS 26.667 7.449 <0.001 0.025 
FN vs. Serum-free control 13.000 3.632 0.011 0.050 
 
Comparison Significant?  
30nM STS vs. Serum-free c Yes  
30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
30nM STS vs. FN + 30nM STS Yes  
FN vs. Serum-free control Yes  
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4.3.3  WHCO5 
 
One Way Repeated Measures Analysis of Variance  
 
Normality Test (Shapiro-Wilk) Passed (P = 0.898) 
 
Equal Variance Test: Passed (P = 0.319) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 6.333 3.215 1.856  
FN 3 0 8.667 2.517 1.453  
FN + 30nM STS 3 0 68.000 2.646 1.528  
30nM STS 3 0 76.333 6.658 3.844  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 50.667 25.333    
Between Treatments 3 12657.667 4219.222 296.664 <0.001  
Residual 6 85.333 14.222    
Total 11 12793.667     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. Serum-free c 70.000 22.733 <0.001 0.009 
30nM STS vs. FN 67.667 21.975 <0.001 0.010 
FN + 30nM ST vs. Serum-free c 61.667 20.027 <0.001 0.013 
FN + 30nM STS vs. FN 59.333 19.269 <0.001 0.017 
30nM STS vs. FN + 30nM STS 8.333 2.706 0.035 0.025 
FN vs. Serum-free control 2.333 0.758 0.477 0.050 
 
Comparison Significant?  
30nM STS vs. Serum-free c Yes  
30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
30nM STS vs. FN + 30nM STS No  
FN vs. Serum-free control No  
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4.3.4  WHCO6 
 
One Way Repeated Measures Analysis of Variance  
 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.959) 
 
Equal Variance Test: Passed (P = 0.103) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 3.667 2.082 1.202  
FN 3 0 4.333 3.055 1.764  
FN + 30nM STS 3 0 48.333 10.066 5.812  
30nM STS 3 0 65.000 3.606 2.082  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 10.667 5.333    
Between Treatments 3 8738.667 2912.889 71.239 <0.001  
Residual 6 245.333 40.889    
Total 11 8994.667     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. Serum-free c 61.333 11.747 <0.001 0.009 
30nM STS vs. FN 60.667 11.620 <0.001 0.010 
FN + 30nM ST vs. Serum-free c 44.667 8.555 <0.001 0.013 
FN + 30nM STS vs. FN 44.000 8.427 <0.001 0.017 
30nM STS vs. FN + 30nM STS 16.667 3.192 0.019 0.025 
FN vs. Serum-free control 0.667 0.128 0.903 0.050 
 
Comparison Significant?  
30nM STS vs. Serum-free c Yes  
30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
30nM STS vs. FN + 30nM STS Yes  
FN vs. Serum-free control No  
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4.3.5  SNO 
 
One Way Repeated Measures Analysis of Variance  
 
Data source: Data 1 in Notebook7 
 
Normality Test (Shapiro-Wilk) Passed (P = 0.677) 
 
Equal Variance Test: Passed (P = 0.374) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 3.000 1.000 0.577  
FN 3 0 2.000 1.000 0.577  
FN + 30nM STS 3 0 47.333 7.767 4.485  
30nM STS 3 0 54.000 2.000 1.155  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 38.167 19.083    
Between Treatments 3 7028.250 2342.750 148.746 <0.001  
Residual 6 94.500 15.750    
Total 11 7160.917     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. FN 52.000 16.048 <0.001 0.009 
30nM STS vs. Serum-free c 51.000 15.739 <0.001 0.010 
FN + 30nM STS vs. FN 45.333 13.990 <0.001 0.013 
FN + 30nM ST vs. Serum-free c 44.333 13.682 <0.001 0.017 
30nM STS vs. FN + 30nM STS 6.667 2.057 0.085 0.025 
Serum-free control vs. FN 1.000 0.309 0.768 0.050 
 
Comparison Significant?  
30nM STS vs. FN Yes  
30nM STS vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
30nM STS vs. FN + 30nM STS No  
Serum-free control vs. FN No  
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4.3.6  MCF7 
 
One Way Repeated Measures Analysis of Variance  
 
Normality Test (Shapiro-Wilk) Passed (P = 0.778) 
 
Equal Variance Test: Passed (P = 0.488) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 4.000 1.000 0.577  
FN 3 0 4.333 2.082 1.202  
FN + 30nM STS 3 0 30.000 2.000 1.155  
30nM STS 3 0 37.667 7.371 4.256  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 18.500 9.250    
Between Treatments 3 2728.667 909.556 50.144 <0.001  
Residual 6 108.833 18.139    
Total 11 2856.000     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. Serum-free c 33.667 9.681 <0.001 0.009 
30nM STS vs. FN 33.333 9.586 <0.001 0.010 
FN + 30nM ST vs. Serum-free c 26.000 7.477 <0.001 0.013 
FN + 30nM STS vs. FN 25.667 7.381 <0.001 0.017 
30nM STS vs. FN + 30nM STS 7.667 2.205 0.070 0.025 
FN vs. Serum-free control 0.333 0.0959 0.927 0.050 
 
Comparison Significant?  
30nM STS vs. Serum-free c Yes  
30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
30nM STS vs. FN + 30nM STS No  
FN vs. Serum-free control No  
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4.3.7  HT29 
 
One Way Repeated Measures Analysis of Variance  
 
Normality Test (Shapiro-Wilk) Passed (P = 0.352) 
 
Equal Variance Test: Passed (P = 0.149) 
 
Treatment Name  N  Missing Mean Std Dev SEM  
Serum-free control 3 0 3.000 1.000 0.577  
FN 3 0 2.000 1.000 0.577  
FN + 30nM STS 3 0 23.000 4.583 2.646  
30nM STS 3 0 29.333 3.055 1.764  
 
Source of Variation  DF   SS   MS    F    P   
Between Subjects 2 3.167 1.583    
Between Treatments 3 1742.000 580.667 56.650 <0.001  
Residual 6 61.500 10.250    
Total 11 1806.667     
 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001). To isolate the group or 
groups that differ from the others use a multiple comparison procedure. 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level 
30nM STS vs. FN 27.333 10.456 <0.001 0.009 
30nM STS vs. Serum-free c 26.333 10.074 <0.001 0.010 
FN + 30nM STS vs. FN 21.000 8.033 <0.001 0.013 
FN + 30nM ST vs. Serum-free c 20.000 7.651 <0.001 0.017 
30nM STS vs. FN + 30nM STS 6.333 2.423 0.052 0.025 
Serum-free control vs. FN 1.000 0.383 0.715 0.050 
 
Comparison Significant?  
30nM STS vs. FN Yes  
30nM STS vs. Serum-free c Yes  
FN + 30nM STS vs. FN Yes  
FN + 30nM ST vs. Serum-free c Yes  
30nM STS vs. FN + 30nM STS No  
Serum-free control vs. FN No           No 
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Appendix 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
